{"ef597b391c2451a7f2f6870e1efd3b04902f17e0": [["Noninvasive positive pressure ventilation (NPPV) \u00b1 the use of mask ventilation to avoid airway invasion in patients with respiratory failure \u00b1 has seen rapidly expanding use in intensive care units throughout the world.", [["airway", "ANATOMY", 88, 94], ["respiratory", "ANATOMY", 121, 132], ["airway invasion", "DISEASE", 88, 103], ["respiratory failure", "DISEASE", 121, 140], ["airway", "MULTI-TISSUE_STRUCTURE", 88, 94], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["Noninvasive positive pressure ventilation", "TREATMENT", 0, 41], ["NPPV", "TREATMENT", 43, 47], ["mask ventilation", "TREATMENT", 62, 78], ["airway invasion", "PROBLEM", 88, 103], ["respiratory failure", "PROBLEM", 121, 140], ["positive", "OBSERVATION_MODIFIER", 12, 20], ["pressure ventilation", "OBSERVATION", 21, 41], ["airway", "ANATOMY", 88, 94], ["invasion", "OBSERVATION", 95, 103], ["respiratory failure", "OBSERVATION", 121, 140], ["rapidly", "OBSERVATION_MODIFIER", 152, 159], ["expanding", "OBSERVATION_MODIFIER", 160, 169]]], ["Solid evidence is accumulating to support these applications.", [["these applications", "TREATMENT", 42, 60]]], ["For several years, NPPV administered using pressure support ventilation (PSV) has been widely accepted as the ventilatory modality of first choice in selected patients with COPD exacerbation [1] .", [["COPD", "DISEASE", 173, 177], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["NPPV", "TREATMENT", 19, 23], ["pressure support ventilation", "TREATMENT", 43, 71], ["PSV", "TREATMENT", 73, 76], ["the ventilatory modality", "TREATMENT", 106, 130], ["COPD exacerbation", "PROBLEM", 173, 190]]], ["However, the role of NPPV for most non-COPD causes of respiratory failure remains controversial.", [["respiratory", "ANATOMY", 54, 65], ["non-COPD", "DISEASE", 35, 43], ["respiratory failure", "DISEASE", 54, 73], ["NPPV", "TREATMENT", 21, 25], ["respiratory failure", "PROBLEM", 54, 73], ["respiratory failure", "OBSERVATION", 54, 73]]]], "PMC7262122": [["PATIENT PRESENTATIONA 57\u2010year\u2010old Chinese man presented to the emergency department with fever, cough, and atypical chest pain.", [["chest", "ANATOMY", 116, 121], ["fever", "DISEASE", 89, 94], ["cough", "DISEASE", 96, 101], ["chest pain", "DISEASE", 116, 126], ["man", "ORGANISM", 42, 45], ["chest", "ORGANISM_SUBDIVISION", 116, 121], ["man", "SPECIES", 42, 45], ["fever", "PROBLEM", 89, 94], ["cough", "PROBLEM", 96, 101], ["atypical chest pain", "PROBLEM", 107, 126], ["fever", "OBSERVATION", 89, 94], ["cough", "OBSERVATION", 96, 101], ["atypical", "OBSERVATION_MODIFIER", 107, 115], ["chest", "ANATOMY", 116, 121], ["pain", "OBSERVATION", 122, 126]]], ["He had no medical history of note.", [["no", "UNCERTAINTY", 7, 9]]], ["At triage, his temperature was 101.2\u00b0F (38.4\u00b0C).", [["his temperature", "TEST", 11, 26]]], ["His physical examination was unremarkable.", [["His physical examination", "TEST", 0, 24], ["unremarkable", "OBSERVATION", 29, 41]]], ["His white cell count was normal, but he was both lymphopenic and thrombocytopenic.", [["white cell", "ANATOMY", 4, 14], ["thrombocytopenic", "DISEASE", 65, 81], ["white cell", "CELL", 4, 14], ["His white cell count", "TEST", 0, 20], ["lymphopenic", "PROBLEM", 49, 60], ["thrombocytopenic", "PROBLEM", 65, 81], ["lymphopenic", "OBSERVATION", 49, 60], ["thrombocytopenic", "OBSERVATION", 65, 81]]], ["High sensitivity troponin I was not elevated.", [["troponin I", "GENE_OR_GENE_PRODUCT", 17, 27], ["troponin I", "PROTEIN", 17, 27], ["High sensitivity troponin I", "TEST", 0, 27], ["elevated", "PROBLEM", 36, 44]]], ["The patient's 12\u2010lead electrocardiography (ECG) at triage is shown (Figure 1).DIAGNOSISThe ECG is consistent with a type 1 Brugada ECG pattern.", [["Brugada", "DISEASE", 123, 130], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["The patient's 12\u2010lead electrocardiography", "TEST", 0, 41], ["ECG", "TEST", 43, 46], ["triage", "TEST", 51, 57], ["ECG", "TEST", 91, 94], ["a type 1 Brugada ECG pattern", "PROBLEM", 114, 142], ["consistent with", "UNCERTAINTY", 98, 113]]], ["It demonstrates an rSR\u2019 pattern with coved ST\u2010segment elevations both in V1 and V2 (Figure 1).", [["an rSR\u2019 pattern", "PROBLEM", 16, 31], ["coved ST\u2010segment elevations", "PROBLEM", 37, 64], ["rSR\u2019 pattern", "OBSERVATION", 19, 31], ["segment", "ANATOMY_MODIFIER", 46, 53], ["elevations", "OBSERVATION_MODIFIER", 54, 64], ["V1", "ANATOMY_MODIFIER", 73, 75]]], ["Given a positive contact history with COVID\u201019 cases, the patient was isolated given the clinical suspicion of COVID\u201019 pneumonia.", [["COVID", "DISEASE", 111, 116], ["pneumonia", "DISEASE", 120, 129], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["COVID\u201019 pneumonia", "PROBLEM", 111, 129], ["pneumonia", "OBSERVATION", 120, 129]]], ["His nasopharyngeal swab for COVID\u201019 RNA polymerase chain reaction testing returned positive.", [["nasopharyngeal swab", "ANATOMY", 4, 23], ["nasopharyngeal swab", "CANCER", 4, 23], ["His nasopharyngeal swab", "TEST", 0, 23], ["COVID", "TEST", 28, 33], ["RNA polymerase chain reaction testing", "TEST", 37, 74], ["nasopharyngeal", "ANATOMY", 4, 18]]], ["He was managed supportively with supplemental oxygen, and was discharged after 20 days (Figure 2).", [["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["supplemental oxygen", "TREATMENT", 33, 52]]], ["His ECG showed normalization of ST\u2010segment elevations once afebrile (Figure 3).DIAGNOSISTo the best of our knowledge, this is the first reported case of a type 1 Brugada ECG pattern unmasked by COVID\u201019 pneumonia.", [["ST\u2010segment", "ANATOMY", 32, 42], ["afebrile", "DISEASE", 59, 67], ["Brugada", "DISEASE", 162, 169], ["pneumonia", "DISEASE", 203, 212], ["His ECG", "TEST", 0, 7], ["ST\u2010segment elevations", "PROBLEM", 32, 53], ["afebrile", "PROBLEM", 59, 67], ["a type 1 Brugada ECG pattern", "PROBLEM", 153, 181], ["pneumonia", "PROBLEM", 203, 212], ["pneumonia", "OBSERVATION", 203, 212]]], ["Brugada syndrome is more prevalent within Asia than in Europe or the United States.1Several factors such as certain drugs, increase in vagal tone, and fever can unmask the type 1 Brugada ECG pattern.2Our patient's presentation to hospital with COVID\u201019 pneumonia allowed for opportunistic diagnosis of an asymptomatic type 1 Brugada ECG pattern, and he has since been advised on avoiding specific medications, excessive exercise, and reducing fever.3", [["Brugada syndrome", "DISEASE", 0, 16], ["fever", "DISEASE", 151, 156], ["Brugada", "DISEASE", 179, 186], ["pneumonia", "DISEASE", 253, 262], ["Brugada", "DISEASE", 325, 332], ["fever", "DISEASE", 443, 448], ["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 204, 211], ["Brugada syndrome", "PROBLEM", 0, 16], ["Several factors", "PROBLEM", 84, 99], ["certain drugs", "TREATMENT", 108, 121], ["increase in vagal tone", "PROBLEM", 123, 145], ["fever", "PROBLEM", 151, 156], ["the type 1 Brugada ECG pattern", "PROBLEM", 168, 198], ["pneumonia", "PROBLEM", 253, 262], ["an asymptomatic type 1 Brugada ECG pattern", "PROBLEM", 302, 344], ["specific medications", "TREATMENT", 388, 408], ["excessive exercise", "PROBLEM", 410, 428], ["reducing fever", "PROBLEM", 434, 448], ["more prevalent", "OBSERVATION_MODIFIER", 20, 34], ["vagal tone", "OBSERVATION", 135, 145], ["pneumonia", "OBSERVATION", 253, 262]]]], "ff844513e36a8372df9419d172c27e943a3f1ee0": [["IntroductionThe history of man contains a number of occasions of disease outbreaks, ranging from endemic to pandemic, which is the highest form of disease threat to humanity.", [["pandemic", "DISEASE", 108, 116], ["man", "ORGANISM", 27, 30], ["man", "SPECIES", 27, 30], ["disease outbreaks", "PROBLEM", 65, 82], ["pandemic", "PROBLEM", 108, 116], ["disease", "OBSERVATION", 65, 72], ["disease", "OBSERVATION", 147, 154]]], ["According to WHO 2020, COVID-19 has led to the death of more than 431,541 persons as of June 16, 2020.", [["death", "DISEASE", 47, 52], ["persons", "SPECIES", 74, 81]]], ["Thus the mortality rate attached to COVID-19 pandemic requires a swift response, especially in the case of a new disease outbreak which demands an absolute need for new therapeutic developments [1] .", [["the mortality rate", "TEST", 5, 23], ["COVID", "TREATMENT", 36, 41], ["a new disease outbreak", "PROBLEM", 107, 129], ["new", "OBSERVATION_MODIFIER", 109, 112], ["disease", "OBSERVATION", 113, 120]]], ["Even though the curative therapeutic approach is highly clamoured for, there cannot be an effective solution to a pandemic unless preventive approach of which vaccination is a highly effective method is taken to immunize uninfected persons [2] .IntroductionThe importance of immunotherapy is not unknown to the scientific community who have turned to research, to develop viable vaccines to curb the disease outbreak.", [["persons", "SPECIES", 232, 239], ["immunotherapy", "TREATMENT", 275, 288], ["viable vaccines", "TREATMENT", 372, 387], ["the disease outbreak", "PROBLEM", 396, 416]]], ["Developing a vaccine for a novel virus requires explicit knowledge of the mechanism of action of the virus, also the understanding of the immune system complexities should be exploited [3] .", [["a vaccine", "TREATMENT", 11, 20], ["a novel virus", "PROBLEM", 25, 38], ["the virus", "PROBLEM", 97, 106]]], ["Development of vaccine involves joint efforts of immunologists, chemical engineers and molecular biologists, who construct and create safe and efficient purified vaccines [4] .Immunization via vaccine operates based on the principle of immune system stimulation; this explicitly implies that the human body triggers its natural disease-fighting system in response to the administration of vaccine into the body [5] .IntroductionCOVID-19 is a respiratory infection that is caused by a beta-coronavirus known as SARS-COV-2.", [["immune system", "ANATOMY", 236, 249], ["body", "ANATOMY", 302, 306], ["body", "ANATOMY", 406, 410], ["respiratory", "ANATOMY", 442, 453], ["respiratory infection", "DISEASE", 442, 463], ["human", "ORGANISM", 296, 301], ["body", "ORGANISM_SUBDIVISION", 302, 306], ["body", "ORGANISM_SUBDIVISION", 406, 410], ["beta-coronavirus", "ORGANISM", 484, 500], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 510, 520], ["human", "SPECIES", 296, 301], ["human", "SPECIES", 296, 301], ["vaccine", "TREATMENT", 15, 22], ["efficient purified vaccines", "TREATMENT", 143, 170], ["Immunization via vaccine", "TREATMENT", 176, 200], ["immune system stimulation", "TREATMENT", 236, 261], ["the human body", "PROBLEM", 292, 306], ["the administration of vaccine", "TREATMENT", 367, 396], ["IntroductionCOVID", "TEST", 416, 433], ["a respiratory infection", "PROBLEM", 440, 463], ["a beta-coronavirus", "PROBLEM", 482, 500], ["natural disease", "OBSERVATION", 320, 335], ["respiratory", "ANATOMY", 442, 453], ["infection", "OBSERVATION", 454, 463]]], ["It is an RNA virus, and it consists 14 receptor binding residue on it glycoprotein that interact by the angiotensin-converting enzyme 2 (ACE2) receptor [6] .", [["angiotensin", "CHEMICAL", 104, 115], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 104, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 137, 141], ["glycoprotein", "PROTEIN", 70, 82], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 104, 151], ["an RNA virus", "PROBLEM", 6, 18], ["receptor binding residue", "PROBLEM", 39, 63], ["it glycoprotein", "TREATMENT", 67, 82], ["the angiotensin-converting enzyme 2 (ACE2) receptor", "TREATMENT", 100, 151], ["RNA virus", "OBSERVATION", 9, 18]]], ["This mediates the entry of the viral RNA into the host cell for infection to occur as the virus proliferate using the host cell [6] .", [["cell", "ANATOMY", 55, 59], ["cell", "ANATOMY", 123, 127], ["infection", "DISEASE", 64, 73], ["host cell", "CELL", 50, 59], ["cell", "CELL", 123, 127], ["viral RNA", "RNA", 31, 40], ["infection", "PROBLEM", 64, 73], ["the virus proliferate", "PROBLEM", 86, 107], ["viral RNA", "OBSERVATION", 31, 40], ["host cell", "OBSERVATION", 50, 59], ["infection", "OBSERVATION", 64, 73], ["host cell", "OBSERVATION", 118, 127]]], ["Since the SARS-COV-2 glycoproteins (S) facilitate the viral entry into the host cell, they become the main target of antibodies.", [["cell", "ANATOMY", 80, 84], ["COV-2 glycoproteins", "GENE_OR_GENE_PRODUCT", 15, 34], ["host cell", "CELL", 75, 84], ["SARS-COV-2 glycoproteins", "PROTEIN", 10, 34], ["S", "PROTEIN", 36, 37], ["host cell", "CELL_TYPE", 75, 84], ["antibodies", "PROTEIN", 117, 127], ["the SARS", "TEST", 6, 14], ["host cell", "OBSERVATION", 75, 84]]], ["Therefore SARS-COV-2 spike glycoproteins are essential proteins for sub-unit vaccine construct.", [["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 10, 20], ["SARS-COV-2 spike glycoproteins", "PROTEIN", 10, 40], ["sub-unit vaccine construct", "DNA", 68, 94], ["SARS", "TEST", 10, 14], ["COV", "TEST", 15, 18], ["2 spike glycoproteins", "PROBLEM", 19, 40], ["essential proteins", "PROBLEM", 45, 63], ["sub-unit vaccine construct", "TREATMENT", 68, 94]]], ["This implies that the antigenicity of the spike glycoprotein will be exploited.", [["spike glycoprotein", "PROTEIN", 42, 60], ["the spike glycoprotein", "TREATMENT", 38, 60]]], ["Thus, recognition of T-cell and B cell epitopes of the spike glycoproteins is crucial for vaccine development [7] .IntroductionVaccination is the most efficient approach towards the prevention of infectious diseases, especially influenza, which is a highly contagious respiratory infection.", [["T-cell", "ANATOMY", 21, 27], ["B cell", "ANATOMY", 32, 38], ["respiratory", "ANATOMY", 268, 279], ["infectious diseases", "DISEASE", 196, 215], ["influenza", "DISEASE", 228, 237], ["respiratory infection", "DISEASE", 268, 289], ["T-cell", "CELL", 21, 27], ["B cell", "CELL", 32, 38], ["T-cell and B cell epitopes", "PROTEIN", 21, 47], ["spike glycoproteins", "PROTEIN", 55, 74], ["T-cell", "PROBLEM", 21, 27], ["B cell epitopes", "TREATMENT", 32, 47], ["the spike glycoproteins", "TREATMENT", 51, 74], ["IntroductionVaccination", "TREATMENT", 115, 138], ["infectious diseases", "PROBLEM", 196, 215], ["influenza", "PROBLEM", 228, 237], ["a highly contagious respiratory infection", "PROBLEM", 248, 289], ["infectious", "OBSERVATION", 196, 206], ["highly", "OBSERVATION_MODIFIER", 250, 256], ["contagious", "OBSERVATION_MODIFIER", 257, 267], ["respiratory", "OBSERVATION_MODIFIER", 268, 279], ["infection", "OBSERVATION", 280, 289]]], ["Human vaccines that are licensed are mostly based on their capability to elicit humoral antibodies that block infection and possibly reduce pathogen loads [8] .IntroductionTherefore, this study proposed the design of a multi-epitope protein subunit based vaccine which is comprised of immune stimulating epitopes that can evoke humoral and cell-mediated immune response to prevent COVID-19 infection in this study.Retrieval of SequencesThe whole-genome nucleotide sequences were retrieved from the National Center for Biotechnology Information (NCBI) and Global Initiative on Sharing All Influenza Data (GISAID).", [["cell", "ANATOMY", 340, 344], ["infection", "DISEASE", 110, 119], ["infection", "DISEASE", 390, 399], ["Human", "ORGANISM", 0, 5], ["cell", "CELL", 340, 344], ["COVID-19", "CELL", 381, 389], ["humoral antibodies", "PROTEIN", 80, 98], ["multi-epitope protein subunit", "PROTEIN", 219, 248], ["immune stimulating epitopes", "PROTEIN", 285, 312], ["whole-genome nucleotide sequences", "DNA", 440, 473], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human vaccines", "TREATMENT", 0, 14], ["humoral antibodies", "PROBLEM", 80, 98], ["block infection", "PROBLEM", 104, 119], ["pathogen loads", "PROBLEM", 140, 154], ["this study", "TEST", 183, 193], ["a multi-epitope protein subunit based vaccine", "TREATMENT", 217, 262], ["immune stimulating epitopes", "PROBLEM", 285, 312], ["COVID-19 infection", "PROBLEM", 381, 399], ["this study", "TEST", 403, 413], ["Retrieval of Sequences", "TREATMENT", 414, 436], ["infection", "OBSERVATION", 110, 119], ["infection", "OBSERVATION", 390, 399]]], ["Thirty whole-genome nucleotides were selected in GISAID from six African countries (Congo-16, South Africa -3, Senegal -7, Gambia-2, Egypt -1, Ghana -5).", [["Thirty whole-genome nucleotides", "PROBLEM", 0, 31], ["Congo", "TEST", 84, 89], ["South Africa", "TEST", 94, 106], ["Senegal", "TEST", 111, 118], ["Gambia", "TEST", 123, 129]]], ["The whole-genome nucleotide sequences were selected based on their submission date (between March 15 and May 3, 2020) the date was picked to avoid imported cases considering community transmission (https://www.epicov.org) [9] .", [["nucleotide", "CHEMICAL", 17, 27], ["whole-genome nucleotide sequences", "DNA", 4, 37]]], ["Five available sequences for three African countries, Nigeria -1, Tunisia -3 and South -Africa -1 as at May 5, 2020, were retrieved from NCBI.", [["Nigeria", "TEST", 54, 61]]], ["A total of thirty-five sequences from eight African countries were used for this study.Annotation of Retrieved SequencesThe retrieved African SARS-CoV-2 sequences from GISAID were annotated using the retrieved Wuhan isolate with accession number NC_045512.2 as a reference sequence using NCBI tools (https://www.ncbi.nlm.nih.gov/guide/data-software/) [11] .", [["GISAID", "CANCER", 168, 174], ["Retrieved Sequences", "DNA", 101, 120], ["African SARS-CoV-2 sequences", "DNA", 134, 162], ["GISAID", "DNA", 168, 174], ["African SARS-CoV", "SPECIES", 134, 150], ["this study", "TEST", 76, 86]]], ["The whole-genome sequences were annotated to identify the position of the spike glycoprotein using pairwise alignment (https://www.ebi.ac.uk/Tools/psa/emboss needle/ ) [12] , and the aligned nucleotide sequences of the spike glycoprotein were translated to protein with protein transeq (https://www.ebi.ac.uk/Tools/st/emboss_transeq/) [13] .Antigenicity Prediction of Spike GlycoproteinThe antigenicity of the spike glycoprotein was predicted using ANTIGENpro on the scratch protein (http://scratch.proteomics.ics.uci.edu/) [14] and VaxiJen (http://www.ddgpharmfac.net/vaxijen/VaxiJen/VaxiJen.html) [15] .", [["nucleotide", "CHEMICAL", 191, 201], ["nucleotide", "CHEMICAL", 191, 201], ["Spike Glycoprotein", "GENE_OR_GENE_PRODUCT", 368, 386], ["whole-genome sequences", "DNA", 4, 26], ["spike glycoprotein", "PROTEIN", 74, 92], ["aligned nucleotide sequences", "DNA", 183, 211], ["spike glycoprotein", "PROTEIN", 219, 237], ["Spike Glycoprotein", "PROTEIN", 368, 386], ["spike glycoprotein", "PROTEIN", 410, 428], ["scratch protein", "PROTEIN", 467, 482], ["the aligned nucleotide sequences", "TREATMENT", 179, 211], ["the spike glycoprotein", "TREATMENT", 215, 237], ["Spike Glycoprotein", "PROBLEM", 368, 386], ["the spike glycoprotein", "PROBLEM", 406, 428], ["ANTIGENpro", "TREATMENT", 449, 459], ["VaxiJen (http://www.ddgpharmfac.net/vaxijen/VaxiJen/VaxiJen.html)", "TREATMENT", 533, 598]]], ["On scratch protein, sequences above the threshold of 0.8 were selected [14] , while protein sequences above the limit of 0.4 were chosen on VaxiJen [16] .", [["scratch protein", "PROTEIN", 3, 18], ["scratch protein", "TEST", 3, 18], ["sequences", "TEST", 20, 29], ["protein sequences", "TEST", 84, 101]]], ["The spike glycoproteins that met the criteria of at least one of the predictive analyses were further subjected to the next phase of the study.Prediction of Cytotoxic T Lymphocytes (CTL) EpitopesNetCTL 1.2 server accessed through http://www.cbs.dtu.dk/services/NetCTL/ was utilized in the prediction of CTL epitopes of SARS-CoV-2 spike glycoprotein sequences that passed either ANTIGENpro (http://scratch.proteomics.ics.uci.edu/) or VaxiJen (http://www.ddgpharmfac.net/vaxijen/VaxiJen/VaxiJen.html).", [["Cytotoxic T Lymphocytes", "ANATOMY", 157, 180], ["Cytotoxic T Lymphocytes", "CELL", 157, 180], ["CTL", "CELL", 182, 185], ["spike glycoproteins", "PROTEIN", 4, 23], ["Cytotoxic T Lymphocytes", "CELL_TYPE", 157, 180], ["CTL", "CELL_TYPE", 182, 185], ["http://www.cbs.dtu.dk/services/NetCTL", "PROTEIN", 230, 267], ["CTL epitopes", "PROTEIN", 303, 315], ["SARS-CoV-2 spike glycoprotein sequences", "DNA", 319, 358], ["SARS-CoV", "SPECIES", 319, 327], ["The spike glycoproteins", "PROBLEM", 0, 23], ["the predictive analyses", "TEST", 65, 88], ["the study", "TEST", 133, 142], ["Cytotoxic T Lymphocytes", "PROBLEM", 157, 180], ["CTL", "TEST", 182, 185], ["EpitopesNetCTL", "TEST", 187, 201], ["SARS", "PROBLEM", 319, 323], ["CoV", "TEST", 324, 327], ["glycoprotein sequences", "TEST", 336, 358], ["VaxiJen (http://www.ddgpharmfac.net/vaxijen/VaxiJen/VaxiJen.html", "TREATMENT", 433, 497], ["Cytotoxic T Lymphocytes", "OBSERVATION", 157, 180]]], ["The MHC-1 binding peptides, Proteasomal Cterminal cleavages and Transporter Associated with Antigen Processing (TAP) transport efficiency were the three major components that the prediction was based.", [["MHC-1", "GENE_OR_GENE_PRODUCT", 4, 9], ["MHC", "PROTEIN", 4, 7], ["TAP", "PROTEIN", 112, 115], ["The MHC-1 binding peptides", "TREATMENT", 0, 26], ["Proteasomal Cterminal cleavages", "TREATMENT", 28, 59], ["Antigen Processing (TAP) transport efficiency", "TREATMENT", 92, 137], ["Cterminal cleavages", "OBSERVATION", 40, 59]]], ["The threshold value used for the Epitopes identification during the CTL Epitopes prediction was 0.75 while the weights on C-terminal cleavage and TAP transport efficiency used during the prediction were 0.15 and 0.05 respectively [17] .Projection of Helper T-Cell (HTL) EpitopeThe HTL Epitopes on SARS COV-2 surface glycoprotein were projected using the Immune Epitope Database (IEDB) (tools.IEDB.org/mhcii/) [18] .", [["Helper T-Cell", "ANATOMY", 250, 263], ["C", "CHEMICAL", 122, 123], ["TAP", "GENE_OR_GENE_PRODUCT", 146, 149], ["SARS COV-2", "GENE_OR_GENE_PRODUCT", 297, 307], ["TAP", "PROTEIN", 146, 149], ["Helper T-Cell (HTL) Epitope", "PROTEIN", 250, 277], ["SARS COV-2 surface glycoprotein", "PROTEIN", 297, 328], ["IEDB.org", "PROTEIN", 392, 400], ["mhcii", "PROTEIN", 401, 406], ["The threshold value", "TEST", 0, 19], ["the Epitopes identification", "TEST", 29, 56], ["the CTL Epitopes prediction", "TEST", 64, 91], ["C-terminal cleavage", "TREATMENT", 122, 141], ["TAP transport efficiency", "TREATMENT", 146, 170], ["Helper T-Cell (HTL)", "TREATMENT", 250, 269], ["EpitopeThe HTL Epitopes", "TREATMENT", 270, 293], ["SARS COV-2 surface glycoprotein", "TREATMENT", 297, 328]]], ["For the Major Histocompatibility Class II (MHC II), three mouse alleles which are H2-IAb, H2-IEd and H2-IAd were selected.", [["H2", "CHEMICAL", 90, 92], ["H2-IAd", "CHEMICAL", 101, 107], ["mouse", "ORGANISM", 58, 63], ["H2-IAb", "GENE_OR_GENE_PRODUCT", 82, 88], ["H2-IEd", "GENE_OR_GENE_PRODUCT", 90, 96], ["H2-IAd", "GENE_OR_GENE_PRODUCT", 101, 107], ["Major Histocompatibility Class II", "PROTEIN", 8, 41], ["MHC II", "PROTEIN", 43, 49], ["mouse alleles", "DNA", 58, 71], ["H2", "DNA", 90, 92], ["IEd", "DNA", 93, 96], ["H2", "DNA", 101, 103], ["IAd", "DNA", 104, 107], ["mouse", "SPECIES", 58, 63], ["mouse", "SPECIES", 58, 63], ["H2", "TEST", 82, 84]]], ["The predicted Epitopes were chosen by making use of their MHC-II affinity and percentile rank (which has an inverse relationship with the affinity of the epitopes predicted in the database) [19] .", [["MHC-II", "GENE_OR_GENE_PRODUCT", 58, 64], ["MHC", "PROTEIN", 58, 61], ["epitopes", "PROTEIN", 154, 162]]], ["The six lowest scored epitopes were selected for each allele.Projection of B-Cell EpitopesThe linear B-cell Epitopes of SARS COV-2 surface glycoproteins were projected using B-cell Epitope prediction server; BepiPred (http://www.cbs.dtu.dk/services/BepiPred) and BCPREDS (http://ailab-projects1.ist.psu.edu:8080/bcpred/index.html).", [["Cell", "ANATOMY", 77, 81], ["B-cell", "ANATOMY", 101, 107], ["B-cell", "CELL", 101, 107], ["COV-2", "GENE_OR_GENE_PRODUCT", 125, 130], ["B-cell", "CELL", 174, 180], ["allele", "DNA", 54, 60], ["SARS COV-2 surface glycoproteins", "PROTEIN", 120, 152], ["B-Cell Epitopes", "TREATMENT", 75, 90], ["SARS COV-2 surface glycoproteins", "TREATMENT", 120, 152], ["B-cell Epitope prediction server", "TREATMENT", 174, 206], ["B-Cell Epitopes", "OBSERVATION", 75, 90], ["linear", "OBSERVATION_MODIFIER", 94, 100], ["-cell", "OBSERVATION_MODIFIER", 102, 107], ["Epitopes", "OBSERVATION_MODIFIER", 108, 116]]], ["All epitopes above 0.5 thresholds (BepiPred) and justified by BCPREDS were selected and subjected to further analysis [20, 21] .", [["epitopes", "PROTEIN", 4, 12], ["All epitopes", "TREATMENT", 0, 12], ["further analysis", "TEST", 101, 117]]], ["In totality, eight B-cell Epitopes were chosen for the vaccine construct.Construction of Multi-Epitope Vaccine SequenceSubsequent to the predictions made above using different immuno-informatics tools, a multiepitope vaccine was built using the predicted CTL, HTL and B-Cell epitopes.", [["B-cell", "ANATOMY", 19, 25], ["B-cell", "CELL", 19, 25], ["CTL", "CELL", 255, 258], ["B-Cell", "CELL", 268, 274], ["CTL", "CELL_TYPE", 255, 258], ["HTL", "PROTEIN", 260, 263], ["B-Cell epitopes", "PROTEIN", 268, 283], ["eight B-cell Epitopes", "TREATMENT", 13, 34], ["the vaccine construct", "TREATMENT", 51, 72], ["Multi-Epitope Vaccine", "TREATMENT", 89, 110], ["a multiepitope vaccine", "TREATMENT", 202, 224], ["the predicted CTL", "TREATMENT", 241, 258], ["B-Cell epitopes", "TREATMENT", 268, 283]]], ["The predicted epitopes for CTL and HTL were subjected to toxicity test using ToxinPred (http://crdd.osdd.net/raghava/toxinpred).", [["toxicity", "DISEASE", 57, 65], ["CTL", "CELL", 27, 30], ["HTL", "SIMPLE_CHEMICAL", 35, 38], ["CTL", "CELL_TYPE", 27, 30], ["CTL and HTL", "TREATMENT", 27, 38], ["toxicity test", "TEST", 57, 70], ["ToxinPred (http://crdd.osdd.net/raghava/toxinpred", "TREATMENT", 77, 126]]], ["RS09 motif was used as an adjuvant to improve the immunogenicity of the vaccine [22] .", [["RS09", "CHEMICAL", 0, 4], ["RS09 motif", "DNA", 0, 10], ["RS09 motif", "TREATMENT", 0, 10], ["an adjuvant", "TREATMENT", 23, 34], ["the vaccine", "TREATMENT", 68, 79]]], ["The CTL Epitopes were linked using AAY, while HTL and B cell epitopes were linked using GPGPG [23] .Allergenicity Prediction of Constructed VaccineAllerTOP (https://www.ddg-pharmfac.net/AllerTOP/) was employed in the prediction the allergenicity of the final constructed vaccine; the server uses k nearest neighbours (kNN) model with 85.3% accuracy [24] .", [["B cell", "ANATOMY", 54, 60], ["B cell", "CELL", 54, 60], ["AAY", "PROTEIN", 35, 38], ["HTL", "PROTEIN", 46, 49], ["B cell epitopes", "PROTEIN", 54, 69], ["The CTL Epitopes", "TREATMENT", 0, 16], ["AAY", "TREATMENT", 35, 38], ["HTL", "TREATMENT", 46, 49], ["B cell epitopes", "TREATMENT", 54, 69], ["Constructed VaccineAllerTOP (https://www.ddg-pharmfac.net/AllerTOP/)", "TREATMENT", 128, 196]]], ["Also, AlgPred was used to predict multi-epitope (http://www.imtech.res.in/raghava/algpred/submission.html) vaccine allergenicity with high precision, different algorithm were combined (SVMc + MAST + ARPs BLAST + IgEepitope) and exploited using AlgPred.", [["AlgPred", "PROTEIN", 6, 13], ["SVMc", "PROTEIN", 185, 189], ["AlgPred", "PROTEIN", 244, 251], ["AlgPred", "TREATMENT", 6, 13], ["multi-epitope (http://www.imtech.res.in/raghava/algpred/submission.html) vaccine allergenicity", "TREATMENT", 34, 128], ["different algorithm", "TEST", 150, 169], ["SVMc", "TEST", 185, 189], ["MAST", "PROBLEM", 192, 196], ["MAST", "ANATOMY", 192, 196]]], ["The different approaches used can be employed in the high accuracy prediction of allergenic proteins [25] .Antigenicity projection of Constructed VaccineVaxiJen (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) was employed in the prediction of antigenicity of the vaccine; this server calculates antigenicity based on two sets of data, 100 known antigenic peptides and 100 non-antigenic peptides which were modelled with an accuracy of 70% to 89% [15, 16] .", [["allergenic proteins", "PROTEIN", 81, 100], ["The different approaches", "TREATMENT", 0, 24], ["allergenic proteins", "PROBLEM", 81, 100], ["Constructed VaccineVaxiJen (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html)", "TREATMENT", 134, 219], ["the vaccine", "TREATMENT", 270, 281], ["an accuracy", "TEST", 431, 442]]], ["The antigenicity prediction was based on five machine learning algorithms and multiple representations of the primary sequence which gives result based on protein microarray data [14] .Physiochemical Properties and Domain IdentificationProtparam (https://web.expasy.org/cgi-bin/protparam/) was employed in the determination of various physiochemical parameters of the constructed vaccine, the following parameters among others were accessed: molecular weight, theoretical Protrusion Index (PI), hydropathicity (GRAVY), Aliphatic index, Instability index, Extinction coefficients, Atomic Composition, Charged Residues, in vitro and in vivo half-life [26] .Physiochemical Properties and Domain IdentificationJ o u r n a l P r e -p r o o fPrediction of Secondary StructureThePrediction of Secondary StructureSelf-Optimized Prediction Method (SOPMA) (https://npsa-prabi.ibcp.fr/cgibin/npsa_automat.pl?page=npsa_sopma.html) was employed for predicting the secondary structure of the vaccine construct.", [["the primary sequence", "TEST", 106, 126], ["protein microarray data", "TEST", 155, 178], ["Physiochemical Properties", "TREATMENT", 185, 210], ["Domain IdentificationProtparam (https://web.expasy.org/cgi-bin/protparam/)", "TREATMENT", 215, 289], ["the constructed vaccine", "TREATMENT", 364, 387], ["molecular weight", "TEST", 442, 458], ["theoretical Protrusion Index", "TEST", 460, 488], ["hydropathicity (GRAVY)", "PROBLEM", 495, 517], ["Aliphatic index", "PROBLEM", 519, 534], ["Instability index", "PROBLEM", 536, 553], ["Extinction coefficients", "PROBLEM", 555, 578], ["fPrediction", "PROBLEM", 735, 746], ["Secondary Structure", "PROBLEM", 750, 769], ["Secondary StructureSelf", "PROBLEM", 786, 809], ["Optimized Prediction Method (SOPMA) (https://npsa-prabi.ibcp.fr/cgibin/npsa_automat.pl?page=npsa_sopma.html)", "TREATMENT", 810, 918], ["Protrusion", "OBSERVATION_MODIFIER", 472, 482], ["Aliphatic index", "OBSERVATION", 519, 534], ["Instability index", "OBSERVATION", 536, 553], ["Secondary Structure", "OBSERVATION", 750, 769], ["Secondary StructureSelf", "OBSERVATION", 786, 809]]], ["SOPMA predict parameters that include the helices, sheets, turns and coils [27, 28] .Prediction of 3D Configuration and Discountinous B-Cell EpitopesI-TASSER (https://zhanglab.ccmb.med.umich.edu/I-TASSER) was used to predict the tertiary structure of the multi-epitope vaccine construct.", [["SOPMA", "SIMPLE_CHEMICAL", 0, 5], ["SOPMA", "PROTEIN", 0, 5], ["Discountinous B", "PROTEIN", 120, 135], ["TASSER", "DNA", 151, 157], ["multi-epitope vaccine construct", "DNA", 255, 286], ["the helices, sheets, turns and coils", "TREATMENT", 38, 74], ["3D Configuration", "TEST", 99, 115], ["the multi-epitope vaccine construct", "TREATMENT", 251, 286], ["Cell EpitopesI", "OBSERVATION", 136, 150]]], ["I-TASSER tertiary structure prediction server is designed to generate a tertiary protein structure using a quantitative assessment scoring system to obtain models.", [["a quantitative assessment", "TEST", 105, 130]]], ["The I-TASSER server gives up to five full-length output for each query.", [["I-TASSER server", "DNA", 4, 19]]], ["The estimated TM-score, the confidence score, the standard deviation and Root Mean Square Deviation (RMSD) of the estimations were also predicted [29] .", [["TM", "PROTEIN", 14, 16], ["The estimated TM", "TEST", 0, 16], ["the confidence score", "TEST", 24, 44], ["the standard deviation and Root Mean Square Deviation (RMSD) of the estimations", "PROBLEM", 46, 125], ["Root", "OBSERVATION_MODIFIER", 73, 77]]], ["The tertiary structure of the vaccine construct was used for the prediction of B-Cell 3D conformational structure using Ellipro (http://tools.iedb.org/ellipro), this assigned each epitope a Protrusion Index (PI).", [["B-Cell", "CELL", 79, 85], ["the vaccine construct", "TREATMENT", 26, 47], ["Ellipro (http://tools.iedb.org/ellipro)", "TREATMENT", 120, 159], ["tertiary", "OBSERVATION_MODIFIER", 4, 12], ["Protrusion", "OBSERVATION", 190, 200]]], ["Ellipro was used to determine the conformational 3D structure of the linear B-cell epitope predicted.", [["B-cell", "ANATOMY", 76, 82], ["B-cell", "CELL", 76, 82], ["linear B-cell epitope", "PROTEIN", 69, 90], ["Ellipro", "TREATMENT", 0, 7], ["cell epitope", "OBSERVATION", 78, 90]]], ["Jmol viewer was used in visualizing the antibody epitope predicted.", [["antibody epitope", "PROTEIN", 40, 56]]], ["The ellipro results contain the number of residue in each of the epitopes, the higher the residue, the greater its solvent availabilities [30] .Refinement of the Tertiary StructureIn other to refine the multi-epitope vaccine construct, Galaxy Refine web (http://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE) which is based on CASP 10refinement method was employed for protein side-chain reconstruction which was followed by relaxation of the structure through repacking and molecular dynamic simulation.", [["epitopes", "PROTEIN", 65, 73], ["multi-epitope vaccine construct", "DNA", 203, 234], ["the higher the residue", "PROBLEM", 75, 97], ["the multi-epitope vaccine construct", "TREATMENT", 199, 234], ["CASP 10refinement method", "TREATMENT", 331, 355], ["protein side-chain reconstruction", "TREATMENT", 373, 406], ["residue", "OBSERVATION_MODIFIER", 42, 49], ["dynamic simulation", "OBSERVATION", 489, 507]]], ["Galaxy Refine is a proven performing algorithm for the enhancement of the quality of the local structure [31, 32] .Validation of Tertiary structureProSA-web server (https://prosa.services.came.sbg.ac.at/prosa.php) is used for validation of the projected and refined 3D configuration of proteins as this is an essential step in modeling of sequences.", [["structureProSA", "PROTEIN", 138, 152]]], ["ProSA server was employed in the validation of the 3D configuration of the vaccine construct; ProSA provided an overall magnitude of quality for the input structure.", [["ProSA", "PROTEIN", 0, 5], ["the vaccine construct", "TREATMENT", 71, 92]]], ["Outliers outside the characterized range of the native protein indicate a probability of occurrence of error.", [["native protein", "PROTEIN", 48, 62]]], ["Ramachandran plot was also obtained by inputting the PDB file of the vaccine structure on PROCHEK server; this also validates the vaccine and authenticates this potential functionality.", [["Ramachandran plot", "TEST", 0, 17], ["the vaccine", "TREATMENT", 126, 137]]], ["[33, 34, 36, 36] .Validation of Tertiary structureJ o u r n a l P r e -p r o o fMolecular Docking of vaccine with Toll-Like ReceptorsStimulating immune response is the target for vaccine design; this necessitates the importance of evaluating the interactions between an antigen and TLRs.", [["TLRs", "GENE_OR_GENE_PRODUCT", 282, 286], ["Toll", "PROTEIN", 114, 118], ["TLRs", "PROTEIN", 282, 286], ["a l P r e -p r o o fMolecular Docking of vaccine", "TREATMENT", 60, 108], ["vaccine design", "TREATMENT", 179, 193]]], ["ClusPro 2.0 server (http://cluspro.org/login.php?redir=/qeueue.php) was used to predict the binding pocket among TLR-2 (5d3i), TLR-3 (3ciy), TLR-4 (2z64) and TLR-9 (5zln) in the most stable complex form.", [["TLR-2", "GENE_OR_GENE_PRODUCT", 113, 118], ["5d3i", "GENE_OR_GENE_PRODUCT", 120, 124], ["TLR-3", "GENE_OR_GENE_PRODUCT", 127, 132], ["3ciy", "GENE_OR_GENE_PRODUCT", 134, 138], ["TLR-4", "GENE_OR_GENE_PRODUCT", 141, 146], ["2z64", "GENE_OR_GENE_PRODUCT", 148, 152], ["TLR-9", "GENE_OR_GENE_PRODUCT", 158, 163], ["5zln", "GENE_OR_GENE_PRODUCT", 165, 169], ["TLR", "PROTEIN", 113, 116], ["TLR", "PROTEIN", 127, 130], ["3ciy", "PROTEIN", 134, 138], ["TLR-4", "DNA", 141, 146], ["2z64", "PROTEIN", 148, 152], ["TLR-9", "DNA", 158, 163], ["5zln", "DNA", 165, 169], ["TLR", "TEST", 113, 116], ["TLR", "TEST", 127, 130], ["TLR", "TEST", 141, 144], ["TLR", "TEST", 158, 161], ["stable", "OBSERVATION_MODIFIER", 183, 189], ["complex", "OBSERVATION", 190, 197]]], ["This was achieved by uploading the PDB file of TRLs, and the vaccine constructs onto cluspro 2.0 sever for processing and prediction [37, 38] .Stability Enhancement of Final Vaccine Construct through Disulfide EngineeringDisulfide by design (http://cptweb.cpt.wayne.edu/DbD2/) was employed in the in silico process of Disulfide engineering, which provides strength to the 3D configuration of the Vaccine construct by using disulfide.", [["Disulfide", "CHEMICAL", 200, 209], ["Disulfide", "CHEMICAL", 221, 230], ["Disulfide", "CHEMICAL", 318, 327], ["disulfide", "CHEMICAL", 423, 432], ["TRLs", "GENE_OR_GENE_PRODUCT", 47, 51], ["Disulfide", "SIMPLE_CHEMICAL", 318, 327], ["TRLs", "PROTEIN", 47, 51], ["vaccine constructs", "DNA", 61, 79], ["the vaccine constructs", "TREATMENT", 57, 79], ["Final Vaccine Construct", "TREATMENT", 168, 191], ["Disulfide engineering", "TREATMENT", 318, 339], ["the Vaccine construct", "TREATMENT", 392, 413]]], ["The process of examining protein dynamics and interactions enhances the stability of the protein structure.", [["protein structure", "PROTEIN", 89, 106], ["examining protein dynamics", "TEST", 15, 41]]], ["Conformational entropy of unfolded protein slate is reduced due to the stability of protein after the increase.", [["unfolded protein slate", "PROTEIN", 26, 48], ["Conformational entropy of unfolded protein slate", "PROBLEM", 0, 48], ["the stability of protein", "PROBLEM", 67, 91], ["unfolded", "OBSERVATION_MODIFIER", 26, 34], ["protein slate", "OBSERVATION", 35, 48], ["increase", "OBSERVATION_MODIFIER", 102, 110]]], ["The quantification of the dynamic mobility of atoms in a protein known as B-factor is the criteria for selection [39] .Molecular Dynamics Simulation of Receptor-ligand ComplexPredicting the stability of the protein-ligand complex is essential and molecular dynamics simulation is a well-accepted method to achieve this. iMOD server (http://inods.chaconlab.org) was used to carry out simulation; this approach studies the physical basis, the structure and function attributed to the biological molecules to determine the stability of the complex.", [["B-factor", "GENE_OR_GENE_PRODUCT", 74, 82], ["B-factor", "PROTEIN", 74, 82], ["protein-ligand complex", "PROTEIN", 207, 229], ["this approach studies", "TEST", 395, 416], ["the biological molecules", "PROBLEM", 478, 502], ["dynamic", "OBSERVATION_MODIFIER", 26, 33], ["mobility", "OBSERVATION_MODIFIER", 34, 42], ["stability", "OBSERVATION_MODIFIER", 190, 199]]], ["This can be deduced from the result obtained as deformability, eigenvalues, and covariance [40, 41] .Immune Response SimulationIn silico tool C-ImmSim (http://150.146.2.1/C-IMMSIM/index.php) was used in profiling immune response of the multi-epitope vaccine construct both humoral and cellular response against the predicted vaccine was illustrated.", [["cellular", "ANATOMY", 285, 293], ["C-ImmSim", "GENE_OR_GENE_PRODUCT", 142, 150], ["cellular", "CELL", 285, 293], ["ImmSim", "DNA", 144, 150], ["http://150.146.2.1/C-IMMSIM/index.php", "DNA", 152, 189], ["silico tool", "TEST", 130, 141], ["the multi-epitope vaccine", "TREATMENT", 232, 257], ["the predicted vaccine", "TREATMENT", 311, 332]]], ["One shot of the vaccine product was administered.", [["the vaccine product", "TREATMENT", 12, 31]]], ["One step of simulation is equivalent to Eight hours of real time; the simulation was performed using default parameters.", [["the simulation", "TEST", 66, 80], ["default parameters", "TEST", 101, 119]]], ["The volume simulated and simulation steps of 1000 was used, (random seed = 12345 with an injection of vaccine containing no LPS)The In Silico Cloning and Optimization of the Vaccine Protein.The vaccine construct was codon optimized JCAT Java tool.", [["Vaccine Protein", "PROTEIN", 174, 189], ["an injection of vaccine", "TREATMENT", 86, 109], ["LPS", "TREATMENT", 124, 127], ["the Vaccine Protein", "TREATMENT", 170, 189], ["The vaccine construct", "TREATMENT", 190, 211], ["volume", "OBSERVATION_MODIFIER", 4, 10]]], ["JCAT tool expresses protein sequences into expression systems of another biological host in order to adapt the codon for the new host, JCAT provides GC and CAI value of the adapted codon, the tool also back-translate protein sequences to DNA sequences which are further used in silico cloning.", [["JCAT", "CANCER", 135, 139], ["DNA", "CELLULAR_COMPONENT", 238, 241], ["JCAT", "PROTEIN", 0, 4], ["JCAT", "DNA", 135, 139], ["DNA sequences", "DNA", 238, 251], ["JCAT tool", "TEST", 0, 9], ["the codon", "TREATMENT", 107, 116], ["the tool", "TEST", 188, 196], ["DNA sequences", "TEST", 238, 251]]], ["In this study, JCAT was used to adjust the final vaccine sequences into the E. coli K12 strain expression system by inputting the construct of the final vaccine which is processed for adaptation [42] .", [["strain", "ANATOMY", 88, 94], ["E. coli", "ORGANISM", 76, 83], ["JCAT", "PROTEIN", 15, 19], ["E. coli K12", "SPECIES", 76, 87], ["E. coli", "SPECIES", 76, 83], ["this study", "TEST", 3, 13], ["JCAT", "TEST", 15, 19], ["the final vaccine sequences", "TREATMENT", 39, 66], ["the E. coli K12 strain expression system", "TREATMENT", 72, 112], ["the final vaccine", "TREATMENT", 143, 160]]], ["DNA sequences obtained from back-translation was cloned into the E. coli K12 pET-28a(+) vector expression system at specific restriction enzymes with the aid of SnapGene software [43] .Antigenicity Prediction of Spike GlycoproteinThe antigenicity of spike glycoprotein annotated from each of the sequences was predicted, and 25.7% of the sequences passed AntigenPRO at a threshold 0.8 while 100% of the selected available sequences passed VaxiJen at a threshold of 0.4.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["E. coli", "ORGANISM", 65, 72], ["pET-28a", "GENE_OR_GENE_PRODUCT", 77, 84], ["Spike Glycoprotein", "GENE_OR_GENE_PRODUCT", 212, 230], ["VaxiJen", "GENE_OR_GENE_PRODUCT", 439, 446], ["DNA sequences", "DNA", 0, 13], ["E. coli K12 pET-28a(+) vector", "DNA", 65, 94], ["restriction enzymes", "PROTEIN", 125, 144], ["Spike Glycoprotein", "PROTEIN", 212, 230], ["spike glycoprotein", "PROTEIN", 250, 268], ["AntigenPRO", "DNA", 355, 365], ["VaxiJen", "DNA", 439, 446], ["E. coli", "SPECIES", 65, 72], ["E. coli", "SPECIES", 65, 72], ["DNA sequences", "TEST", 0, 13], ["the E. coli K12 pET", "TEST", 61, 80], ["enzymes", "TEST", 137, 144], ["SnapGene software", "TEST", 161, 178], ["Spike Glycoprotein", "PROBLEM", 212, 230], ["spike glycoprotein", "PROBLEM", 250, 268], ["the sequences", "TEST", 334, 347], ["VaxiJen", "TREATMENT", 439, 446], ["back", "ANATOMY", 28, 32], ["spike", "OBSERVATION_MODIFIER", 250, 255]]], ["The sequences that passed were then subjected to further analysis.Projection of novel Cytotoxic T Lymphocytes (CTL), Helper T Lymphocytes (HTL, MHC-II) and B-cells EpitopesCTL, HTL and B-cell epitopes were projected using a different server with the selected glycoprotein sequences that passed antigenicity screening.", [["Cytotoxic T Lymphocytes", "ANATOMY", 86, 109], ["CTL", "ANATOMY", 111, 114], ["Helper T Lymphocytes", "ANATOMY", 117, 137], ["HTL", "ANATOMY", 139, 142], ["B-cells", "ANATOMY", 156, 163], ["HTL", "ANATOMY", 177, 180], ["B-cell", "ANATOMY", 185, 191], ["Cytotoxic T Lymphocytes", "CELL", 86, 109], ["CTL", "CELL", 111, 114], ["Helper T Lymphocytes", "CELL", 117, 137], ["HTL", "CELL", 139, 142], ["MHC-II", "GENE_OR_GENE_PRODUCT", 144, 150], ["B-cells", "CELL", 156, 163], ["HTL", "CELL", 177, 180], ["B-cell", "CELL", 185, 191], ["Cytotoxic T Lymphocytes", "CELL_TYPE", 86, 109], ["CTL", "CELL_TYPE", 111, 114], ["Helper T Lymphocytes", "CELL_TYPE", 117, 137], ["HTL", "CELL_TYPE", 139, 142], ["MHC", "PROTEIN", 144, 147], ["B-cells", "CELL_TYPE", 156, 163], ["EpitopesCTL", "PROTEIN", 164, 175], ["HTL", "PROTEIN", 177, 180], ["B-cell epitopes", "PROTEIN", 185, 200], ["glycoprotein sequences", "DNA", 259, 281], ["The sequences", "TEST", 0, 13], ["further analysis", "TEST", 49, 65], ["novel Cytotoxic T Lymphocytes", "TEST", 80, 109], ["CTL", "TEST", 111, 114], ["Helper T Lymphocytes", "TEST", 117, 137], ["HTL", "TEST", 139, 142], ["MHC", "TEST", 144, 147], ["EpitopesCTL", "TEST", 164, 175], ["HTL", "PROBLEM", 177, 180], ["B-cell epitopes", "TREATMENT", 185, 200], ["the selected glycoprotein sequences", "TEST", 246, 281], ["antigenicity screening", "TEST", 294, 316], ["Cytotoxic T Lymphocytes", "OBSERVATION", 86, 109]]], ["T Helper Lymphocytes epitopes were also predicted; those with low percentile rank were selected (Table 1b) .", [["Lymphocytes", "ANATOMY", 9, 20], ["Lymphocytes epitopes", "TEST", 9, 29]]], ["B-Cell epitopes within the threshold of 0.5 were selected (Table 1c ) and used in vaccine construction along with the HTL and CTL.Construction of Novel Multiple Epitope Subunit VaccineA multi-epitope vaccine was constructed from the predicted CTL, HTL and B-cell binding epitopes, linkers were employed in the linking of the epitopes and an adjuvant was linked to the construct to aid the potency of the vaccine.", [["Cell", "ANATOMY", 2, 6], ["B-cell", "ANATOMY", 256, 262], ["B-Cell", "CELL", 0, 6], ["CTL", "CELL", 243, 246], ["HTL", "CELL", 248, 251], ["B-cell", "CELL", 256, 262], ["CTL", "CELL_TYPE", 126, 129], ["CTL, HTL and B-cell binding epitopes", "PROTEIN", 243, 279], ["epitopes", "PROTEIN", 325, 333], ["vaccine construction", "TREATMENT", 82, 102], ["the HTL and CTL", "TREATMENT", 114, 129], ["Novel Multiple Epitope Subunit VaccineA multi-epitope vaccine", "TREATMENT", 146, 207], ["HTL", "PROBLEM", 248, 251], ["B-cell binding epitopes", "TREATMENT", 256, 279], ["linkers", "TREATMENT", 281, 288], ["the epitopes", "TREATMENT", 321, 333], ["an adjuvant", "TREATMENT", 338, 349], ["the vaccine", "TREATMENT", 400, 411], ["Cell epitopes", "OBSERVATION", 2, 15]]], ["AAY was used to link CTL together, GPGPG was used to connect HTL and B-cells, and EAAK was used to link the adjuvant [22] to the whole construct.", [["HTL", "ANATOMY", 61, 64], ["B-cells", "ANATOMY", 69, 76], ["AAY", "SIMPLE_CHEMICAL", 0, 3], ["CTL", "CELL", 21, 24], ["GPGPG", "SIMPLE_CHEMICAL", 35, 40], ["HTL", "CELL", 61, 64], ["B-cells", "CELL", 69, 76], ["EAAK", "GENE_OR_GENE_PRODUCT", 82, 86], ["AAY", "PROTEIN", 0, 3], ["CTL", "CELL_TYPE", 21, 24], ["GPGPG", "PROTEIN", 35, 40], ["HTL", "PROTEIN", 61, 64], ["B-cells", "CELL_TYPE", 69, 76], ["EAAK", "PROTEIN", 82, 86], ["GPGPG", "TREATMENT", 35, 40], ["B-cells", "TREATMENT", 69, 76], ["EAAK", "TREATMENT", 82, 86]]], ["This construct is the final vaccine construct (Fig.1 ).Allergenicity, antigenicity and toxicity Prediction of Constructed VaccineThe final vaccine construct was subjected to allergenicity, antigenicity and toxicity screening; the vaccine was non-allergenic as reported on the AllerTOP and Algpred server, VaxiJen 2.0 and ANTIGENpro predicted that the vaccine could elicit an antigenic reaction and tonxinPred predicted its non-toxicity.", [["Allergenicity", "DISEASE", 55, 68], ["toxicity", "DISEASE", 87, 95], ["toxicity", "DISEASE", 206, 214], ["tonxinPred", "SIMPLE_CHEMICAL", 398, 408], ["Allergenicity", "PROBLEM", 55, 68], ["Constructed Vaccine", "TREATMENT", 110, 129], ["The final vaccine construct", "TREATMENT", 129, 156], ["allergenicity", "PROBLEM", 174, 187], ["toxicity screening", "TEST", 206, 224], ["the vaccine", "TREATMENT", 226, 237], ["VaxiJen", "TREATMENT", 305, 312], ["ANTIGENpro", "TREATMENT", 321, 331], ["the vaccine", "TREATMENT", 347, 358], ["an antigenic reaction", "PROBLEM", 372, 393]]], ["A comparative analysis of the epitopes in the vaccine with the human proteome was done using BLASTp server, which shows that no significant similarity exists between the vaccine and human proteome.Physiochemical Properties and Domain IdentificationJ o u r n a l P r e -p r o o f Physiochemical analysis done on protparam showed that the molecular weight of the construct was73253.02.", [["protparam", "CHEMICAL", 311, 320], ["human", "ORGANISM", 63, 68], ["human", "ORGANISM", 182, 187], ["protparam", "SIMPLE_CHEMICAL", 311, 320], ["epitopes", "PROTEIN", 30, 38], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 182, 187], ["A comparative analysis", "TEST", 0, 22], ["the human proteome", "TEST", 59, 77], ["BLASTp server", "TEST", 93, 106], ["the vaccine", "TREATMENT", 166, 177], ["a l P r e -p r o o f", "TEST", 258, 278], ["Physiochemical analysis", "TEST", 279, 302], ["protparam", "TEST", 311, 320]]], ["The construct has a molecular formula of C 3330 H 4905 N 895 O 952 S 17 ; the theoretical isoelectric point value was predicted at 9.22.", [["S", "TEST", 67, 68], ["the theoretical isoelectric point value", "TEST", 74, 113]]], ["The half-life was predicted to be 4.4 hours in mammalian reticulocytes in vitro, >20 hours for yeast and >10 hours in E. coli.", [["reticulocytes", "ANATOMY", 57, 70], ["reticulocytes", "CELL", 57, 70], ["E. coli", "ORGANISM", 118, 125], ["mammalian reticulocytes", "CELL_TYPE", 47, 70], ["yeast", "SPECIES", 95, 100], ["E. coli", "SPECIES", 118, 125], ["yeast", "SPECIES", 95, 100], ["E. coli", "SPECIES", 118, 125], ["vitro", "TEST", 74, 79], ["yeast", "PROBLEM", 95, 100], ["E. coli", "PROBLEM", 118, 125], ["E. coli", "OBSERVATION", 118, 125]]], ["Instability index (II) was 25.82; aliphatic index prediction was 56.60.", [["aliphatic index prediction", "TEST", 34, 60]]], ["The GRAVY was at-0.425.", [["The GRAVY", "TEST", 0, 9]]], ["Alanine, Glycine and serine were observed to be in abundant.Projection of Secondary StructureSOPMA online server was utilized in the prediction of the secondary structure of the constructed vaccine.", [["Alanine", "CHEMICAL", 0, 7], ["Glycine", "CHEMICAL", 9, 16], ["Alanine", "CHEMICAL", 0, 7], ["Glycine", "CHEMICAL", 9, 16], ["serine", "CHEMICAL", 21, 27], ["Alanine", "AMINO_ACID", 0, 7], ["Glycine", "AMINO_ACID", 9, 16], ["serine", "AMINO_ACID", 21, 27], ["Alanine, Glycine", "TREATMENT", 0, 16], ["serine", "TREATMENT", 21, 27], ["Secondary StructureSOPMA online server", "TREATMENT", 74, 112], ["the constructed vaccine", "TREATMENT", 174, 197]]], ["The server provided in addition to the secondary structure information on the vaccine construct, which include, Alpha helix 15.75%, extended strand 19.35%, Random coil 63.29% and Beta turn structure 2.60%.", [["the vaccine construct", "TEST", 74, 95], ["Alpha helix", "TEST", 112, 123], ["Random coil", "TEST", 156, 167], ["Beta turn structure", "TEST", 179, 198]]], ["The high percentage of the random coil, as seen from the figure, indicates the high concentration of epitope at that point [44] .Prediction of 3D Configuration and Discountinous B-Cell EpitopesI-TASSER (https://zhanglab.ccmb.med.umich.edu/I-TASSER) was employed in predicting the 3D configuration of the multi-epitope vaccine construct.", [["epitope", "PROTEIN", 101, 108], ["Discountinous B", "PROTEIN", 164, 179], ["TASSER", "DNA", 195, 201], ["multi-epitope vaccine construct", "DNA", 304, 335], ["the random coil", "TREATMENT", 23, 38], ["the high concentration of epitope", "PROBLEM", 75, 108], ["3D Configuration", "TEST", 143, 159], ["the multi-epitope vaccine construct", "TREATMENT", 300, 335], ["high", "OBSERVATION_MODIFIER", 4, 8], ["percentage", "OBSERVATION_MODIFIER", 9, 19], ["random coil", "OBSERVATION", 27, 38], ["high", "OBSERVATION_MODIFIER", 79, 83], ["concentration", "OBSERVATION_MODIFIER", 84, 97], ["B-Cell EpitopesI", "OBSERVATION", 178, 194]]], ["Five models were predicted, but model 1 was chosen based on the confidence score of -2.14, the estimated TM-score, 0.46\u00b10.15 and Root Mean Square Deviation (RMSD) at 13.3 \u00b14.1 \u00c5.", [["the confidence score", "TEST", 60, 80], ["the estimated TM", "TEST", 91, 107], ["Root Mean Square Deviation", "TEST", 129, 155], ["RMSD", "TEST", 157, 161]]], ["The B-cell conformational epitope for the vaccine construct was identified using Ellipro server (Fig 4.)Refinement of the Tertiary StructureRefinement of the 3D configuration involves reconstruction of side chains of the protein, molecular dynamic simulation and repacking; this is to relax the tertiary structure of the vaccine.", [["B-cell", "ANATOMY", 4, 10], ["B-cell", "CELL", 4, 10], ["B-cell conformational epitope", "PROTEIN", 4, 33], ["The B-cell conformational epitope", "TREATMENT", 0, 33], ["the vaccine construct", "TREATMENT", 38, 59], ["reconstruction of side chains", "TREATMENT", 184, 213], ["Tertiary", "OBSERVATION_MODIFIER", 122, 130], ["protein", "ANATOMY", 221, 228], ["dynamic simulation", "OBSERVATION", 240, 258]]], ["Galaxy Refine webserver was employed to refine the configuration of the vaccine, five refined models were predicted, and model 1 was selected on the criteria which include 0.9187 GDT-HA, 0.501 RMSD, 2.814 MolProbity, Clash score of 38.1, Poor rotamers of 1.1, Rama favoured 82.0.Validation of Tertiary structureThe Ramachandran map showed ( Figure 5 ) distribution for the protein model for which 83.3% was in the favoured region, 11.3% in the allowed area and 5.4% found in the disallowed region.", [["GDT", "TEST", 179, 182], ["HA", "TEST", 183, 185], ["RMSD", "TEST", 193, 197], ["Clash score", "TEST", 217, 228], ["The Ramachandran map", "TEST", 311, 331], ["the protein model", "TEST", 369, 386], ["Tertiary structure", "OBSERVATION", 293, 311], ["11.3%", "OBSERVATION_MODIFIER", 431, 436], ["5.4%", "OBSERVATION_MODIFIER", 461, 465]]], ["ProSA web predicted a Z-score of -1.46 for the inputted vaccine model; this is lying outside the score range that is frequently found in the case of native proteins of comparable size and ERRAT online server revealed a quality score of 68.64%.Disulfide EngineeringDisulfide engineering was done via the disulfide by Design v2.0 server; this is necessary to enhance and aid the stability of the structure of the refined vaccine.", [["Disulfide", "CHEMICAL", 243, 252], ["Disulfide", "CHEMICAL", 264, 273], ["disulfide", "CHEMICAL", 303, 312], ["ProSA", "PROTEIN", 0, 5], ["native proteins", "PROTEIN", 149, 164], ["ERRAT", "PROTEIN", 188, 193], ["a Z-score", "TEST", 20, 29], ["the inputted vaccine model", "TREATMENT", 43, 69], ["the refined vaccine", "TREATMENT", 407, 426], ["size", "OBSERVATION_MODIFIER", 179, 183]]], ["A total of 98 pair of residue J o u r n a l P r e -p r o o f useful for disulfide engineering was found from which ten pair (PRO511-SER532 ARG574-TYR577 ARG48-GLY77 ASP587-TYR602 SER597-SER601 VAL106-GLY543 ALA593-ARG598 PRO168-GLU566 GLY51-ASN514 MET64-ARG69) were selected on the ground of their energy, Chi3 value and high B-factor as shown in Figure 6 .Molecular DockingDocking is the in silico process of simulating the binding of the vaccine with TLRs to predict how the vaccine would bind to TLRs In vivo.", [["disulfide", "CHEMICAL", 72, 81], ["B-factor", "GENE_OR_GENE_PRODUCT", 326, 334], ["TLRs", "GENE_OR_GENE_PRODUCT", 453, 457], ["P r e", "DNA", 44, 49], ["SER601 VAL106", "DNA", 186, 199], ["GLY543 ALA593", "DNA", 200, 213], ["ARG598 PRO168", "DNA", 214, 227], ["GLU566 GLY51", "DNA", 228, 240], ["ASN514 MET64", "DNA", 241, 253], ["ARG69", "DNA", 254, 259], ["Chi3", "PROTEIN", 306, 310], ["B-factor", "PROTEIN", 326, 334], ["TLRs", "PROTEIN", 453, 457], ["TLRs", "PROTEIN", 499, 503], ["PRO511", "TEST", 125, 131], ["ARG48", "TEST", 153, 158], ["ASP587", "TEST", 165, 171], ["VAL106", "TEST", 193, 199], ["ALA593", "TEST", 207, 213], ["PRO168", "TEST", 221, 227], ["GLY51", "TEST", 235, 240], ["Chi3 value", "TEST", 306, 316], ["TLRs", "TREATMENT", 453, 457], ["the vaccine", "TREATMENT", 473, 484]]], ["Molecular docking for this vaccine was done using ClusPro 2.0, TLR2, TLR3, TLR4 and TLR9 were used individually as the receptor (Figure 7) .", [["TLR2", "GENE_OR_GENE_PRODUCT", 63, 67], ["TLR3", "GENE_OR_GENE_PRODUCT", 69, 73], ["TLR4", "GENE_OR_GENE_PRODUCT", 75, 79], ["TLR9", "GENE_OR_GENE_PRODUCT", 84, 88], ["TLR2", "PROTEIN", 63, 67], ["TLR3", "PROTEIN", 69, 73], ["TLR4", "PROTEIN", 75, 79], ["TLR9", "PROTEIN", 84, 88], ["this vaccine", "TREATMENT", 22, 34], ["ClusPro", "TEST", 50, 57], ["TLR2, TLR3, TLR4 and TLR9", "TREATMENT", 63, 88]]], ["The projection of Molecular interaction of the vaccine with the receptors generated models from which the best were selected for each receptor-ligand complex based on their binding energy weight as indicated in Table 2 .3.12: Molecular Dynamic SimulationNormal Model Analysis (NMA) for the selected docked vaccine-receptor complex was carried out to study the stability and mobility employing the iMODs server.", [["receptor-ligand complex", "PROTEIN", 134, 157], ["receptor complex", "PROTEIN", 314, 330], ["the vaccine", "TREATMENT", 43, 54], ["each receptor-ligand complex", "TREATMENT", 129, 157], ["their binding energy weight", "TEST", 167, 194], ["the selected docked vaccine", "TREATMENT", 286, 313]]], ["The vaccine protein and its receptor were predicted to spin towards each other; the relationship is represented by small black arrows as shown in figure 8a, 9a, 10a and 11a for TLR2, TLR3, TLR4 and TLR9, respectively.", [["11a", "GENE_OR_GENE_PRODUCT", 169, 172], ["TLR2", "GENE_OR_GENE_PRODUCT", 177, 181], ["TLR3", "GENE_OR_GENE_PRODUCT", 183, 187], ["TLR4", "GENE_OR_GENE_PRODUCT", 189, 193], ["TLR9", "GENE_OR_GENE_PRODUCT", 198, 202], ["vaccine protein", "PROTEIN", 4, 19], ["TLR2", "PROTEIN", 177, 181], ["TLR3", "PROTEIN", 183, 187], ["TLR4", "PROTEIN", 189, 193], ["TLR9", "PROTEIN", 198, 202], ["The vaccine protein", "TREATMENT", 0, 19], ["its receptor", "TREATMENT", 24, 36], ["small black arrows", "PROBLEM", 115, 133], ["TLR2", "TEST", 177, 181], ["small", "OBSERVATION_MODIFIER", 115, 120], ["black arrows", "OBSERVATION", 121, 133]]], ["The hinges in the high deformability region indicate the deformability of the vaccine-receptor complex as shown in figure 8e, 9e, 10e and 11e for TLR2, TLR3, TLR4 and TLR9 respectively.", [["10e", "GENE_OR_GENE_PRODUCT", 130, 133], ["11e", "GENE_OR_GENE_PRODUCT", 138, 141], ["TLR2", "GENE_OR_GENE_PRODUCT", 146, 150], ["TLR3", "GENE_OR_GENE_PRODUCT", 152, 156], ["TLR4", "GENE_OR_GENE_PRODUCT", 158, 162], ["TLR9", "GENE_OR_GENE_PRODUCT", 167, 171], ["vaccine-receptor complex", "PROTEIN", 78, 102], ["TLR2", "PROTEIN", 146, 150], ["TLR3", "PROTEIN", 152, 156], ["TLR4", "PROTEIN", 158, 162], ["TLR9", "PROTEIN", 167, 171], ["the high deformability region", "PROBLEM", 14, 43], ["the vaccine", "TREATMENT", 74, 85], ["TLR2", "TEST", 146, 150], ["TLR3", "TEST", 152, 156], ["hinges", "OBSERVATION_MODIFIER", 4, 10], ["high deformability", "OBSERVATION", 18, 36], ["deformability", "OBSERVATION_MODIFIER", 57, 70]]], ["The B-factor is directly proportional to the value of RMS as inferred through NMA (fig 8d, 9d, 10d, and 11d) .", [["B-factor", "GENE_OR_GENE_PRODUCT", 4, 12], ["B-factor", "PROTEIN", 4, 12]]], ["Eigenvalue for the vaccine-receptor complexes as obtained from iMODs server were 2.27e-05, 2.06e-06 and 1.53e-05 for TLR2, TLR3, TLR4 and TLR9 respectively (Fig. 8c, 9c, 10c and 11c) .", [["TLR2", "GENE_OR_GENE_PRODUCT", 117, 121], ["TLR3", "GENE_OR_GENE_PRODUCT", 123, 127], ["TLR4", "GENE_OR_GENE_PRODUCT", 129, 133], ["TLR9", "GENE_OR_GENE_PRODUCT", 138, 142], ["11c", "GENE_OR_GENE_PRODUCT", 178, 181], ["vaccine-receptor complexes", "PROTEIN", 19, 45], ["TLR2", "PROTEIN", 117, 121], ["TLR3", "PROTEIN", 123, 127], ["TLR4", "PROTEIN", 129, 133], ["TLR9", "PROTEIN", 138, 142], ["the vaccine", "TEST", 15, 26], ["iMODs server", "TEST", 63, 75], ["TLR2", "TEST", 117, 121], ["TLR3", "TEST", 123, 127], ["TLR4", "TEST", 129, 133], ["TLR9", "TEST", 138, 142], ["Fig.", "TEST", 157, 161]]], ["Variance is reported to be inversely proportional to the Eigen's value.", [["the Eigen's value", "TEST", 53, 70]]], ["The graphs of the variance can be seen from figure 8g, 9g, 10g, and 11g for TLR2, TLR3, TLR4 and TLR9 respectively.", [["TLR2", "GENE_OR_GENE_PRODUCT", 76, 80], ["TLR3", "GENE_OR_GENE_PRODUCT", 82, 86], ["TLR4", "GENE_OR_GENE_PRODUCT", 88, 92], ["TLR9", "GENE_OR_GENE_PRODUCT", 97, 101], ["TLR2", "PROTEIN", 76, 80], ["TLR3", "PROTEIN", 82, 86], ["TLR4", "PROTEIN", 88, 92], ["TLR9", "PROTEIN", 97, 101], ["TLR2", "TEST", 76, 80]]], ["From the graphs of the residual index, the colour codes red, blue and white represent the correlated, anti-correlated and uncorrelated pairs of residues in the variance matrix ( fig. 8b 9b, 10b and 11b) .", [["matrix", "CELLULAR_COMPONENT", 169, 175], ["the variance matrix", "TEST", 156, 175], ["residual", "OBSERVATION_MODIFIER", 23, 31], ["index", "OBSERVATION_MODIFIER", 32, 37], ["colour", "OBSERVATION_MODIFIER", 43, 49], ["codes red", "OBSERVATION", 50, 59], ["blue", "OBSERVATION_MODIFIER", 61, 65]]], ["The map was observed to be different for each of the vaccine-TLR docking.", [["TLR", "PROTEIN", 61, 64], ["The map", "TEST", 0, 7], ["the vaccine", "TREATMENT", 49, 60], ["TLR docking", "TREATMENT", 61, 72]]], ["The elastic network model generated by iMODs ( fig. 8f, 9f, 10f and 11f) represents the pair of atoms connected via springs.", [["elastic network", "MULTI-TISSUE_STRUCTURE", 4, 19], ["iMODs", "PROTEIN", 39, 44], ["11f", "PROTEIN", 68, 71], ["springs", "OBSERVATION", 116, 123]]], ["Each dot represents one spring between the corresponding pairs of atoms; stiffer springs are represented by the dark grey areas in the elastic graph.Codon Adaptation and In silico cloningThe integration of COVID-19 vaccine construct into the E. coli expression system requires the use of JCAT and SnapGene server.", [["E. coli", "ORGANISM", 242, 249], ["COVID-19 vaccine construct", "DNA", 206, 232], ["JCAT", "PROTEIN", 288, 292], ["SnapGene", "PROTEIN", 297, 305], ["E. coli", "SPECIES", 242, 249], ["E. coli", "SPECIES", 242, 249], ["stiffer springs", "TREATMENT", 73, 88], ["Codon Adaptation", "TREATMENT", 149, 165], ["COVID-19 vaccine construct", "TREATMENT", 206, 232], ["the E. coli expression system", "TREATMENT", 238, 267], ["JCAT", "TREATMENT", 288, 292], ["SnapGene server", "TREATMENT", 297, 312], ["one spring", "OBSERVATION_MODIFIER", 20, 30], ["atoms", "ANATOMY_MODIFIER", 66, 71], ["stiffer springs", "OBSERVATION", 73, 88], ["dark", "OBSERVATION_MODIFIER", 112, 116], ["grey areas", "OBSERVATION", 117, 127], ["elastic graph", "OBSERVATION", 135, 148]]], ["Adapting the vaccine into E. coli k12 strain predicted a GC content of 57.03%, Codon Adaptation Index (CAI) of 0.92 and back-translate the protein sequence to an E. coli codon compatible nucleotide.", [["nucleotide", "CHEMICAL", 187, 197], ["nucleotide", "CHEMICAL", 187, 197], ["E. coli", "ORGANISM", 26, 33], ["k12", "ORGANISM", 34, 37], ["E. coli", "ORGANISM", 162, 169], ["E. coli", "SPECIES", 26, 33], ["E. coli", "SPECIES", 162, 169], ["E. coli", "SPECIES", 26, 33], ["E. coli", "SPECIES", 162, 169], ["the vaccine", "TREATMENT", 9, 20], ["E. coli k12 strain", "PROBLEM", 26, 44], ["a GC content", "TEST", 55, 67], ["Codon Adaptation Index", "TEST", 79, 101], ["CAI", "TEST", 103, 106], ["the protein sequence", "TEST", 135, 155], ["an E. coli codon", "PROBLEM", 159, 175], ["nucleotide", "PROBLEM", 187, 197], ["coli codon", "OBSERVATION", 165, 175]]], ["The back-translated nucleotide was adapted into the expression system of E. coli using restriction enzyme XhoI (158) and XbaI (335) as a cloning site (Fig 12) .3.14: Immune Response ModelThe C-ImmSim server (http://150.146.2.1/C-IMMSIM/index.php) revealed the system of successful immune response and the increased half-life of the vaccine candidate.", [["nucleotide", "CHEMICAL", 20, 30], ["nucleotide", "CHEMICAL", 20, 30], ["E. coli", "ORGANISM", 73, 80], ["XhoI (158)", "GENE_OR_GENE_PRODUCT", 106, 116], ["XbaI", "GENE_OR_GENE_PRODUCT", 121, 125], ["restriction enzyme XhoI (158) and XbaI (335", "DNA", 87, 130], ["cloning site", "DNA", 137, 149], ["C-ImmSim server", "DNA", 191, 206], ["E. coli", "SPECIES", 73, 80], ["E. coli", "SPECIES", 73, 80], ["E. coli", "PROBLEM", 73, 80], ["restriction enzyme XhoI", "TREATMENT", 87, 110], ["XbaI", "TEST", 121, 125], ["The C-ImmSim server", "TEST", 187, 206], ["back", "ANATOMY", 4, 8], ["E. coli", "OBSERVATION", 73, 80], ["increased", "OBSERVATION_MODIFIER", 305, 314]]], ["The specific immunoglobulin and interleukin concentrate was shown (fig 13a & c) .", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 13, 27], ["interleukin", "GENE_OR_GENE_PRODUCT", 32, 43], ["immunoglobulin", "PROTEIN", 13, 27], ["interleukin", "PROTEIN", 32, 43], ["The specific immunoglobulin", "TEST", 0, 27], ["interleukin concentrate", "TEST", 32, 55]]], ["Activity of the CD4, Thelper lymphocytes count (fig 13b) as well as B lymphocytes count was uncovered.4.0: DiscussionThe recent outbreak of the COVID-19 pandemic placed the world in a state of emergency, that resulted in the need for solution against the viral scourge by the world of science and research.", [["CD4", "ANATOMY", 16, 19], ["Thelper lymphocytes", "ANATOMY", 21, 40], ["B lymphocytes", "ANATOMY", 68, 81], ["CD4", "GENE_OR_GENE_PRODUCT", 16, 19], ["Thelper lymphocytes", "CELL", 21, 40], ["B lymphocytes", "CELL", 68, 81], ["CD4", "PROTEIN", 16, 19], ["B lymphocytes", "CELL_TYPE", 68, 81], ["the CD4", "TEST", 12, 19], ["Thelper lymphocytes count", "TEST", 21, 46], ["fig", "TEST", 48, 51], ["B lymphocytes count", "TEST", 68, 87], ["the COVID", "TREATMENT", 140, 149], ["solution", "TREATMENT", 234, 242]]], ["It is a well-known fact that prevention is far better than cure, this can never be over-emphasized hence it demands quick response of scientist all over the world.4.0: DiscussionVaccine is known as the surest way to prevent the spread of infectious diseases.", [["infectious diseases", "DISEASE", 238, 257], ["DiscussionVaccine", "TREATMENT", 168, 185], ["infectious diseases", "PROBLEM", 238, 257], ["infectious", "OBSERVATION", 238, 248]]], ["Immunoinformatics has made vaccine development possible in a shorter period of time and subunit vaccines which is a type of vaccine derived from fragment of whole genome of the organism having the ability to induce humoral and cellular mediated response, without reverting to wide type strain and eliminating the risk of pathogen handling has impacted positively the vaccine design and development as Fauci once said \"the global need for a vaccine and the wide geographical diversity of the pandemic require more than one effective vaccine approach.\"", [["cellular", "ANATOMY", 227, 235], ["cellular", "CELL", 227, 235], ["Immunoinformatics", "TREATMENT", 0, 17], ["vaccine", "TREATMENT", 27, 34], ["subunit vaccines", "TREATMENT", 88, 104], ["a type of vaccine", "TREATMENT", 114, 131], ["wide type strain", "PROBLEM", 276, 292], ["pathogen handling", "PROBLEM", 321, 338], ["a vaccine", "TREATMENT", 438, 447]]], ["For this study, amino acid sequence of SARS-CoV-2 spike glycoproteins were gotten from NCBI and GISAID.", [["amino acid", "CHEMICAL", 16, 26], ["amino acid", "CHEMICAL", 16, 26], ["amino acid", "AMINO_ACID", 16, 26], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 39, 49], ["SARS-CoV-2 spike glycoproteins", "PROTEIN", 39, 69], ["SARS-CoV", "SPECIES", 39, 47], ["this study", "TEST", 4, 14], ["amino acid sequence", "TEST", 16, 35], ["SARS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["spike glycoproteins", "PROBLEM", 50, 69]]], ["SARS-CoV-2 spike glycoproteins were selected based on the report that they possess receptor binding domain (RBD) which is specific to ACE-II receptor, this mediates viral entry into the host.", [["ACE-II", "CHEMICAL", 134, 140], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["ACE-II receptor", "GENE_OR_GENE_PRODUCT", 134, 149], ["SARS-CoV-2 spike glycoproteins", "PROTEIN", 0, 30], ["receptor binding domain", "PROTEIN", 83, 106], ["RBD", "PROTEIN", 108, 111], ["ACE-II receptor", "PROTEIN", 134, 149], ["SARS", "TEST", 0, 4], ["2 spike glycoproteins", "TREATMENT", 9, 30], ["receptor binding domain (RBD)", "PROBLEM", 83, 112], ["ACE-II receptor", "TREATMENT", 134, 149]]], ["Spike glycoproteins are also known to be antigenic with relatively conserved protein residue [6] hence, making it a good target for inducing immunogenic response.4.0: DiscussionThe selected sequences were subjected to antigenic and allergenic screening and were found to be antigenic and non-allergenic; which is a crucial aspect of vaccinology.", [["Spike glycoproteins", "GENE_OR_GENE_PRODUCT", 0, 19], ["Spike glycoproteins", "PROTEIN", 0, 19], ["Spike glycoproteins", "PROBLEM", 0, 19], ["relatively conserved protein residue", "PROBLEM", 56, 92], ["allergenic screening", "TEST", 232, 252], ["antigenic", "PROBLEM", 274, 283], ["non-allergenic", "PROBLEM", 288, 302], ["protein residue", "OBSERVATION", 77, 92]]], ["CTL, HTL and B-Cell epitope prediction was carried out because multi-epitope vaccine requires CTL, HTL and B-Cell epitopes [45] .", [["CTL", "CELL", 0, 3], ["HTL", "CELL", 5, 8], ["B-Cell", "CELL", 13, 19], ["CTL", "CELL", 94, 97], ["B-Cell", "CELL", 107, 113], ["CTL", "CELL_TYPE", 0, 3], ["CTL", "CELL_TYPE", 94, 97], ["HTL", "PROTEIN", 99, 102], ["CTL", "PROBLEM", 0, 3], ["HTL", "PROBLEM", 5, 8], ["B-Cell epitope prediction", "TREATMENT", 13, 38], ["multi-epitope vaccine", "TREATMENT", 63, 84], ["CTL", "PROBLEM", 94, 97], ["B-Cell epitopes", "TREATMENT", 107, 122]]], ["This is important since T-cells recognize the surface antigen presented by the MHC molecules.", [["T-cells", "ANATOMY", 24, 31], ["surface", "ANATOMY", 46, 53], ["T-cells", "CELL", 24, 31], ["T-cells", "CELL_TYPE", 24, 31], ["surface antigen", "PROTEIN", 46, 61], ["MHC molecules", "PROTEIN", 79, 92]]], ["MHC class II molecules present surface antigen to T-helper cells and B-cell;4.0: Discussionrecognize and bind to B-cell epitopes to elicit antibody and memory cells.", [["surface", "ANATOMY", 31, 38], ["T-helper cells", "ANATOMY", 50, 64], ["B-cell", "ANATOMY", 69, 75], ["B-cell", "ANATOMY", 113, 119], ["memory cells", "ANATOMY", 152, 164], ["T-helper cells", "CELL", 50, 64], ["B-cell", "CELL", 69, 75], ["B-cell", "CELL", 113, 119], ["memory cells", "CELL", 152, 164], ["MHC class II molecules", "PROTEIN", 0, 22], ["T-helper cells", "CELL_TYPE", 50, 64], ["B-cell epitopes", "PROTEIN", 113, 128], ["antibody and memory cells", "CELL_TYPE", 139, 164], ["surface antigen", "TEST", 31, 46], ["B-cell", "TEST", 69, 75], ["antibody", "TEST", 139, 147], ["memory cells", "OBSERVATION", 152, 164]]], ["The result obtained J o u r n a l P r e -p r o o f from these analyses revealed the spike glycoproteins comprise a large quantity of MHC-II and Bcell binding epitope; these were employed in building the vaccine candidate using appropriate linkers.", [["MHC-II", "GENE_OR_GENE_PRODUCT", 133, 139], ["spike glycoproteins", "PROTEIN", 84, 103], ["MHC-II", "PROTEIN", 133, 139], ["Bcell binding epitope", "PROTEIN", 144, 165], ["a l P r e -p r o o f", "TEST", 30, 50], ["these analyses", "TEST", 56, 70], ["the spike glycoproteins", "PROBLEM", 80, 103], ["Bcell binding epitope", "PROBLEM", 144, 165], ["large", "OBSERVATION_MODIFIER", 115, 120]]], ["Vaccine requires an adjuvant for a robust immune response, attaching an adjuvant to a vaccine implies a linker was also used; hence the complete vaccine construct.4.0: DiscussionUnderstanding the physiochemistry of a vaccine is necessary in order to estimate its stability, solubility and other physical properties of the protein in vitro and in vivo, the properties as predicted by the physiochemical predicting server (protparam) suggests that the vaccine has a molecular weight of 73.5 kDa, this is within the range for an accepted vaccine candidate [26] , theoretical pI value of 9.22 showed a basic vaccine depicting a good structural fold, the aliphatic index was predicted at a score of 56.60 showing that the vaccine has aliphatic side chains, the instability index (25.82) predict the vaccine to be stable.", [["Vaccine", "TREATMENT", 0, 7], ["an adjuvant", "TREATMENT", 17, 28], ["an adjuvant", "TREATMENT", 69, 80], ["a vaccine", "TREATMENT", 84, 93], ["a linker", "TREATMENT", 102, 110], ["the complete vaccine construct", "TREATMENT", 132, 162], ["a vaccine", "TREATMENT", 215, 224], ["the protein in vitro", "TREATMENT", 318, 338], ["the vaccine", "TREATMENT", 446, 457], ["theoretical pI value", "TEST", 560, 580], ["a basic vaccine", "PROBLEM", 596, 611], ["the aliphatic index", "TEST", 646, 665], ["a score", "TEST", 683, 690], ["the vaccine", "TREATMENT", 713, 724], ["aliphatic side chains", "PROBLEM", 729, 750], ["the instability index", "PROBLEM", 752, 773], ["the vaccine", "TREATMENT", 790, 801], ["stable", "OBSERVATION_MODIFIER", 808, 814]]], ["The hydrophobicity of the vaccine was revealed by the GRAVY result of -0.425.", [["the GRAVY result", "TEST", 50, 66], ["hydrophobicity", "OBSERVATION_MODIFIER", 4, 18]]], ["The half-live was predicted to be 4.4 hours in mammalian reticulocyte in vitro, >20 hours inside yeast and 10 hours in E. coli in vivo.4.0: DiscussionThe tertiary structure of the vaccine candidate was predicted using I-TASSER server and the best structure was selected based on its high c-score (-2.14).", [["reticulocyte", "ANATOMY", 57, 69], ["reticulocyte", "CELL", 57, 69], ["E. coli", "ORGANISM", 119, 126], ["mammalian reticulocyte", "CELL_TYPE", 47, 69], ["I-TASSER server", "DNA", 218, 233], ["yeast", "SPECIES", 97, 102], ["E. coli", "SPECIES", 119, 126], ["yeast", "SPECIES", 97, 102], ["E. coli", "SPECIES", 119, 126], ["mammalian reticulocyte", "OBSERVATION", 47, 69], ["E. coli", "OBSERVATION", 119, 126]]], ["Tertiary structure prediction provided information that includes TM-score (0.46\u00b10.15) and RMSD at 13.3 \u00b14.1 \u00c5, the arrangement of the residue that are important in the protein study of the vaccine was also provided.", [["TM", "TEST", 65, 67], ["RMSD", "TEST", 90, 94], ["the residue", "PROBLEM", 130, 141], ["the protein study", "TEST", 164, 181], ["the vaccine", "TREATMENT", 185, 196]]], ["The structure was further used for various studies which include, molecular docking for receptor-ligand relationship, dynamics study which at the microscopic level gives an insight of the stability of the receptor-ligand complex, and disulfide prediction for vaccine stability that helps in analyzing how the vaccine will react when the vaccine is exposed to biochemical stress within the host system as earlier described by Pandey et al. [46] .4.0: DiscussionStructural prediction expresses the structure of vaccine candidate but the structure requires refinement and validation [34] .", [["disulfide", "CHEMICAL", 234, 243], ["receptor-ligand complex", "PROTEIN", 205, 228], ["various studies", "TEST", 35, 50], ["dynamics study", "TEST", 118, 132], ["the microscopic level", "TEST", 142, 163], ["vaccine stability", "TREATMENT", 259, 276], ["the vaccine", "TREATMENT", 305, 316], ["the vaccine", "TREATMENT", 333, 344]]], ["Performing refinement provides a refined 3D vaccine model Pattern-recognition receptors (PRRs) are means by which the immune system recognizes pathogen-associated molecular pattern (PAMPs).", [["Pattern-recognition receptors", "GENE_OR_GENE_PRODUCT", 58, 87], ["pathogen-associated molecular pattern", "GENE_OR_GENE_PRODUCT", 143, 180], ["PAMPs", "GENE_OR_GENE_PRODUCT", 182, 187], ["Pattern-recognition receptors", "PROTEIN", 58, 87], ["PRRs", "PROTEIN", 89, 93], ["pathogen-associated molecular pattern", "PROTEIN", 143, 180], ["PAMPs", "PROTEIN", 182, 187], ["a refined 3D vaccine model Pattern", "TREATMENT", 31, 65]]], ["Vertebrate host encompasses different class of PRRs such as RIG-I-like receptor (RLRs), C-type lectin receptor, NOD-like receptor and Tolllike receptors (TLRs) [47] .", [["PRRs", "GENE_OR_GENE_PRODUCT", 47, 51], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 60, 79], ["RLRs", "GENE_OR_GENE_PRODUCT", 81, 85], ["C-type lectin receptor", "GENE_OR_GENE_PRODUCT", 88, 110], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 112, 129], ["Tolllike receptors", "GENE_OR_GENE_PRODUCT", 134, 152], ["TLRs", "GENE_OR_GENE_PRODUCT", 154, 158], ["PRRs", "PROTEIN", 47, 51], ["RIG-I-like receptor", "PROTEIN", 60, 79], ["RLRs", "PROTEIN", 81, 85], ["C-type lectin receptor", "PROTEIN", 88, 110], ["NOD-like receptor", "PROTEIN", 112, 129], ["Tolllike receptors", "PROTEIN", 134, 152], ["TLRs", "PROTEIN", 154, 158], ["RIG", "TEST", 60, 63], ["RLRs", "TEST", 81, 85]]], ["TLRs ligands activate the maturation of dendritic cells and consequently activate their ability to trigger adaptive immune responses and in effect, tag antigens as pathogenic.", [["dendritic cells", "ANATOMY", 40, 55], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["dendritic cells", "CELL", 40, 55], ["TLRs", "PROTEIN", 0, 4], ["dendritic cells", "CELL_TYPE", 40, 55], ["tag antigens", "PROTEIN", 148, 160], ["TLRs ligands", "TREATMENT", 0, 12], ["dendritic cells", "PROBLEM", 40, 55], ["pathogenic", "PROBLEM", 164, 174], ["dendritic cells", "OBSERVATION", 40, 55]]], ["Another significance of TLR-induced DC maturation is the amplification of a variety of cytokines and chemokines [47] .", [["DC", "ANATOMY", 36, 38], ["TLR", "GENE_OR_GENE_PRODUCT", 24, 27], ["DC", "CELL", 36, 38], ["TLR", "PROTEIN", 24, 27], ["DC", "CELL_TYPE", 36, 38], ["cytokines", "PROTEIN", 87, 96], ["chemokines", "PROTEIN", 101, 111], ["TLR-induced DC maturation", "TREATMENT", 24, 49]]], ["Malcolm et al. [48] pointed out that TLR signaling is a fundamental link between innate and adaptive immunity, TLRs expression varies among different host cell.", [["cell", "ANATOMY", 155, 159], ["TLR", "GENE_OR_GENE_PRODUCT", 37, 40], ["TLRs", "GENE_OR_GENE_PRODUCT", 111, 115], ["host cell", "CELL", 150, 159], ["TLR", "PROTEIN", 37, 40], ["TLRs", "PROTEIN", 111, 115], ["host cell", "OBSERVATION", 150, 159]]], ["Several TLRs have been associated in antiviral immunity, TLR 2 are responsible for recognition of structural and non-structural viral protein which induce inflammatory cytokine production, TLR 2, 3, 4 and 9 identify specific forms of viral nucleic acids and are sacrosanct in recognizing viral genetic materials in endolysosomal compartment hence responsible for antiviral signaling [49] .4.0: DiscussionThe binding energy and molecular relatioship of the multi-epitope subunit vaccine with TLR (2, 3, 4 and 9) was probed by molecular docking.", [["endolysosomal compartment", "ANATOMY", 315, 340], ["nucleic acids", "CHEMICAL", 240, 253], ["TLRs", "GENE_OR_GENE_PRODUCT", 8, 12], ["TLR 2", "GENE_OR_GENE_PRODUCT", 57, 62], ["TLR 2", "GENE_OR_GENE_PRODUCT", 189, 194], ["3", "GENE_OR_GENE_PRODUCT", 196, 197], ["4", "GENE_OR_GENE_PRODUCT", 199, 200], ["9", "GENE_OR_GENE_PRODUCT", 205, 206], ["endolysosomal compartment", "MULTI-TISSUE_STRUCTURE", 315, 340], ["TLR", "GENE_OR_GENE_PRODUCT", 491, 494], ["TLRs", "PROTEIN", 8, 12], ["TLR 2", "PROTEIN", 57, 62], ["non-structural viral protein", "PROTEIN", 113, 141], ["inflammatory cytokine", "PROTEIN", 155, 176], ["TLR 2, 3, 4 and 9", "PROTEIN", 189, 206], ["multi-epitope subunit", "PROTEIN", 456, 477], ["TLR (2, 3, 4 and 9", "PROTEIN", 491, 509], ["antiviral immunity", "TREATMENT", 37, 55], ["TLR 2", "TREATMENT", 57, 62], ["structural and non-structural viral protein", "PROBLEM", 98, 141], ["inflammatory cytokine production", "PROBLEM", 155, 187], ["TLR", "TEST", 189, 192], ["viral nucleic acids", "PROBLEM", 234, 253], ["sacrosanct", "PROBLEM", 262, 272], ["antiviral signaling", "PROBLEM", 363, 382], ["The binding energy", "PROBLEM", 404, 422], ["the multi-epitope subunit vaccine", "TREATMENT", 452, 485], ["non-structural viral protein", "OBSERVATION", 113, 141], ["inflammatory", "OBSERVATION_MODIFIER", 155, 167], ["viral nucleic acids", "OBSERVATION", 234, 253], ["viral genetic materials", "OBSERVATION", 288, 311], ["endolysosomal compartment", "OBSERVATION", 315, 340]]], ["One model was selected from each of the docked complex on the basis of their proper receptor interactions, low binding energy and center energy scores [50] .", [["docked complex", "PROTEIN", 40, 54], ["low binding energy", "PROBLEM", 107, 125]]], ["Dynamics result showed a positive eigenvalue (2.27e-05; 2.06e-06; 2.03e-05; 1.53e-05) which is significant in the vaccine and rotation of the constructed vaccine which has been reported from several studies [51, 52, 53] .4.0: DiscussionHow soluble the over expressed recombinant protein in the E. coli host occur is critical for many biochemical and functional investigations, thus adapting the vaccine model into an E. coli expression system is an essential step in vaccine design and codon adaptation is one of the preferred ways to express the rate of foreign genes in a host, this is because when the codon used by the host differs from that of the organisms gene, minor expression rate may occur when the genes are not adapted.", [["E. coli", "ORGANISM", 294, 301], ["E. coli", "ORGANISM", 417, 424], ["recombinant protein", "PROTEIN", 267, 286], ["foreign genes", "DNA", 555, 568], ["organisms gene", "DNA", 653, 667], ["E. coli", "SPECIES", 294, 301], ["E. coli", "SPECIES", 417, 424], ["E. coli", "SPECIES", 294, 301], ["E. coli", "SPECIES", 417, 424], ["functional investigations", "TEST", 350, 375], ["the vaccine model", "TREATMENT", 391, 408], ["an E. coli expression system", "TREATMENT", 414, 442], ["an essential step in vaccine design", "TREATMENT", 446, 481], ["codon adaptation", "TREATMENT", 486, 502], ["the codon", "TREATMENT", 601, 610], ["minor expression rate", "PROBLEM", 669, 690], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["foreign genes", "OBSERVATION", 555, 568]]], ["Therefore we adapted the final vaccine protein sequences to E. coli strain K12 utilizing JCAT server and obtained results that was satisfactory.", [["E. coli", "ORGANISM", 60, 67], ["vaccine protein sequences", "DNA", 31, 56], ["E. coli", "SPECIES", 60, 67], ["E. coli", "SPECIES", 60, 67], ["K12", "SPECIES", 75, 78], ["the final vaccine protein sequences", "TREATMENT", 21, 56]]], ["JCAT also back-translated the protein sequences to nucleotides, the nucleotide was cloned into E. coli pET28a(+) vector J o u r n a l P r e -p r o o f XhoI and XbaI restriction sites, the total length of the clone was 7.2Kbp and is represented in red.", [["nucleotide", "CHEMICAL", 68, 78], ["nucleotides", "CHEMICAL", 51, 62], ["nucleotide", "CHEMICAL", 68, 78], ["JCAT", "GENE_OR_GENE_PRODUCT", 0, 4], ["E. coli", "ORGANISM", 95, 102], ["pET28a", "GENE_OR_GENE_PRODUCT", 103, 109], ["XhoI", "GENE_OR_GENE_PRODUCT", 151, 155], ["XbaI", "GENE_OR_GENE_PRODUCT", 160, 164], ["clone", "CELL", 208, 213], ["JCAT", "PROTEIN", 0, 4], ["P r e -p r o o f XhoI", "DNA", 134, 155], ["XbaI restriction sites", "DNA", 160, 182], ["E. coli", "SPECIES", 95, 102], ["E. coli", "SPECIES", 95, 102], ["JCAT", "TEST", 0, 4], ["nucleotides", "TREATMENT", 51, 62], ["the nucleotide", "TREATMENT", 64, 78], ["E. coli", "TEST", 95, 102], ["a l P r e -p", "TREATMENT", 130, 142], ["XhoI", "PROBLEM", 151, 155], ["XbaI restriction sites", "TREATMENT", 160, 182], ["the clone", "TEST", 204, 213], ["coli pET28a", "OBSERVATION", 98, 109], ["total", "OBSERVATION_MODIFIER", 188, 193], ["length", "OBSERVATION_MODIFIER", 194, 200], ["red", "OBSERVATION", 247, 250]]], ["The target sequence was encoded between 6-histidine residues, this would prove useful in purification purpose.4.0: DiscussionThe memory of the immune cells patterned by a mechanism that increases cell half-life and successful immune response is reflected by C-ImmSim.", [["immune cells", "ANATOMY", 143, 155], ["cell", "ANATOMY", 196, 200], ["6-histidine", "CHEMICAL", 40, 51], ["6-histidine", "CHEMICAL", 40, 51], ["6-histidine residues", "SIMPLE_CHEMICAL", 40, 60], ["immune cells", "CELL", 143, 155], ["cell", "CELL", 196, 200], ["C-ImmSim", "GENE_OR_GENE_PRODUCT", 258, 266], ["immune cells", "CELL_TYPE", 143, 155], ["C-ImmSim", "PROTEIN", 258, 266], ["6-histidine residues", "TREATMENT", 40, 60]]], ["The pathway enables some cells to live longer than others by increasing their half-life .", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["some cells", "PROBLEM", 20, 30]]], ["The primary response is designated by IgM, and the antigen clearance is a result of immunoglobulins secretion; a property of an increased B-cell population.", [["B-cell", "ANATOMY", 138, 144], ["IgM", "GENE_OR_GENE_PRODUCT", 38, 41], ["antigen", "GENE_OR_GENE_PRODUCT", 51, 58], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 84, 99], ["B-cell", "CELL", 138, 144], ["IgM", "PROTEIN", 38, 41], ["immunoglobulins", "PROTEIN", 84, 99], ["B-cell population", "CELL_TYPE", 138, 155], ["IgM", "TEST", 38, 41], ["the antigen clearance", "TEST", 47, 68], ["immunoglobulins secretion", "PROBLEM", 84, 109], ["an increased B-cell population", "PROBLEM", 125, 155], ["increased", "OBSERVATION_MODIFIER", 128, 137], ["B-cell population", "OBSERVATION", 138, 155]]], ["The steady rise in Th (helper) cell population with memory development was noticed and IFN-g was provoked after simulation (Figure 13a-d) .", [["Th (helper) cell", "ANATOMY", 19, 35], ["Th (helper) cell", "CELL", 19, 35], ["IFN-g", "GENE_OR_GENE_PRODUCT", 87, 92], ["Th (helper) cell population", "CELL_TYPE", 19, 46], ["IFN", "PROTEIN", 87, 90], ["steady", "OBSERVATION_MODIFIER", 4, 10], ["rise", "OBSERVATION_MODIFIER", 11, 15]]], ["B cells and T cells population were highly reactive with consistency in other immune cells.", [["B cells", "ANATOMY", 0, 7], ["T cells", "ANATOMY", 12, 19], ["immune cells", "ANATOMY", 78, 90], ["B cells", "CELL", 0, 7], ["T cells", "CELL", 12, 19], ["immune cells", "CELL", 78, 90], ["B cells", "CELL_TYPE", 0, 7], ["T cells", "CELL_TYPE", 12, 19], ["immune cells", "CELL_TYPE", 78, 90], ["B cells", "TEST", 0, 7], ["T cells population", "TEST", 12, 30], ["consistency in other immune cells", "PROBLEM", 57, 90], ["cells", "ANATOMY", 2, 7], ["reactive", "OBSERVATION_MODIFIER", 43, 51], ["immune cells", "OBSERVATION", 78, 90]]], ["The IFN-g which is capable of inducing and modulating an array of immune response that was observed in this study, is different from the IFN-c reported by Peele et al. [54] .", [["IFN-g", "GENE_OR_GENE_PRODUCT", 4, 9], ["IFN-c", "GENE_OR_GENE_PRODUCT", 137, 142], ["IFN", "PROTEIN", 4, 7], ["IFN", "PROTEIN", 137, 140], ["The IFN-g", "TREATMENT", 0, 9], ["immune response", "PROBLEM", 66, 81], ["this study", "TEST", 103, 113], ["immune response", "OBSERVATION", 66, 81]]], ["Also the difference in data output could be due to administration of successive dose at intervals compared to the single dose administered in our study.", [["data output", "TEST", 23, 34], ["our study", "TEST", 142, 151], ["difference", "OBSERVATION_MODIFIER", 9, 19]]], ["However, it was observed that the B cell lymphocyte curve was maintained with time (which is an indication of a stable/prolonged half-life and invariably the efficacy of the vaccine prototype within the host cell with time), contrary to the curve in the report of Peele et al. [54] .4.0: DiscussionTransforming growth factor (TGF) is responsible for sustaining tolerance against self and mild antigen and in controlling immune responses to pathogen.", [["B cell lymphocyte", "ANATOMY", 34, 51], ["cell", "ANATOMY", 208, 212], ["B cell lymphocyte", "CELL", 34, 51], ["cell", "CELL", 208, 212], ["Transforming growth factor", "GENE_OR_GENE_PRODUCT", 298, 324], ["TGF", "GENE_OR_GENE_PRODUCT", 326, 329], ["Transforming growth factor", "PROTEIN", 298, 324], ["TGF", "PROTEIN", 326, 329], ["the B cell lymphocyte curve", "TEST", 30, 57], ["the vaccine prototype", "TREATMENT", 170, 191], ["self and mild antigen", "PROBLEM", 379, 400], ["pathogen", "PROBLEM", 440, 448], ["cell lymphocyte", "OBSERVATION", 36, 51], ["stable", "OBSERVATION_MODIFIER", 112, 118]]], ["Interleukin (IL 2, 4, 10 & 12) maintains the propagation, enhancement of cytotoxicity, IFN-g secretion, and antibody production; Immune suppression, decreases antigen presentation and MHC class II expression of dendritic cells, down-regulates pathogenic Th (1, 2, 17) responses.", [["dendritic cells", "ANATOMY", 211, 226], ["Interleukin (IL 2", "GENE_OR_GENE_PRODUCT", 0, 17], ["4", "GENE_OR_GENE_PRODUCT", 19, 20], ["IFN-g", "GENE_OR_GENE_PRODUCT", 87, 92], ["MHC class II", "GENE_OR_GENE_PRODUCT", 184, 196], ["dendritic cells", "CELL", 211, 226], ["IFN", "PROTEIN", 87, 90], ["MHC class II", "PROTEIN", 184, 196], ["dendritic cells", "CELL_TYPE", 211, 226], ["Interleukin (IL", "TREATMENT", 0, 15], ["cytotoxicity", "PROBLEM", 73, 85], ["IFN", "TEST", 87, 90], ["g secretion", "PROBLEM", 91, 102], ["antibody production", "PROBLEM", 108, 127], ["Immune suppression", "PROBLEM", 129, 147], ["dendritic cells", "PROBLEM", 211, 226], ["cytotoxicity", "OBSERVATION", 73, 85], ["dendritic cells", "OBSERVATION", 211, 226]]], ["IL (4&10) has specific antiinflammatory properties by suppressing the expression of inflammatory cytokines.", [["IL", "GENE_OR_GENE_PRODUCT", 0, 2], ["inflammatory cytokines", "PROTEIN", 84, 106], ["specific antiinflammatory properties", "TREATMENT", 14, 50], ["inflammatory cytokines", "PROBLEM", 84, 106], ["inflammatory cytokines", "OBSERVATION", 84, 106]]], ["IL12 stimulates cytokine secretion and boosts cytotoxic activity enhancing T and NK cells for IFN-g production which promotes Th1 differentiation and plays functional interaction between the innate and adaptive immunity [55] .", [["T", "ANATOMY", 75, 76], ["NK cells", "ANATOMY", 81, 89], ["IL12", "GENE_OR_GENE_PRODUCT", 0, 4], ["T", "CELL", 75, 76], ["NK cells", "CELL", 81, 89], ["IFN-g", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL12", "PROTEIN", 0, 4], ["cytokine", "PROTEIN", 16, 24], ["T and NK cells", "CELL_TYPE", 75, 89], ["IFN", "PROTEIN", 94, 97], ["cytokine secretion", "TEST", 16, 34], ["IFN", "PROBLEM", 94, 97], ["g production", "PROBLEM", 98, 110]]], ["Immune simulation results authenticates consistency with actual immune responses.ConclusionEradicating SARS-COV-2 will be unachievable unless novel control methods are implemented among which vaccine should be taking as very important because the number of infected people are still very few compared to the uninfected at the risk of being infected due to the high rate of J o u r n a l P r e -p r o o f transmission resulting from it being extremely contagious.", [["SARS", "DISEASE", 103, 107], ["COV-2", "CELL", 108, 113], ["people", "ORGANISM", 266, 272], ["people", "SPECIES", 266, 272], ["Immune simulation", "TEST", 0, 17], ["novel control methods", "TREATMENT", 142, 163], ["transmission", "PROBLEM", 404, 416], ["infected", "OBSERVATION", 257, 265], ["infected", "OBSERVATION", 340, 348]]], ["In this research, immunoinformatics approach was employed to construct a potential vaccine using the spike glycoproteins coding for multiple T-cell (HTL and CTL) and B-cell epitopes.", [["T-cell", "ANATOMY", 141, 147], ["HTL", "ANATOMY", 149, 152], ["CTL", "ANATOMY", 157, 160], ["B-cell", "ANATOMY", 166, 172], ["T-cell", "CELL", 141, 147], ["HTL", "CELL", 149, 152], ["CTL", "CELL", 157, 160], ["B-cell", "CELL", 166, 172], ["spike glycoproteins", "PROTEIN", 101, 120], ["multiple T-cell (HTL and CTL) and B-cell epitopes", "PROTEIN", 132, 181], ["immunoinformatics approach", "TREATMENT", 18, 44], ["a potential vaccine", "TREATMENT", 71, 90], ["the spike glycoproteins", "TREATMENT", 97, 120], ["multiple T-cell (HTL and CTL)", "TREATMENT", 132, 161], ["B-cell epitopes", "TREATMENT", 166, 181], ["cell epitopes", "OBSERVATION", 168, 181]]], ["The vaccine peptide has potential to confer prophylactic benefits.", [["The vaccine peptide", "TREATMENT", 0, 19], ["prophylactic benefits", "TREATMENT", 44, 65]]], ["Howbeit, this a priori computational work requires experimental validation to substantiate this study, and this may include the development of the designed subunit vaccine followed by in vitro and in vivo study to establish the immunogenicity and safety of potential vaccine.", [["this study", "TEST", 91, 101], ["the designed subunit vaccine", "TREATMENT", 143, 171], ["vivo study", "TEST", 200, 210], ["potential vaccine", "TREATMENT", 257, 274]]]], "f6f1ec12291f743de1504003929ea654217f2af6": [["4 map corresponding regions in the 2019-nCoV sequences, and predict likely epitopes.", [["2019-nCoV sequences", "DNA", 35, 54], ["epitopes", "PROTEIN", 75, 83], ["the 2019-nCoV sequences", "TEST", 31, 54], ["epitopes", "PROBLEM", 75, 83]]], ["We also used validated bioinformatic tools to predict B and T cell epitopes that are likely to be recognized in humans, and to assess the conservation of these epitopes across different coronavirus species.", [["T cell", "ANATOMY", 60, 66], ["B", "CELL", 54, 55], ["T cell", "CELL", 60, 66], ["humans", "ORGANISM", 112, 118], ["coronavirus", "ORGANISM", 186, 197], ["B and T cell epitopes", "PROTEIN", 54, 75], ["epitopes", "PROTEIN", 160, 168], ["humans", "SPECIES", 112, 118], ["humans", "SPECIES", 112, 118], ["B and T cell epitopes", "TREATMENT", 54, 75], ["these epitopes across different coronavirus species", "PROBLEM", 154, 205], ["coronavirus species", "OBSERVATION", 186, 205]]]], "PMC7127789": [["Blood Component Recalls: 20 Years of ProgressThe term recall is commonly used generically to refer to notices from blood suppliers to consignees about blood components.", [["Blood", "ANATOMY", 0, 5], ["blood", "ANATOMY", 115, 120], ["blood", "ANATOMY", 151, 156], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["blood", "ORGANISM_SUBSTANCE", 151, 156]]], ["Market withdrawals are not published.Blood Component Recalls: 20 Years of Progress", [["Blood", "ANATOMY", 37, 42], ["Blood", "ORGANISM_SUBSTANCE", 37, 42], ["Market withdrawals", "PROBLEM", 0, 18], ["withdrawals", "OBSERVATION", 7, 18]]]], "PMC7334643": [["For the medical field and society as a whole, 2020 will be remembered as the year of the COVID-19 coronavirus pandemic, yet for genitourinary medical oncologists, 2020 also brings encouraging therapeutic advances for our patients with advanced prostate, bladder, and renal cell carcinomas (RCC).", [["prostate", "ANATOMY", 244, 252], ["bladder", "ANATOMY", 254, 261], ["renal cell carcinomas", "ANATOMY", 267, 288], ["RCC", "ANATOMY", 290, 293], ["coronavirus pandemic", "DISEASE", 98, 118], ["prostate, bladder, and renal cell carcinomas", "DISEASE", 244, 288], ["RCC", "DISEASE", 290, 293], ["COVID-19 coronavirus", "ORGANISM", 89, 109], ["patients", "ORGANISM", 221, 229], ["prostate", "CANCER", 244, 252], ["bladder", "ORGAN", 254, 261], ["renal cell carcinomas", "CANCER", 267, 288], ["RCC", "CANCER", 290, 293], ["patients", "SPECIES", 221, 229], ["COVID-19 coronavirus", "SPECIES", 89, 109], ["advanced prostate, bladder", "PROBLEM", 235, 261], ["renal cell carcinomas", "PROBLEM", 267, 288], ["prostate", "ANATOMY", 244, 252], ["bladder", "ANATOMY", 254, 261], ["renal", "ANATOMY", 267, 272], ["cell carcinomas", "OBSERVATION", 273, 288]]], ["Prior to 2020, the last time a novel treatment was approved for patients with metastatic castration-resistant prostate cancer (mCRPC) was 2014.", [["metastatic castration-resistant prostate cancer", "ANATOMY", 78, 125], ["mCRPC", "ANATOMY", 127, 132], ["castration-resistant prostate cancer", "DISEASE", 89, 125], ["mCRPC", "DISEASE", 127, 132], ["patients", "ORGANISM", 64, 72], ["metastatic castration-resistant prostate cancer", "CANCER", 78, 125], ["mCRPC", "CANCER", 127, 132], ["patients", "SPECIES", 64, 72], ["a novel treatment", "TREATMENT", 29, 46], ["metastatic castration", "TREATMENT", 78, 99], ["resistant prostate cancer", "PROBLEM", 100, 125], ["metastatic", "OBSERVATION_MODIFIER", 78, 88], ["prostate", "ANATOMY", 110, 118], ["cancer", "OBSERVATION", 119, 125]]], ["In 2020, two PARP inhibitors, olaparib and rucaparib, were approved by the US Food and Drug Administration (FDA) for the treatment of mCRPC.", [["mCRPC", "ANATOMY", 134, 139], ["olaparib", "CHEMICAL", 30, 38], ["rucaparib", "CHEMICAL", 43, 52], ["mCRPC", "DISEASE", 134, 139], ["olaparib", "CHEMICAL", 30, 38], ["rucaparib", "CHEMICAL", 43, 52], ["PARP", "GENE_OR_GENE_PRODUCT", 13, 17], ["olaparib", "SIMPLE_CHEMICAL", 30, 38], ["rucaparib", "SIMPLE_CHEMICAL", 43, 52], ["mCRPC", "CANCER", 134, 139], ["two PARP inhibitors", "TREATMENT", 9, 28], ["olaparib and rucaparib", "TREATMENT", 30, 52], ["the treatment of mCRPC", "TREATMENT", 117, 139]]], ["Over the past few years, multiple novel therapeutic classes were added for patients with platinum-refractory metastatic urothelial carcinoma (mUC); however, a first-line treatment had not improved overall survival (OS) compared to platinum-based chemotherapy until the JAVELIN Bladder 100 trial was presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting in 2020.", [["metastatic urothelial carcinoma", "ANATOMY", 109, 140], ["mUC", "ANATOMY", 142, 145], ["Bladder", "ANATOMY", 277, 284], ["platinum", "CHEMICAL", 89, 97], ["urothelial carcinoma", "DISEASE", 120, 140], ["mUC", "DISEASE", 142, 145], ["platinum", "CHEMICAL", 231, 239], ["platinum", "CHEMICAL", 89, 97], ["platinum", "CHEMICAL", 231, 239], ["patients", "ORGANISM", 75, 83], ["urothelial carcinoma", "CANCER", 120, 140], ["mUC", "CANCER", 142, 145], ["platinum", "SIMPLE_CHEMICAL", 231, 239], ["patients", "SPECIES", 75, 83], ["multiple novel therapeutic classes", "PROBLEM", 25, 59], ["platinum", "TREATMENT", 89, 97], ["refractory metastatic urothelial carcinoma", "PROBLEM", 98, 140], ["a first-line treatment", "TREATMENT", 157, 179], ["platinum-based chemotherapy", "TREATMENT", 231, 258], ["the JAVELIN Bladder", "TREATMENT", 265, 284], ["refractory", "OBSERVATION_MODIFIER", 98, 108], ["metastatic", "OBSERVATION_MODIFIER", 109, 119], ["urothelial", "ANATOMY", 120, 130], ["carcinoma", "OBSERVATION", 131, 140], ["Bladder", "ANATOMY", 277, 284]]], ["Herein, we will briefly review these studies as an introduction to the more in-depth articles available in this special issue of Cancer Treatments and Research Communications.", [["Cancer", "DISEASE", 129, 135], ["Cancer", "CANCER", 129, 135], ["these studies", "TEST", 31, 44], ["Cancer Treatments", "TREATMENT", 129, 146], ["Cancer", "OBSERVATION", 129, 135]]]], "6d0a486ca43b88008946756ae10736715f886ff8": [["coronavirus case numbers.", [["coronavirus", "ORGANISM", 0, 11], ["coronavirus", "SPECIES", 0, 11], ["coronavirus", "SPECIES", 0, 11]]], ["Based on these models and predictions, we also question the reluctance of Canadian policy makers to learn from jurisdictions such as Taiwan and Hong Kong, where the COVID-19 outbreak appears to have been brought under control.", [["the COVID", "TEST", 161, 170]]], ["6 These countries have also extensively adopted face masks for the wider public, which along with hand hygiene are demonstrated to be effective against viral spread.", [["hand", "ANATOMY", 98, 102], ["hand", "ORGANISM_SUBDIVISION", 98, 102], ["face masks", "TREATMENT", 48, 58], ["hand hygiene", "TREATMENT", 98, 110], ["viral spread", "PROBLEM", 152, 164]]], ["7, 8Methodology and Results.Methodology and ResultsIn order to predict the trajectory of COVID-19 in Canada, we fit an exponential model to data on COVID-19 cases, in line with prior literature, which suggests that an epidemic's early stages can be exponential.", [["COVID", "TEST", 89, 94], ["COVID", "TEST", 148, 153], ["an epidemic's", "PROBLEM", 215, 228]]], ["9 This fit is conducted via non-linear least squares estimation using the statistical package R. In particular, consider the following exponential model:Methodology and Resultswhere y is the number of confirmed COVID-19 cases, and X is the number of days that the region has had the novel coronavirus.", [["coronavirus", "DISEASE", 289, 300], ["coronavirus", "ORGANISM", 289, 300], ["COVID", "TEST", 211, 216], ["the novel coronavirus", "PROBLEM", 279, 300], ["coronavirus", "OBSERVATION", 289, 300]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 27, 2020. .(which was not certified by peer review)The number of those infected with COVID-19 has been published daily since January 25, 2020.", [["CC", "CHEMICAL", 0, 2], ["COVID-19", "CHEMICAL", 351, 359], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["COVID", "TEST", 351, 356], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infected", "OBSERVATION", 337, 345]]], ["Based on these data from government sources, we can calculate the exponential fit for these cases, as seen in Appendix, Figure 1 .", [["Appendix", "ANATOMY", 110, 118]]], ["The parameter values from this fit are shown in Table 1 .", [["The parameter values", "TEST", 0, 20]]], ["For policymakers to get a sense of how quickly the number of cases can grow across time, consider Appendix Figure 2 .", [["Appendix", "ANATOMY", 98, 106]]], ["On March 20, 2020, there were 1,087 cases of SARS-CoV-2 in Canada.", [["SARS", "DISEASE", 45, 49], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "TEST", 45, 49], ["CoV", "TEST", 50, 53]]], ["As of March 20, 2020, 92 percent of Canada's COVID-19 cases come from these four provinces.", [["Canada's COVID", "TEST", 36, 50]]], ["These four provinces also contain 86 percent of Canada's population, and contain a number of other factors that make them more susceptible to disease transmission: densely populated urban areas, international and national travel hubs, and immigration.", [["Canada's population", "TREATMENT", 48, 67], ["densely", "OBSERVATION_MODIFIER", 164, 171], ["populated", "OBSERVATION_MODIFIER", 172, 181], ["urban", "OBSERVATION_MODIFIER", 182, 187]]], ["The same non-linear least squares method was applied to each individual province's number of COVID-19 case numbers, with results shown in Appendix Figure 3 (British Columbia), Figure 4 (Ontario), Figure 5 (Alberta), and Figure 6 (Quebec).", [["COVID", "TEST", 93, 98], ["Appendix", "ANATOMY", 138, 146]]], ["In each of these provinces, an exponential fit appears to model the data well, strongly suggesting good prediction..As with any discussion of exponential virus growth, it is difficult to predict exactly when the peak of the outbreak will take place in Canada.", [["exponential virus growth", "PROBLEM", 142, 166]]], ["However our models are consistent with other models of exponential growth, including those from Italy where the exponential growth pattern continues unabated.", [["exponential growth", "PROBLEM", 55, 73], ["the exponential growth pattern", "PROBLEM", 108, 138], ["consistent with", "UNCERTAINTY", 23, 38], ["exponential", "OBSERVATION_MODIFIER", 55, 66], ["growth", "OBSERVATION_MODIFIER", 67, 73]]], ["Both these nations have used a multitude of early, aggressive interventions including rapid border controls, social distancing, the innovative and population-wide use of smart phone technology and the ubiquitous wearing of surgical masks in healthcare settings as well as the general population.", [["aggressive interventions", "TREATMENT", 51, 75], ["rapid border controls", "TREATMENT", 86, 107], ["smart phone technology", "TREATMENT", 170, 192], ["surgical masks", "TREATMENT", 223, 237]]], ["In particular, there is not yet any attempt to mobilize smart phone technology or use face masks for all healthcare workers.", [["face masks", "TREATMENT", 86, 96]]], ["Face masks have been shown to reduce infection rates in influenza epidemics and WHO officials have been shown in news media to be wearing face masks whilst addressing news 3 .", [["infection", "DISEASE", 37, 46], ["influenza", "DISEASE", 56, 65], ["Face masks", "TREATMENT", 0, 10], ["infection rates in influenza epidemics", "PROBLEM", 37, 75], ["infection", "OBSERVATION", 37, 46]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 27, 2020. . conferences.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Smart phone technology adapted to Canadian needs would involve the creation of a national-level app which can be downloaded and used to track COVID-19 cases in real time, provide uniform updates on public policy and announcements; and make simple, consistent messaging available on a national scale.", [["a national scale", "TREATMENT", 282, 298]]], ["The ubiquitous use of face masks, at least in healthcare settings is a rapid adoption NPI which can have major impacts on COVID-19 related morbidity and mortality in Canada and elsewhere.", [["face masks", "TREATMENT", 22, 32], ["a rapid adoption NPI", "TREATMENT", 69, 89], ["COVID", "TEST", 122, 127]]], ["11 Policymakers in Canada should also implement a rapid roll out of policies that harness the power of smart phone technology [12] [13] [14] [15] and the wearing of face masks by the public.", [["face masks", "TREATMENT", 165, 175]]], ["Unfortunately, the messaging in Canada has been counterproductive and has included various versions of \"face masks don't work unless properly used.\"", [["\"face masks", "TREATMENT", 103, 114]]], ["This is the same as claiming that hand washing does not work, unless properly carried out.", [["hand", "ANATOMY", 34, 38]]], ["Mandating healthcare workers to wear a mask in work places is a good start.", [["a mask", "TREATMENT", 37, 43]]], ["Failure to make bold and rapid moves based on the successful measures that have been implemented in Taiwan and Hong Kong is likely to prove very costly in terms of overloaded ICU resources, public mistrust of health officials and an exponential increase in morbidity and mortality, the latter of which were observed in countries like Italy.4.", [["Failure to make bold and rapid moves", "PROBLEM", 0, 36], ["an exponential increase in morbidity", "PROBLEM", 230, 266], ["exponential", "OBSERVATION_MODIFIER", 233, 244], ["increase", "OBSERVATION_MODIFIER", 245, 253], ["morbidity", "OBSERVATION", 257, 266]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)4The copyright holder for this preprint this version posted March 27, 2020. . https://doi.org/10.1101/2020.03.21.20040667 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 203, 223], ["medRxiv", "TREATMENT", 329, 336], ["med", "ANATOMY", 105, 108]]]], "PMC7236693": [], "52d1c87f7efab1d1340615324e5313f22444cf44": [["INTRODUCTIONimmune responses and on their interference with experimental models of infection.", [["infection", "DISEASE", 83, 92], ["infection", "PROBLEM", 83, 92], ["infection", "OBSERVATION", 83, 92]]], ["Most reports deal with virulent laboratory Mouse hepatitis virus (MHV ) collectively designates corona strains, although more recently, attenuated MHV laboratory viruses of a wide range of virulence.", [["Mouse hepatitis virus", "DISEASE", 43, 64], ["laboratory", "ORGANISM", 32, 42], ["Mouse hepatitis virus", "ORGANISM", 43, 64], ["MHV", "ORGANISM", 66, 69], ["corona strains", "ORGANISM", 96, 110], ["MHV", "ORGANISM", 147, 150], ["Mouse hepatitis virus", "SPECIES", 43, 64], ["Mouse hepatitis virus", "SPECIES", 43, 64], ["MHV", "SPECIES", 66, 69], ["MHV", "SPECIES", 147, 150], ["virulent laboratory Mouse hepatitis virus", "PROBLEM", 23, 64], ["corona strains", "PROBLEM", 96, 110], ["virulence", "PROBLEM", 189, 198], ["corona strains", "OBSERVATION", 96, 110], ["wide", "OBSERVATION_MODIFIER", 175, 179]]], ["The strains that are strains have been used in an attempt to mimic the prevalent endemic in most mouse colonies over the world show relatively strains.", [["colonies", "ANATOMY", 103, 111], ["mouse", "ORGANISM", 97, 102], ["mouse", "SPECIES", 97, 102], ["mouse", "SPECIES", 97, 102], ["The strains", "PROBLEM", 0, 11], ["strains", "PROBLEM", 21, 28]]], ["2 The objective of this study was to investigate the low virulence and animals from infected colonies do not effects of a natural acute outbreak of MHV due to accidental present overt signs of illness.", [["colonies", "ANATOMY", 93, 101], ["MHV", "DISEASE", 148, 151], ["illness", "DISEASE", 193, 200], ["MHV", "ORGANISM", 148, 151], ["MHV", "SPECIES", 148, 151], ["this study", "TEST", 19, 29], ["the low virulence", "PROBLEM", 49, 66], ["infected colonies", "PROBLEM", 84, 101], ["illness", "PROBLEM", 193, 200], ["infected colonies", "OBSERVATION", 84, 101], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["illness", "OBSERVATION", 193, 200]]], ["Nevertheless, although tolerated exposure, in our otherwise specific-pathogen-free (SPF ) inbred by many researchers, evidence has accumulated over the years mouse colonies, and of enzootic chronic MHV infection on that results from several investigation areas can be comprocytokine production and resistance to the intracellular pathomised by concomitant MHV infections.", [["colonies", "ANATOMY", 164, 172], ["intracellular", "ANATOMY", 316, 329], ["MHV infection", "DISEASE", 198, 211], ["comprocytokine", "CHEMICAL", 268, 282], ["MHV infections", "DISEASE", 356, 370], ["mouse", "ORGANISM", 158, 163], ["MHV", "ORGANISM", 198, 201], ["comprocytokine", "SIMPLE_CHEMICAL", 268, 282], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 316, 329], ["MHV", "ORGANISM", 356, 359], ["mouse", "SPECIES", 158, 163], ["mouse", "SPECIES", 158, 163], ["MHV", "SPECIES", 198, 201], ["MHV", "SPECIES", 356, 359], ["enzootic chronic MHV infection", "PROBLEM", 181, 211], ["comprocytokine production", "PROBLEM", 268, 293], ["concomitant MHV infections", "PROBLEM", 344, 370], ["enzootic", "OBSERVATION_MODIFIER", 181, 189], ["chronic", "OBSERVATION_MODIFIER", 190, 197], ["MHV", "OBSERVATION_MODIFIER", 198, 201], ["infection", "OBSERVATION", 202, 211], ["MHV", "OBSERVATION_MODIFIER", 356, 359], ["infections", "OBSERVATION", 360, 370]]], ["In particular, the gen Trypanosoma cruzi. study of immunological parameters that determine resistance Trypanosoma cruzi is a dygenetic protozoan that infects to infections can be seriously affected by MHV infection several kinds of mammals and is the aetiological agent of (reviewed in refs 1,2) .", [["Trypanosoma cruzi", "DISEASE", 23, 40], ["Trypanosoma cruzi", "DISEASE", 102, 119], ["infections", "DISEASE", 161, 171], ["MHV infection", "DISEASE", 201, 214], ["Trypanosoma cruzi", "ORGANISM", 23, 40], ["Trypanosoma cruzi", "ORGANISM", 102, 119], ["MHV", "ORGANISM", 201, 204], ["Trypanosoma cruzi", "SPECIES", 23, 40], ["Trypanosoma cruzi", "SPECIES", 102, 119], ["Trypanosoma cruzi", "SPECIES", 23, 40], ["Trypanosoma cruzi", "SPECIES", 102, 119], ["MHV", "SPECIES", 201, 204], ["the gen Trypanosoma cruzi", "PROBLEM", 15, 40], ["study of immunological parameters", "TEST", 42, 75], ["resistance Trypanosoma cruzi", "PROBLEM", 91, 119], ["a dygenetic protozoan", "PROBLEM", 123, 144], ["infections", "PROBLEM", 161, 171], ["MHV infection", "PROBLEM", 201, 214], ["MHV", "OBSERVATION_MODIFIER", 201, 204], ["infection", "OBSERVATION", 205, 214]]], ["There are few studies on the effects of Chagas' disease in man.", [["Chagas' disease", "DISEASE", 40, 55], ["man", "ORGANISM", 59, 62], ["man", "SPECIES", 59, 62], ["few studies", "TEST", 10, 21], ["Chagas' disease", "PROBLEM", 40, 55], ["few", "OBSERVATION_MODIFIER", 10, 13]]], ["3 The parasite replicates in the cytoinfection by natural-low-virulence enzootic MHV strains on plasm of virtually any nucleated cell type including macrophages; non-dividing forms of the parasite are found free in more resistant.6 Susceptible mice have higher parasite numbers 3), pneumonia virus of mice (PVM ), minute virus of mice (MVM ), lymphocytic chorio-meningitis virus (LCMV ), in the blood and tissues and most animals die within 6 weeks of inoculation of as few as 50 parasites; in contrast, resistant Sendai virus, Ectromelia virus, mouse polio virus (GD7), and on ELISA for the bacteria Mycoplasma pulmonis.", [["plasm", "ANATOMY", 96, 101], ["cell", "ANATOMY", 129, 133], ["macrophages", "ANATOMY", 149, 160], ["blood", "ANATOMY", 395, 400], ["tissues", "ANATOMY", 405, 412], ["pneumonia", "DISEASE", 282, 291], ["chorio-meningitis", "DISEASE", 355, 372], ["MHV", "ORGANISM", 81, 84], ["plasm", "ORGANISM_SUBSTANCE", 96, 101], ["cell type", "CELL", 129, 138], ["macrophages", "CELL", 149, 160], ["mice", "ORGANISM", 244, 248], ["pneumonia virus", "ORGANISM", 282, 297], ["mice", "ORGANISM", 301, 305], ["PVM", "ORGANISM_SUBDIVISION", 307, 310], ["minute virus", "ORGANISM", 314, 326], ["mice", "ORGANISM", 330, 334], ["MVM", "ORGANISM", 336, 339], ["lymphocytic chorio-meningitis virus", "ORGANISM", 343, 378], ["LCMV", "ORGANISM", 380, 384], ["blood", "ORGANISM_SUBSTANCE", 395, 400], ["tissues", "TISSUE", 405, 412], ["Sendai virus", "ORGANISM", 514, 526], ["Ectromelia virus", "ORGANISM", 528, 544], ["mouse polio virus", "ORGANISM", 546, 563], ["GD7", "ORGANISM", 565, 568], ["Mycoplasma pulmonis", "ORGANISM", 601, 620], ["macrophages", "CELL_TYPE", 149, 160], ["mice", "SPECIES", 244, 248], ["mice", "SPECIES", 301, 305], ["mice", "SPECIES", 330, 334], ["chorio-meningitis virus", "SPECIES", 355, 378], ["Sendai virus", "SPECIES", 514, 526], ["Ectromelia virus", "SPECIES", 528, 544], ["mouse", "SPECIES", 546, 551], ["polio virus", "SPECIES", 552, 563], ["Mycoplasma pulmonis", "SPECIES", 601, 620], ["MHV", "SPECIES", 81, 84], ["mice", "SPECIES", 244, 248], ["mice", "SPECIES", 301, 305], ["mice", "SPECIES", 330, 334], ["MVM", "SPECIES", 336, 339], ["chorio-meningitis virus", "SPECIES", 355, 378], ["LCMV", "SPECIES", 380, 384], ["Sendai virus", "SPECIES", 514, 526], ["Ectromelia virus", "SPECIES", 528, 544], ["mouse polio virus", "SPECIES", 546, 563], ["Mycoplasma pulmonis", "SPECIES", 601, 620], ["virulence enzootic MHV strains", "PROBLEM", 62, 92], ["the parasite", "PROBLEM", 184, 196], ["higher parasite numbers", "PROBLEM", 254, 277], ["pneumonia virus of mice (PVM )", "PROBLEM", 282, 312], ["minute virus of mice (MVM", "PROBLEM", 314, 339], ["lymphocytic chorio", "PROBLEM", 343, 361], ["meningitis virus", "PROBLEM", 362, 378], ["LCMV", "PROBLEM", 380, 384], ["the blood and tissues", "PROBLEM", 391, 412], ["inoculation", "PROBLEM", 452, 463], ["resistant Sendai virus", "PROBLEM", 504, 526], ["Ectromelia virus", "PROBLEM", 528, 544], ["mouse polio virus", "PROBLEM", 546, 563], ["ELISA", "TEST", 578, 583], ["the bacteria Mycoplasma pulmonis", "PROBLEM", 588, 620], ["parasite", "OBSERVATION_MODIFIER", 6, 14], ["enzootic MHV", "OBSERVATION", 72, 84], ["nucleated cell type", "OBSERVATION", 119, 138], ["macrophages", "OBSERVATION", 149, 160], ["parasite", "OBSERVATION_MODIFIER", 188, 196], ["more resistant", "OBSERVATION_MODIFIER", 215, 229], ["pneumonia", "OBSERVATION", 282, 291], ["lymphocytic chorio", "OBSERVATION", 343, 361], ["meningitis", "OBSERVATION", 362, 372], ["blood", "ANATOMY", 395, 400], ["tissues", "ANATOMY", 405, 412], ["Sendai virus", "OBSERVATION", 514, 526], ["Ectromelia virus", "OBSERVATION", 528, 544], ["pulmonis", "ANATOMY", 612, 620]]], ["All pro-mice have lower parasite loads and survive infection with 50 000 parasites.7 Both T. cruzi-resistant and -susceptible cedures with the animals were in accordance with the principles of the 'Brazilian Code of Laboratory Animals Use'. mouse strains show elevated production of interferon-c (IFN-c) during infection8 and very low interleukin-2 (IL-2) and IL-4 production.8-11 IFN-c and tumour necrosis factor-a Trypanosoma cruzi infection, parasitaemia counting and experimental design (TNF-a), triggered by IL-12, are essential to control of parasitism by innate and acquired cellular immune systems in Infective blood trypomastigotes were obtained from Y strain T. cruzi-infected anaesthetized mice by drawing cardiac blood; mice.12-14 IL-10 exerts an important in vivo regulatory role on IFN-c and nitric oxide production12,15 and its absence in motile blood forms were counted and the desired number of parasites was injected intraperitoneally (i.p.).", [["pro-mice", "ANATOMY", 4, 12], ["cellular", "ANATOMY", 582, 590], ["blood trypomastigotes", "ANATOMY", 619, 640], ["cardiac blood", "ANATOMY", 717, 730], ["blood", "ANATOMY", 861, 866], ["infection", "DISEASE", 51, 60], ["tumour necrosis", "DISEASE", 391, 406], ["Trypanosoma cruzi infection", "DISEASE", 416, 443], ["parasitaemia", "DISEASE", 445, 457], ["nitric oxide", "CHEMICAL", 806, 818], ["nitric oxide", "CHEMICAL", 806, 818], ["pro-mice", "CANCER", 4, 12], ["cedures", "CANCER", 126, 133], ["mouse", "ORGANISM", 241, 246], ["interferon-c", "GENE_OR_GENE_PRODUCT", 283, 295], ["IFN-c", "GENE_OR_GENE_PRODUCT", 297, 302], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 335, 348], ["IL-2", "GENE_OR_GENE_PRODUCT", 350, 354], ["IL-4", "GENE_OR_GENE_PRODUCT", 360, 364], ["IFN-c", "GENE_OR_GENE_PRODUCT", 381, 386], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 391, 413], ["Trypanosoma cruzi", "ORGANISM", 416, 433], ["TNF", "GENE_OR_GENE_PRODUCT", 492, 495], ["IL-12", "GENE_OR_GENE_PRODUCT", 513, 518], ["cellular", "CELL", 582, 590], ["blood trypomastigotes", "ORGANISM_SUBSTANCE", 619, 640], ["Y strain T.", "ORGANISM", 660, 671], ["cruzi-infected anaesthetized mice", "ORGANISM", 672, 705], ["blood", "ORGANISM_SUBSTANCE", 725, 730], ["mice", "ORGANISM", 732, 736], ["IL-10", "GENE_OR_GENE_PRODUCT", 743, 748], ["IFN-c", "GENE_OR_GENE_PRODUCT", 796, 801], ["nitric oxide", "SIMPLE_CHEMICAL", 806, 818], ["12,15", "SIMPLE_CHEMICAL", 829, 834], ["blood", "ORGANISM_SUBSTANCE", 861, 866], ["interferon-c (IFN-c", "PROTEIN", 283, 302], ["IFN", "PROTEIN", 381, 384], ["tumour necrosis factor", "PROTEIN", 391, 413], ["TNF", "PROTEIN", 492, 495], ["IL", "PROTEIN", 513, 515], ["IFN", "PROTEIN", 796, 799], ["mouse", "SPECIES", 241, 246], ["Trypanosoma cruzi", "SPECIES", 416, 433], ["mice", "SPECIES", 701, 705], ["mice", "SPECIES", 732, 736], ["mouse", "SPECIES", 241, 246], ["Trypanosoma cruzi", "SPECIES", 416, 433], ["mice", "SPECIES", 701, 705], ["mice", "SPECIES", 732, 736], ["lower parasite loads", "PROBLEM", 18, 38], ["survive infection", "PROBLEM", 43, 60], ["mouse strains", "PROBLEM", 241, 254], ["elevated production of interferon", "PROBLEM", 260, 293], ["c (IFN-c) during infection8", "PROBLEM", 294, 321], ["very low interleukin", "PROBLEM", 326, 346], ["IL", "TEST", 350, 352], ["tumour necrosis factor", "PROBLEM", 391, 413], ["Trypanosoma cruzi infection", "PROBLEM", 416, 443], ["parasitaemia counting", "PROBLEM", 445, 466], ["experimental design (TNF", "PROBLEM", 471, 495], ["parasitism", "PROBLEM", 548, 558], ["acquired cellular immune systems", "PROBLEM", 573, 605], ["Infective blood trypomastigotes", "PROBLEM", 609, 640], ["IFN", "TREATMENT", 796, 799], ["nitric oxide production", "TREATMENT", 806, 829], ["motile blood forms", "TEST", 854, 872], ["lower", "OBSERVATION_MODIFIER", 18, 23], ["parasite loads", "OBSERVATION", 24, 38], ["infection", "OBSERVATION", 51, 60], ["tumour", "ANATOMY", 391, 397], ["necrosis", "OBSERVATION", 398, 406], ["cruzi infection", "OBSERVATION", 428, 443], ["parasitaemia", "OBSERVATION_MODIFIER", 445, 457], ["parasitism", "OBSERVATION", 548, 558]]], ["Infection was IL-10-gene-deprived mice12,16 or neutralization by monoclonal antibody (mAb) treatment17 results in lower parasitism, maintained by weekly i.p. infection of BALB/c mice.", [["infection", "DISEASE", 158, 167], ["IL-10", "GENE_OR_GENE_PRODUCT", 14, 19], ["mice", "ORGANISM", 34, 38], ["12,16", "SIMPLE_CHEMICAL", 38, 43], ["BALB/c mice", "ORGANISM", 171, 182], ["IL-10-gene", "DNA", 14, 24], ["monoclonal antibody (mAb) treatment17", "PROTEIN", 65, 102], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 178, 182], ["Infection", "PROBLEM", 0, 9], ["IL", "TEST", 14, 16], ["neutralization", "TREATMENT", 47, 61], ["monoclonal antibody (mAb", "TREATMENT", 65, 89], ["lower parasitism", "PROBLEM", 114, 130], ["lower parasitism", "OBSERVATION", 114, 130]]], ["In the experiments designated 'acute' MHV infection, parasites were whereas increased parasitism occurs when mice are treated with recombinant IL-10 (rIL-10)12 or receive IL-10-and IL-maintained in mice coming from either recently infected MHV+ or from MHV\u2212 colonies and 500 or 5000 forms were 4-producing T cells.15 IL-4, depending on the parasite strain, is also involved in negative regulation of parasitism.18 inoculated in recipient BALB/c or C57BL/6 mice from MHV\u2212 colonies.", [["colonies", "ANATOMY", 258, 266], ["T cells", "ANATOMY", 306, 313], ["colonies", "ANATOMY", 471, 479], ["MHV infection", "DISEASE", 38, 51], ["MHV", "ORGANISM", 38, 41], ["mice", "ORGANISM", 109, 113], ["IL-10", "GENE_OR_GENE_PRODUCT", 143, 148], ["rIL-10)12", "GENE_OR_GENE_PRODUCT", 150, 159], ["IL-10", "GENE_OR_GENE_PRODUCT", 171, 176], ["IL", "GENE_OR_GENE_PRODUCT", 181, 183], ["mice", "ORGANISM", 198, 202], ["MHV", "ORGANISM", 240, 243], ["MHV", "ORGANISM", 253, 256], ["T cells", "CELL", 306, 313], ["IL-4", "GENE_OR_GENE_PRODUCT", 317, 321], ["BALB/c", "ORGANISM", 438, 444], ["C57BL/6 mice", "ORGANISM", 448, 460], ["MHV", "ORGANISM", 466, 469], ["IL", "PROTEIN", 143, 145], ["rIL", "PROTEIN", 150, 153], ["IL", "PROTEIN", 171, 173], ["IL", "PROTEIN", 181, 183], ["T cells", "CELL_TYPE", 306, 313], ["IL", "PROTEIN", 317, 319], ["MHV\u2212 colonies", "CELL_LINE", 466, 479], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 198, 202], ["mice", "SPECIES", 456, 460], ["MHV", "SPECIES", 38, 41], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 198, 202], ["MHV", "SPECIES", 240, 243], ["MHV", "SPECIES", 253, 256], ["mice", "SPECIES", 456, 460], ["MHV", "SPECIES", 466, 469], ["'acute' MHV infection", "PROBLEM", 30, 51], ["parasites", "PROBLEM", 53, 62], ["increased parasitism", "PROBLEM", 76, 96], ["recombinant IL", "TREATMENT", 131, 145], ["IL", "TREATMENT", 171, 173], ["IL", "TREATMENT", 181, 183], ["MHV\u2212 colonies", "TEST", 253, 266], ["the parasite strain", "PROBLEM", 336, 355], ["parasitism", "PROBLEM", 400, 410], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["MHV", "OBSERVATION_MODIFIER", 38, 41], ["infection", "OBSERVATION", 42, 51], ["MHV", "OBSERVATION", 240, 243], ["parasitism", "OBSERVATION", 400, 410]]], ["In later experiments, designated 'chronic' MHV We found that BALB/c and C57BL/6 mice that had been injected with blood trypomastigotes from recently MHV-infection, the T. cruzi strain was started anew from tissueculture-grown trypomastigotes and maintained in MHV\u2212 contaminated mice became much more susceptible to T. cruzi infection and produced higher IL-10 levels than their counter-mice, whose blood was used as a source of T. cruzi to infect recipients derived from MHV+ colonies that had been infected parts whose T. cruzi inoculum was derived from MHVnegative (MHV\u2212) donors.", [["blood trypomastigotes", "ANATOMY", 113, 134], ["trypomastigotes", "ANATOMY", 226, 241], ["blood", "ANATOMY", 398, 403], ["colonies", "ANATOMY", 476, 484], ["MHV-infection", "DISEASE", 149, 162], ["T. cruzi infection", "DISEASE", 315, 333], ["MHV", "ORGANISM", 43, 46], ["BALB/c", "ORGANISM", 61, 67], ["C57BL/6 mice", "ORGANISM", 72, 84], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["trypomastigotes", "ORGANISM_SUBSTANCE", 119, 134], ["MHV", "ORGANISM", 149, 152], ["T. cruzi", "ORGANISM", 168, 176], ["strain", "ORGANISM", 177, 183], ["trypomastigotes", "CELL", 226, 241], ["MHV\u2212", "ORGANISM", 260, 264], ["mice", "ORGANISM", 278, 282], ["T. cruzi", "ORGANISM", 315, 323], ["IL-10", "GENE_OR_GENE_PRODUCT", 354, 359], ["mice", "ORGANISM", 386, 390], ["blood", "ORGANISM_SUBSTANCE", 398, 403], ["T. cruzi", "ORGANISM", 428, 436], ["recipients", "ORGANISM", 447, 457], ["MHV", "ORGANISM", 471, 474], ["T. cruzi", "ORGANISM", 520, 528], ["MHVnegative (MHV\u2212", "ORGANISM", 555, 572], ["donors", "ORGANISM", 574, 580], ["IL", "PROTEIN", 354, 356], ["mice", "SPECIES", 80, 84], ["T. cruzi", "SPECIES", 168, 176], ["mice", "SPECIES", 278, 282], ["T. cruzi", "SPECIES", 315, 323], ["mice", "SPECIES", 386, 390], ["T. cruzi", "SPECIES", 428, 436], ["T. cruzi", "SPECIES", 520, 528], ["MHV", "SPECIES", 43, 46], ["mice", "SPECIES", 80, 84], ["MHV", "SPECIES", 149, 152], ["T. cruzi", "SPECIES", 168, 176], ["MHV", "SPECIES", 260, 263], ["mice", "SPECIES", 278, 282], ["T. cruzi", "SPECIES", 315, 323], ["mice", "SPECIES", 386, 390], ["T. cruzi", "SPECIES", 428, 436], ["MHV", "SPECIES", 471, 474], ["T. cruzi", "SPECIES", 520, 528], ["MHV", "SPECIES", 568, 571], ["BALB/c", "TEST", 61, 67], ["C57BL/6 mice", "TREATMENT", 72, 84], ["blood trypomastigotes", "PROBLEM", 113, 134], ["infection", "PROBLEM", 153, 162], ["the T. cruzi strain", "PROBLEM", 164, 183], ["grown trypomastigotes", "PROBLEM", 220, 241], ["T. cruzi infection", "PROBLEM", 315, 333], ["T. cruzi", "PROBLEM", 428, 436], ["MHV+ colonies", "PROBLEM", 471, 484], ["infected parts", "PROBLEM", 499, 513], ["T. cruzi inoculum", "PROBLEM", 520, 537], ["MHV", "OBSERVATION_MODIFIER", 43, 46], ["infection", "OBSERVATION", 153, 162], ["cruzi infection", "OBSERVATION", 318, 333], ["cruzi inoculum", "OBSERVATION", 523, 537]]], ["Comparison between mice coming for more than 4 months or from MHV\u2212 colonies.", [["mice", "ORGANISM", 19, 23], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["MHV", "SPECIES", 62, 65]]], ["In these experiments the infective T. cruzi dose was 50, 500, or 5000 from chronically MHV-infected and from MHV\u2212 colonies, showed higher parasitaemia levels in BALB/c MHV-positive blood forms in BALB/c mice and 500, 5000 (not shown), 50 000, or 200 000 blood forms in C57BL/6 mice.", [["colonies", "ANATOMY", 114, 122], ["blood", "ANATOMY", 181, 186], ["blood", "ANATOMY", 254, 259], ["MHV-infected", "DISEASE", 87, 99], ["parasitaemia", "DISEASE", 138, 150], ["T. cruzi", "ORGANISM", 35, 43], ["MHV", "ORGANISM", 87, 90], ["MHV", "ORGANISM", 109, 112], ["BALB/c MHV", "ORGANISM", 161, 171], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["BALB/c mice", "ORGANISM", 196, 207], ["blood", "ORGANISM_SUBSTANCE", 254, 259], ["C57BL/6 mice", "ORGANISM", 269, 281], ["MHV\u2212 colonies", "CELL_LINE", 109, 122], ["T. cruzi", "SPECIES", 35, 43], ["mice", "SPECIES", 203, 207], ["mice", "SPECIES", 277, 281], ["T. cruzi", "SPECIES", 35, 43], ["MHV", "SPECIES", 87, 90], ["MHV", "SPECIES", 109, 112], ["MHV", "SPECIES", 168, 171], ["mice", "SPECIES", 203, 207], ["mice", "SPECIES", 277, 281], ["the infective T. cruzi dose", "PROBLEM", 21, 48], ["chronically MHV", "PROBLEM", 75, 90], ["infected", "PROBLEM", 91, 99], ["MHV\u2212 colonies", "TEST", 109, 122], ["higher parasitaemia levels in BALB", "PROBLEM", 131, 165], ["MHV", "TEST", 168, 171], ["BALB/c mice", "TEST", 196, 207], ["blood forms", "TEST", 254, 265], ["infective", "OBSERVATION_MODIFIER", 25, 34], ["infected", "OBSERVATION", 91, 99], ["MHV", "ANATOMY", 109, 112], ["higher", "OBSERVATION_MODIFIER", 131, 137], ["parasitaemia levels", "OBSERVATION", 138, 157]]], ["As C57BL/6 (MHV+) mice but otherwise no major significant differences in susceptibility to T. cruzi.", [["T. cruzi", "DISEASE", 91, 99], ["C57BL/6 (MHV+) mice", "ORGANISM", 3, 22], ["T. cruzi", "ORGANISM", 91, 99], ["mice", "SPECIES", 18, 22], ["T. cruzi", "SPECIES", 91, 99], ["MHV", "SPECIES", 12, 15], ["mice", "SPECIES", 18, 22], ["T. cruzi", "SPECIES", 91, 99], ["no", "UNCERTAINTY", 37, 39]]], ["Nevertheless, quantitative differ-mice are much more resistant to T. cruzi infection, the high inocula would allow comparison between MHV\u2212 and MHV+ ences in IFN-c, IL-10 and nitric oxide production were found between MHV-infected and uninfected mice.INTRODUCTIONC57BL/6 colonies submitted to moderate to severe T. cruzi infection.7 Parasitaemia determination was performed by direct microscope (\u00d740) counting of motile parasites in a 5 ml fresh MATERIALS AND METHODS blood sample, obtained from the lateral tail veins.", [["colonies", "ANATOMY", 270, 278], ["blood sample", "ANATOMY", 467, 479], ["lateral tail veins", "ANATOMY", 499, 517], ["T. cruzi infection", "DISEASE", 66, 84], ["nitric oxide", "CHEMICAL", 174, 186], ["MHV-infected", "DISEASE", 217, 229], ["T. cruzi infection", "DISEASE", 311, 329], ["nitric oxide", "CHEMICAL", 174, 186], ["mice", "ORGANISM", 34, 38], ["T. cruzi", "ORGANISM", 66, 74], ["MHV\u2212", "ORGANISM", 134, 138], ["MHV+ ences", "ORGANISM", 143, 153], ["IFN-c", "GENE_OR_GENE_PRODUCT", 157, 162], ["IL-10", "GENE_OR_GENE_PRODUCT", 164, 169], ["nitric oxide", "SIMPLE_CHEMICAL", 174, 186], ["MHV", "ORGANISM", 217, 220], ["mice", "ORGANISM", 245, 249], ["T. cruzi", "ORGANISM", 311, 319], ["blood", "ORGANISM_SUBSTANCE", 467, 472], ["lateral tail veins", "MULTI-TISSUE_STRUCTURE", 499, 517], ["IFN", "PROTEIN", 157, 160], ["INTRODUCTIONC57BL/6 colonies", "CELL_LINE", 250, 278], ["mice", "SPECIES", 34, 38], ["T. cruzi", "SPECIES", 66, 74], ["mice", "SPECIES", 245, 249], ["T. cruzi", "SPECIES", 311, 319], ["mice", "SPECIES", 34, 38], ["T. cruzi", "SPECIES", 66, 74], ["MHV", "SPECIES", 134, 137], ["MHV", "SPECIES", 143, 146], ["MHV", "SPECIES", 217, 220], ["mice", "SPECIES", 245, 249], ["T. cruzi", "SPECIES", 311, 319], ["T. cruzi infection", "PROBLEM", 66, 84], ["the high inocula", "PROBLEM", 86, 102], ["MHV\u2212", "TREATMENT", 134, 138], ["MHV+ ences", "TREATMENT", 143, 153], ["IFN", "TREATMENT", 157, 160], ["IL", "TREATMENT", 164, 166], ["nitric oxide production", "TREATMENT", 174, 197], ["INTRODUCTIONC57BL/6 colonies", "TREATMENT", 250, 278], ["severe T. cruzi infection", "PROBLEM", 304, 329], ["Parasitaemia determination", "TEST", 332, 358], ["direct microscope", "TEST", 376, 393], ["motile parasites", "PROBLEM", 412, 428], ["METHODS blood sample", "TEST", 459, 479], ["cruzi infection", "OBSERVATION", 69, 84], ["infected", "OBSERVATION", 221, 229], ["uninfected mice", "OBSERVATION", 234, 249], ["moderate", "OBSERVATION_MODIFIER", 292, 300], ["severe", "OBSERVATION_MODIFIER", 304, 310], ["cruzi infection", "OBSERVATION", 314, 329], ["lateral", "ANATOMY_MODIFIER", 499, 506], ["tail veins", "ANATOMY", 507, 517]]], ["Mice and MHV infection C57BL/6 and BALB/c female mice (8-10-week-old), acutelyINTRODUCTIONSpleen cell cultures Spleen cell suspensions were prepared from T. cruzi-infected or chronically infected with MHV were obtained from Biot\u00e9rio de Camundongos Isog\u00eanicos do Departamento de Imunologia and uninfected mice, MHV+ or MHV\u2212, depleted of erythrocytes by hypotonic lysis with distilled water and resuspended do ICB/USP (S\u00e3o Paulo, SP, Brazil ).", [["cell", "ANATOMY", 97, 101], ["Spleen cell suspensions", "ANATOMY", 111, 134], ["erythrocytes", "ANATOMY", 336, 348], ["MHV infection", "DISEASE", 9, 22], ["Mice", "ORGANISM", 0, 4], ["MHV infection C57BL/6", "ORGANISM", 9, 30], ["BALB/c female mice", "ORGANISM", 35, 53], ["cell", "CELL", 97, 101], ["Spleen cell suspensions", "CELL", 111, 134], ["MHV", "ORGANISM", 201, 204], ["mice", "ORGANISM", 304, 308], ["MHV", "ORGANISM", 310, 313], ["MHV\u2212", "CELL", 318, 322], ["erythrocytes", "CELL", 336, 348], ["acutelyINTRODUCTIONSpleen cell cultures", "CELL_LINE", 71, 110], ["erythrocytes", "CELL_TYPE", 336, 348], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 304, 308], ["MHV", "SPECIES", 9, 12], ["mice", "SPECIES", 49, 53], ["MHV", "SPECIES", 201, 204], ["mice", "SPECIES", 304, 308], ["MHV", "SPECIES", 310, 313], ["MHV\u2212", "SPECIES", 318, 322], ["MHV infection", "PROBLEM", 9, 22], ["acutelyINTRODUCTIONSpleen cell cultures Spleen cell suspensions", "TREATMENT", 71, 134], ["T. cruzi-infected", "PROBLEM", 154, 171], ["MHV\u2212", "PROBLEM", 318, 322], ["erythrocytes", "TREATMENT", 336, 348], ["hypotonic lysis", "TREATMENT", 352, 367], ["distilled water", "TREATMENT", 373, 388], ["MHV", "OBSERVATION_MODIFIER", 9, 12], ["infection", "OBSERVATION", 13, 22], ["Spleen", "ANATOMY", 111, 117], ["cell suspensions", "OBSERVATION", 118, 134], ["hypotonic lysis", "OBSERVATION", 352, 367]]], ["Mice with negative serological tests for MHV, from both these strains, were in RPMI-1640 (Cultilab, Campinas, SP, Brazil ) complete medium containing 10% fetal calf serum (FCS; Cultilab) and obtained from Biot\u00e9rio de Camundongos Isog\u00eanicos da Universidade Estadual de Campinas (Campinas, SP, Brazil ).INTRODUCTIONsupplemented with glutamine, 2-mercaptoethanol (2-ME ) and antibiotics as described.19 Spleen cell suspensions were pooled MHV\u2212 mice were housed and handled separate from and before those coming from MHV-contaminated animal facili-from three mice and were cultured in duplicate or triplicate in 24-well flat-bottomed plates at 107/ml or at 5\u00d7106/well ties.", [["fetal calf serum", "ANATOMY", 154, 170], ["Spleen cell", "ANATOMY", 400, 411], ["glutamine", "CHEMICAL", 331, 340], ["2-mercaptoethanol", "CHEMICAL", 342, 359], ["2-ME", "CHEMICAL", 361, 365], ["glutamine", "CHEMICAL", 331, 340], ["2-mercaptoethanol", "CHEMICAL", 342, 359], ["2-ME", "CHEMICAL", 361, 365], ["Mice", "ORGANISM", 0, 4], ["MHV", "ORGANISM", 41, 44], ["fetal calf", "ORGANISM_SUBSTANCE", 154, 164], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["FCS", "ORGANISM_SUBSTANCE", 172, 175], ["glutamine", "AMINO_ACID", 331, 340], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 342, 359], ["2-ME", "SIMPLE_CHEMICAL", 361, 365], ["Spleen cell", "CELL", 400, 411], ["MHV\u2212", "ORGANISM", 436, 440], ["mice", "ORGANISM", 441, 445], ["MHV", "ORGANISM", 513, 516], ["mice", "ORGANISM", 555, 559], ["Mice", "SPECIES", 0, 4], ["calf", "SPECIES", 160, 164], ["mice", "SPECIES", 441, 445], ["mice", "SPECIES", 555, 559], ["MHV", "SPECIES", 41, 44], ["MHV", "SPECIES", 436, 439], ["mice", "SPECIES", 441, 445], ["MHV", "SPECIES", 513, 516], ["mice", "SPECIES", 555, 559], ["serological tests", "TEST", 19, 36], ["MHV", "PROBLEM", 41, 44], ["RPMI", "TEST", 79, 83], ["Cultilab", "TEST", 90, 98], ["Campinas", "TEST", 100, 108], ["fetal calf serum", "TEST", 154, 170], ["FCS", "TEST", 172, 175], ["Cultilab", "TEST", 177, 185], ["glutamine", "TREATMENT", 331, 340], ["mercaptoethanol", "TREATMENT", 344, 359], ["antibiotics", "TREATMENT", 372, 383], ["Spleen cell suspensions", "TREATMENT", 400, 423], ["calf", "ANATOMY", 160, 164], ["Spleen", "ANATOMY", 400, 406], ["cell suspensions", "OBSERVATION", 407, 423]]], ["The mice were fed autoclaved food and water, and were handled using disposable gloves.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["disposable gloves", "TREATMENT", 68, 85]]], ["MHV infection was diagnosed and stimulated with T-Ag (5\u00d7106 Frozen-Thawed tissue culture trypomastigotes parasites) prepared as described.9 by antibody testing of the sera.", [["sera", "ANATOMY", 167, 171], ["MHV infection", "DISEASE", 0, 13], ["T-Ag", "CHEMICAL", 48, 52], ["Ag", "CHEMICAL", 50, 52], ["MHV", "ORGANISM", 0, 3], ["T-Ag", "GENE_OR_GENE_PRODUCT", 48, 52], ["sera", "ORGANISM_SUBSTANCE", 167, 171], ["Ag", "PROTEIN", 50, 52], ["MHV", "SPECIES", 0, 3], ["MHV infection", "PROBLEM", 0, 13], ["T", "TEST", 48, 49], ["Frozen-Thawed tissue culture trypomastigotes parasites", "TREATMENT", 60, 114], ["antibody testing", "TEST", 143, 159], ["infection", "OBSERVATION", 4, 13]]], ["The MHV enzyme-linked immunosorbent assay ( ELISA) diagnostic kits sold by Charles Concanavalin A (Con A at 2\u00b75 m/ml ) or plate-bound anti-CD3 [mAb 145-2C11, Americal Type Culture Collection (ATCC ) River Laboratories ( Wilmington, MA) were used according to the manufacturer's instructions.", [["Concanavalin A", "SIMPLE_CHEMICAL", 83, 97], ["Con A", "SIMPLE_CHEMICAL", 99, 104], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 134, 142], ["MHV enzyme", "PROTEIN", 4, 14], ["anti-CD3", "PROTEIN", 134, 142], ["MHV", "SPECIES", 4, 7], ["The MHV enzyme", "TEST", 0, 14], ["immunosorbent assay", "TEST", 22, 41], ["plate-bound anti-CD3", "TREATMENT", 122, 142], ["mAb", "TEST", 144, 147], ["Americal Type Culture Collection (ATCC )", "TREATMENT", 158, 198], ["Wilmington, MA)", "TREATMENT", 220, 235]]], ["When the outbreak of CRL 1973], coated at 10 mg/ml, 500 ml/well ) were also used as T-cell stimulants.11.", [["T-cell", "ANATOMY", 84, 90], ["CRL 1973", "CHEMICAL", 21, 29], ["T-cell", "CELL", 84, 90], ["T-cell stimulants", "TREATMENT", 84, 101]]], ["Supernatants from the cultures were MHV was detected, levels of anti-MHV antibodies were very high with corrected optical density (OD) values for sera harvested after 20 hr from the higher cell-density cultures and after 72 hr from the lower-density cultures.", [["Supernatants", "ANATOMY", 0, 12], ["cultures", "ANATOMY", 22, 30], ["sera", "ANATOMY", 146, 150], ["cell", "ANATOMY", 189, 193], ["MHV", "ORGANISM", 36, 39], ["anti-MHV antibodies", "GENE_OR_GENE_PRODUCT", 64, 83], ["sera", "ORGANISM_SUBSTANCE", 146, 150], ["cell", "CELL", 189, 193], ["anti-MHV antibodies", "PROTEIN", 64, 83], ["MHV", "SPECIES", 36, 39], ["anti-MHV", "SPECIES", 64, 72], ["the cultures", "TEST", 18, 30], ["MHV", "PROBLEM", 36, 39], ["levels of anti-MHV antibodies", "TEST", 54, 83], ["sera harvested", "TREATMENT", 146, 160], ["the lower-density cultures", "TEST", 232, 258]]], ["The following ranging from 8\u00b75 to 23\u00b78 (positive test values >3).", [["positive test values", "TEST", 40, 60]]], ["These were calculated (as indicated by the manufacturer) by the following neutralizing rat mAb anti-mouse cytokines were incorporated to the cultures in some experiments: JES5-2A5 anti-IL-10, and formula: [(OD obtained for the test serum diluted at 1/50 incubated with the cells containing the virus) -(OD obtained XMG1.2 anti-IFN-c; both were used at final concentrations of 20 mg/ml.", [["cultures", "ANATOMY", 141, 149], ["serum", "ANATOMY", 232, 237], ["cells", "ANATOMY", 273, 278], ["rat", "ORGANISM", 87, 90], ["anti-IL-10", "GENE_OR_GENE_PRODUCT", 180, 190], ["serum", "ORGANISM_SUBSTANCE", 232, 237], ["cells", "CELL", 273, 278], ["IFN-c", "GENE_OR_GENE_PRODUCT", 327, 332], ["neutralizing rat mAb anti-mouse cytokines", "PROTEIN", 74, 115], ["IFN", "PROTEIN", 327, 330], ["rat", "SPECIES", 87, 90], ["anti-mouse", "SPECIES", 95, 105], ["rat", "SPECIES", 87, 90], ["neutralizing rat mAb anti-mouse cytokines", "TREATMENT", 74, 115], ["the cultures", "TEST", 137, 149], ["JES5", "TEST", 171, 175], ["the test serum", "TEST", 223, 237], ["anti-IFN-c", "TREATMENT", 322, 332]]], ["The anti-CD4 mAb GK1.5 was added to cultures for the same serum and dilution incubated with uninfected cells)]/0\u00b713.", [["serum", "ANATOMY", 58, 63], ["cells", "ANATOMY", 103, 108], ["anti-CD4", "GENE_OR_GENE_PRODUCT", 4, 12], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["cells", "CELL", 103, 108], ["anti-CD4 mAb", "PROTEIN", 4, 16], ["uninfected cells", "CELL_TYPE", 92, 108], ["The anti-CD4 mAb GK", "TREATMENT", 0, 19], ["cultures", "TEST", 36, 44], ["the same serum", "TEST", 49, 63]]], ["Fluorescence antibody testing was also performed at 10 mg/ml. as an additional control and ranked + + + + for serum incubated with MHV-infected cells.", [["serum", "ANATOMY", 110, 115], ["cells", "ANATOMY", 144, 149], ["+ + + +", "SIMPLE_CHEMICAL", 98, 105], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["MHV", "ORGANISM", 131, 134], ["cells", "CELL", 144, 149], ["MHV-infected cells", "CELL_TYPE", 131, 149], ["MHV", "SPECIES", 131, 134], ["Fluorescence antibody testing", "TEST", 0, 29], ["an additional control", "TEST", 65, 86], ["MHV", "PROBLEM", 131, 134], ["infected cells", "PROBLEM", 135, 149], ["infected cells", "OBSERVATION", 135, 149]]], ["The colonies were serologi-Cytokine assays Cytokine levels in the culture supernatants were measured by cally negative on ELISA and immunofluorescence testing for the following viruses: respiratory-enteric orphan virus (Reo two-site sandwich ELISA using the following mAb pairs of which the second cited was biotinylated.", [["colonies", "ANATOMY", 4, 12], ["supernatants", "ANATOMY", 74, 86], ["Cytokine", "GENE_OR_GENE_PRODUCT", 43, 51], ["Cytokine", "PROTEIN", 27, 35], ["Cytokine", "PROTEIN", 43, 51], ["mAb pairs", "PROTEIN", 268, 277], ["The colonies", "TEST", 0, 12], ["serologi", "TEST", 18, 26], ["Cytokine assays", "TEST", 27, 42], ["Cytokine levels", "TEST", 43, 58], ["the culture supernatants", "TEST", 62, 86], ["ELISA", "TEST", 122, 127], ["immunofluorescence testing", "TEST", 132, 158], ["respiratory-enteric orphan virus", "PROBLEM", 186, 218], ["sandwich ELISA", "TEST", 233, 247], ["the following mAb pairs", "TREATMENT", 254, 277], ["colonies", "OBSERVATION", 4, 12], ["respiratory", "ANATOMY", 186, 197], ["enteric", "ANATOMY", 198, 205]]], ["IFN-c, XMG1.2 and when the inoculum came from MHV\u2212 donor mice.", [["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["XMG1.2", "GENE_OR_GENE_PRODUCT", 7, 13], ["MHV\u2212 donor mice", "ORGANISM", 46, 61], ["IFN", "PROTEIN", 0, 3], ["XMG1.2", "PROTEIN", 7, 13], ["mice", "SPECIES", 57, 61], ["MHV", "SPECIES", 46, 49], ["mice", "SPECIES", 57, 61]]], ["The AN18; IL-10, JES-2A5 and SXC-1; IL-4, 11 B 11 and differences in parasitaemia could be observed with inocula of BVD6 24G2.11 Minimum levels of detection for the assays 500 or 5000 blood trypomastigotes (Fig. 1a,b) .", [["blood", "ANATOMY", 184, 189], ["parasitaemia", "DISEASE", 69, 81], ["BVD6 24G2", "CHEMICAL", 116, 125], ["AN18", "GENE_OR_GENE_PRODUCT", 4, 8], ["IL-10", "GENE_OR_GENE_PRODUCT", 10, 15], ["JES-2A5", "GENE_OR_GENE_PRODUCT", 17, 24], ["SXC-1", "GENE_OR_GENE_PRODUCT", 29, 34], ["IL-4", "GENE_OR_GENE_PRODUCT", 36, 40], ["11 B 11", "ORGANISM", 42, 49], ["blood", "ORGANISM_SUBSTANCE", 184, 189], ["AN18", "PROTEIN", 4, 8], ["IL", "PROTEIN", 10, 12], ["JES", "PROTEIN", 17, 20], ["2A5", "PROTEIN", 21, 24], ["SXC", "DNA", 29, 32], ["IL-4", "DNA", 36, 40], ["BVD6 24G2", "SPECIES", 116, 125], ["The AN18", "TEST", 0, 8], ["IL", "TEST", 10, 12], ["JES", "TEST", 17, 20], ["SXC", "TEST", 29, 32], ["IL", "TEST", 36, 38], ["parasitaemia", "PROBLEM", 69, 81], ["detection", "TEST", 147, 156], ["the assays", "TEST", 161, 171], ["blood trypomastigotes", "TEST", 184, 205], ["parasitaemia", "OBSERVATION", 69, 81]]], ["IFN-c, 1\u00b756 ng/ml; IL-10, 3\u00b725 units/ml; and IL-4, BALB/c mice injected with MHV+ inocula, mortality reached 0\u00b7156 ng/ml.", [["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-10", "GENE_OR_GENE_PRODUCT", 19, 24], ["IL-4", "GENE_OR_GENE_PRODUCT", 45, 49], ["BALB/c mice", "ORGANISM", 51, 62], ["MHV", "ORGANISM", 77, 80], ["IFN", "PROTEIN", 0, 3], ["IL", "PROTEIN", 19, 21], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["MHV", "SPECIES", 77, 80], ["IFN", "TEST", 0, 3], ["IL", "TEST", 19, 21], ["IL", "TEST", 45, 47], ["BALB/c mice", "TREATMENT", 51, 62], ["MHV+ inocula", "TREATMENT", 77, 89]]], ["The rat anti-mouse cytokines producing 80% by day 20 (500 T. cruzi forms) and 100% by day 16 hybridomas were a generous gift from Dr R. L. Coffman, (5000 T. cruzi forms) whereas all recipients of MHV\u2212 inocula DNAX Research Institute of Molecular and Cellular Biology, survived to 30 days after infection.", [["infection", "DISEASE", 294, 303], ["rat", "ORGANISM", 4, 7], ["T. cruzi", "ORGANISM", 154, 162], ["MHV", "ORGANISM", 196, 199], ["rat anti-mouse cytokines", "PROTEIN", 4, 28], ["rat", "SPECIES", 4, 7], ["anti-mouse", "SPECIES", 8, 18], ["T. cruzi", "SPECIES", 58, 66], ["R. L.", "SPECIES", 133, 138], ["T. cruzi", "SPECIES", 154, 162], ["rat", "SPECIES", 4, 7], ["T. cruzi", "SPECIES", 58, 66], ["R. L. Coffman", "SPECIES", 133, 146], ["T. cruzi", "SPECIES", 154, 162], ["MHV", "SPECIES", 196, 199], ["The rat anti-mouse cytokines", "TEST", 0, 28], ["infection", "PROBLEM", 294, 303], ["infection", "OBSERVATION", 294, 303]]], ["All C57BL/6 mice Palo Alto, CA.", [["C57BL/6 mice", "ORGANISM", 4, 16], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16]]], ["Standard curves were obtained with recombisurvived after infection whether inoculated with T. cruzi from nant mouse cytokines.", [["infection", "DISEASE", 57, 66], ["T. cruzi", "ORGANISM", 91, 99], ["mouse", "ORGANISM", 110, 115], ["nant mouse cytokines", "PROTEIN", 105, 125], ["T. cruzi", "SPECIES", 91, 99], ["mouse", "SPECIES", 110, 115], ["T. cruzi", "SPECIES", 91, 99], ["mouse", "SPECIES", 110, 115], ["Standard curves", "TEST", 0, 15], ["infection", "PROBLEM", 57, 66], ["T. cruzi", "PROBLEM", 91, 99]]], ["The supernatants were tested in serial MHV+ or MHV\u2212 donor mice. twofold dilutions and the results were expressed as the arith-Serological tests for MHV became positive in T. cruzimetic mean of duplicate determinations.", [["supernatants", "ANATOMY", 4, 16], ["MHV", "ORGANISM", 39, 42], ["MHV\u2212 donor", "ORGANISM", 47, 57], ["mice", "ORGANISM", 58, 62], ["MHV", "ORGANISM", 148, 151], ["mice", "SPECIES", 58, 62], ["MHV", "SPECIES", 39, 42], ["MHV", "SPECIES", 47, 50], ["mice", "SPECIES", 58, 62], ["MHV", "SPECIES", 148, 151], ["T. cruzimetic", "SPECIES", 171, 184], ["MHV\u2212 donor mice", "TREATMENT", 47, 62], ["twofold dilutions", "TEST", 64, 81], ["the arith", "TEST", 116, 125], ["Serological tests", "TEST", 126, 143], ["MHV", "PROBLEM", 148, 151], ["positive", "PROBLEM", 159, 167]]], ["The SD did not infected (from MHV+ donors) C57BL/6 mice by day 28 after exceed 20% of the mean.INTRODUCTIONinfection and in 30% of a group of 20 BALB/c mice that survived to 28 days after being infected with 50 T. cruzi Statistical analysis forms.", [["MHV+ donors", "ORGANISM", 30, 41], ["C57BL/6 mice", "ORGANISM", 43, 55], ["BALB/c mice", "ORGANISM", 145, 156], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 152, 156], ["T. cruzi", "SPECIES", 211, 219], ["MHV+ donors", "TREATMENT", 30, 41], ["a group of 20 BALB/c mice", "TREATMENT", 131, 156]]], ["Recipients of inocula from MHV\u2212 mice remained The significance of differences in parasitaemia between distinct serologically negative for MHV.", [["parasitaemia", "DISEASE", 81, 93], ["Recipients", "ORGANISM", 0, 10], ["MHV\u2212 mice", "ORGANISM", 27, 36], ["MHV", "ORGANISM", 138, 141], ["mice", "SPECIES", 32, 36], ["MHV", "SPECIES", 27, 30], ["mice", "SPECIES", 32, 36], ["MHV", "SPECIES", 138, 141], ["parasitaemia", "PROBLEM", 81, 93], ["MHV", "PROBLEM", 138, 141], ["inocula", "OBSERVATION", 14, 21]]], ["Looking into possible causes experimental groups was examined by analysis of variance with of the observed increase in susceptibility to T. cruzi of mice repeated measurements followed by Tukey's test for multiple infected with MHV+-derived inocula. we investigated whether comparisons.", [["T. cruzi", "ORGANISM", 137, 145], ["mice", "ORGANISM", 149, 153], ["MHV", "ORGANISM", 228, 231], ["T. cruzi", "SPECIES", 137, 145], ["mice", "SPECIES", 149, 153], ["T. cruzi", "SPECIES", 137, 145], ["mice", "SPECIES", 149, 153], ["MHV", "SPECIES", 228, 231], ["Tukey's test", "TEST", 188, 200], ["increase", "OBSERVATION_MODIFIER", 107, 115], ["infected", "OBSERVATION", 214, 222]]], ["Differences of 0\u00b75 log 10 or over were significant cytokine production was altered concomitant to the viral at least at P<0\u00b705.", [["cytokine", "PROTEIN", 51, 59], ["significant cytokine production", "PROBLEM", 39, 70], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["cytokine production", "OBSERVATION", 51, 70]]], ["Differences in cytokine production levels infection.", [["infection", "DISEASE", 42, 51], ["cytokine", "PROTEIN", 15, 23], ["cytokine production levels infection", "PROBLEM", 15, 51], ["cytokine production", "OBSERVATION", 15, 34], ["levels", "OBSERVATION_MODIFIER", 35, 41], ["infection", "OBSERVATION", 42, 51]]], ["Spleen cells (stimulated with Con A or T-Ag) from were tested by Bonferroni's multiple comparison test.INTRODUCTIONmice that received an MHV+ inoculum of 500 T. cruzi produced detectable and much higher levels of IL-10 during the first 3 weeks of infection than spleen cells from mice that RESULTSINTRODUCTIONreceived an identical inoculum of T. cruzi derived from T. cruzi infection and cytokine production in MHV\u2212 mice MHV\u2212 mice.", [["Spleen cells", "ANATOMY", 0, 12], ["spleen cells", "ANATOMY", 262, 274], ["infection", "DISEASE", 247, 256], ["T. cruzi infection", "DISEASE", 365, 383], ["Ag", "CHEMICAL", 41, 43], ["Spleen cells", "CELL", 0, 12], ["Con A", "GENE_OR_GENE_PRODUCT", 30, 35], ["T-Ag", "GENE_OR_GENE_PRODUCT", 39, 43], ["MHV", "ORGANISM", 137, 140], ["T. cruzi", "ORGANISM", 158, 166], ["IL-10", "GENE_OR_GENE_PRODUCT", 213, 218], ["spleen cells", "CELL", 262, 274], ["mice", "ORGANISM", 280, 284], ["T. cruzi", "ORGANISM", 343, 351], ["T. cruzi", "ORGANISM", 365, 373], ["MHV\u2212 mice MHV\u2212 mice", "ORGANISM", 411, 430], ["Spleen cells", "CELL_TYPE", 0, 12], ["Con A", "PROTEIN", 30, 35], ["T-Ag", "PROTEIN", 39, 43], ["IL", "PROTEIN", 213, 215], ["spleen cells", "CELL_TYPE", 262, 274], ["cytokine", "PROTEIN", 388, 396], ["T. cruzi", "SPECIES", 158, 166], ["mice", "SPECIES", 280, 284], ["T. cruzi", "SPECIES", 343, 351], ["T. cruzi", "SPECIES", 365, 373], ["mice", "SPECIES", 416, 420], ["mice", "SPECIES", 426, 430], ["MHV", "SPECIES", 137, 140], ["T. cruzi", "SPECIES", 158, 166], ["mice", "SPECIES", 280, 284], ["T. cruzi", "SPECIES", 343, 351], ["T. cruzi", "SPECIES", 365, 373], ["MHV", "SPECIES", 411, 414], ["MHV", "SPECIES", 421, 424], ["mice", "SPECIES", 426, 430], ["Bonferroni's multiple comparison test", "TEST", 65, 102], ["an MHV+ inoculum", "TREATMENT", 134, 150], ["infection than spleen cells", "PROBLEM", 247, 274], ["T. cruzi", "PROBLEM", 343, 351], ["T. cruzi infection", "PROBLEM", 365, 383], ["cytokine production", "TREATMENT", 388, 407], ["infection", "OBSERVATION", 247, 256], ["spleen", "ANATOMY", 262, 268], ["cruzi infection", "OBSERVATION", 368, 383]]], ["In fact, IL-10 production in this last situation inoculated with T. cruzi blood forms obtained from donor-mice was very low and often below 3\u00b712 units/ml (Table 1 ).", [["blood", "ANATOMY", 74, 79], ["-mice", "ANATOMY", 105, 110], ["IL-10", "GENE_OR_GENE_PRODUCT", 9, 14], ["T. cruzi", "ORGANISM", 65, 73], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["IL", "PROTEIN", 9, 11], ["T. cruzi", "SPECIES", 65, 73], ["T. cruzi", "SPECIES", 65, 73], ["T. cruzi blood forms", "TEST", 65, 85], ["donor-mice", "TEST", 100, 110]]], ["IL-10 that were serologically MHV+ or MHV\u2212 production, on day 11 after infection, in BALB/c (but not in C57BL/6) mice was CD4-activation dependent as treatment Our preliminary observation, suggestive of an infection with GK1.5 mAb suppressed most of its synthesis outbreak in the mouse colonies, was increased susceptibility (63 units/ml in untreated versus 6 units/ml in GK1.5 treated to T. cruzi infection first detected in BALB/c mice.", [["colonies", "ANATOMY", 286, 294], ["infection", "DISEASE", 71, 80], ["infection", "DISEASE", 206, 215], ["T. cruzi infection", "DISEASE", 389, 407], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["MHV", "ORGANISM", 30, 33], ["MHV\u2212", "ORGANISM", 38, 42], ["BALB/c", "ORGANISM", 85, 91], ["C57BL/6) mice", "ORGANISM", 104, 117], ["CD4", "GENE_OR_GENE_PRODUCT", 122, 125], ["GK", "ORGANISM", 221, 223], ["mouse", "ORGANISM", 280, 285], ["GK1.5", "ORGANISM", 372, 377], ["T. cruzi", "ORGANISM", 389, 397], ["BALB/c mice", "ORGANISM", 426, 437], ["IL", "PROTEIN", 0, 2], ["CD4", "PROTEIN", 122, 125], ["GK1.5 mAb", "PROTEIN", 221, 230], ["mouse colonies", "CELL_LINE", 280, 294], ["mice", "SPECIES", 113, 117], ["mouse", "SPECIES", 280, 285], ["T. cruzi", "SPECIES", 389, 397], ["mice", "SPECIES", 433, 437], ["MHV", "SPECIES", 30, 33], ["MHV", "SPECIES", 38, 41], ["mice", "SPECIES", 113, 117], ["mouse", "SPECIES", 280, 285], ["T. cruzi", "SPECIES", 389, 397], ["mice", "SPECIES", 433, 437], ["IL", "TEST", 0, 2], ["infection", "PROBLEM", 71, 80], ["CD4-activation dependent", "PROBLEM", 122, 146], ["Our preliminary observation", "TEST", 160, 187], ["an infection", "PROBLEM", 203, 215], ["GK1.5 mAb", "TREATMENT", 221, 230], ["increased susceptibility", "PROBLEM", 300, 324], ["T. cruzi infection", "PROBLEM", 389, 407], ["MHV", "OBSERVATION_MODIFIER", 38, 41], ["infection", "OBSERVATION", 71, 80], ["suggestive of", "UNCERTAINTY", 189, 202], ["infection", "OBSERVATION", 206, 215], ["infection", "OBSERVATION", 398, 407]]], ["As the cultures in Con A-stimulated and 22 units/ml versus diagnosis of MHV infection was confirmed, we first investi-6 units/ml, respectively, in T-Ag-stimulated BALB/c spleen gated how a T. cruzi inoculum derived from donor mice that cell cultures).", [["cultures", "ANATOMY", 7, 15], ["BALB/c spleen", "ANATOMY", 163, 176], ["cell cultures", "ANATOMY", 236, 249], ["Con A", "CHEMICAL", 19, 24], ["MHV infection", "DISEASE", 72, 85], ["T-Ag", "CHEMICAL", 147, 151], ["Ag", "CHEMICAL", 149, 151], ["Con A", "SIMPLE_CHEMICAL", 19, 24], ["MHV", "ORGANISM", 72, 75], ["T-Ag", "GENE_OR_GENE_PRODUCT", 147, 151], ["BALB/c spleen", "CELL", 163, 176], ["T. cruzi", "ORGANISM", 189, 197], ["mice", "ORGANISM", 226, 230], ["cell cultures", "CELL", 236, 249], ["Con A", "CELL_LINE", 19, 24], ["Ag", "PROTEIN", 149, 151], ["T. cruzi", "SPECIES", 189, 197], ["mice", "SPECIES", 226, 230], ["MHV", "SPECIES", 72, 75], ["T. cruzi", "SPECIES", 189, 197], ["mice", "SPECIES", 226, 230], ["the cultures", "TEST", 3, 15], ["MHV infection", "PROBLEM", 72, 85], ["a T. cruzi inoculum", "PROBLEM", 187, 206], ["cell cultures", "TEST", 236, 249], ["MHV", "ANATOMY", 72, 75], ["infection", "OBSERVATION", 76, 85], ["spleen", "ANATOMY", 170, 176]]], ["In C57BL/6 mice, the values were 14 units/ml had concomitant MHV infection would compare with a in untreated versus 10 units/ml in GK1.5-treated Con similar inoculum originated in MHV\u2212 mice in regard to their A-stimulated cultures and 13 versus 10 units/ml, respectively, course of infection in a T. cruzi-susceptible (BALB/c) and in after T-Ag stimulation.", [["MHV infection", "DISEASE", 61, 74], ["infection", "DISEASE", 282, 291], ["T-Ag", "CHEMICAL", 340, 344], ["Ag", "CHEMICAL", 342, 344], ["C57BL/6 mice", "ORGANISM", 3, 15], ["MHV", "ORGANISM", 61, 64], ["GK1.5", "SIMPLE_CHEMICAL", 131, 136], ["MHV\u2212 mice", "ORGANISM", 180, 189], ["BALB/c", "ORGANISM", 319, 325], ["T-Ag", "GENE_OR_GENE_PRODUCT", 340, 344], ["A-stimulated cultures", "CELL_LINE", 209, 230], ["Ag", "PROTEIN", 342, 344], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 11, 15], ["MHV", "SPECIES", 61, 64], ["MHV", "SPECIES", 180, 183], ["mice", "SPECIES", 185, 189], ["the values", "TEST", 17, 27], ["concomitant MHV infection", "PROBLEM", 49, 74], ["their A-stimulated cultures", "TEST", 203, 230], ["infection", "PROBLEM", 282, 291], ["T-Ag stimulation", "TREATMENT", 340, 356], ["MHV", "OBSERVATION_MODIFIER", 61, 64], ["infection", "OBSERVATION", 65, 74], ["infection", "OBSERVATION", 282, 291]]], ["In spite of the higher IL-10 proa resistant (C57BL/6) mouse strain.", [["IL-10", "GENE_OR_GENE_PRODUCT", 23, 28], ["C57BL/6)", "ORGANISM", 45, 53], ["mouse", "ORGANISM", 54, 59], ["mouse", "SPECIES", 54, 59], ["mouse", "SPECIES", 54, 59], ["the higher IL-10 proa resistant (C57BL/6) mouse strain", "PROBLEM", 12, 66]]], ["As shown in Fig. 1 , duction by spleen cells from mice that had received the parasitaemia levels during the first 9 days of infection were MHV+ inoculum, IFN-c levels were not significantly different significantly higher for both strains of mice when infected with T. cruzi blood forms derived from MHV+ donors than from those secreted by spleen cells from MHV\u2212 T. cruzi recipients and IL-4 production was below detection levels in resulted in significant increases in IFN-c production of the order of 40-100% (Fig. 2) .", [["spleen cells", "ANATOMY", 32, 44], ["blood", "ANATOMY", 274, 279], ["spleen cells", "ANATOMY", 339, 351], ["parasitaemia", "DISEASE", 77, 89], ["infection", "DISEASE", 124, 133], ["spleen cells", "CELL", 32, 44], ["mice", "ORGANISM", 50, 54], ["MHV", "ORGANISM", 139, 142], ["IFN-c", "GENE_OR_GENE_PRODUCT", 154, 159], ["mice", "ORGANISM", 241, 245], ["T. cruzi blood", "ORGANISM", 265, 279], ["MHV+ donors", "ORGANISM", 299, 310], ["spleen cells", "CELL", 339, 351], ["MHV\u2212", "ORGANISM", 357, 361], ["T. cruzi recipients", "ORGANISM", 362, 381], ["IL-4", "GENE_OR_GENE_PRODUCT", 386, 390], ["IFN-c", "GENE_OR_GENE_PRODUCT", 469, 474], ["spleen cells", "CELL_TYPE", 32, 44], ["IFN", "PROTEIN", 154, 157], ["spleen cells", "CELL_TYPE", 339, 351], ["IFN", "PROTEIN", 469, 472], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 241, 245], ["T. cruzi", "SPECIES", 265, 273], ["T. cruzi", "SPECIES", 362, 370], ["mice", "SPECIES", 50, 54], ["MHV", "SPECIES", 139, 142], ["mice", "SPECIES", 241, 245], ["T. cruzi", "SPECIES", 265, 273], ["MHV", "SPECIES", 299, 302], ["MHV", "SPECIES", 357, 360], ["T. cruzi", "SPECIES", 362, 370], ["the parasitaemia levels", "PROBLEM", 73, 96], ["infection", "PROBLEM", 124, 133], ["MHV+ inoculum", "PROBLEM", 139, 152], ["IFN-c levels", "TEST", 154, 166], ["T. cruzi blood forms", "PROBLEM", 265, 285], ["donors", "PROBLEM", 304, 310], ["detection levels", "TEST", 412, 428], ["significant increases in IFN", "PROBLEM", 444, 472], ["spleen", "ANATOMY", 32, 38], ["infection", "OBSERVATION", 124, 133], ["spleen", "ANATOMY", 339, 345], ["cruzi recipients", "OBSERVATION", 365, 381], ["significant", "OBSERVATION_MODIFIER", 444, 455], ["increases", "OBSERVATION_MODIFIER", 456, 465]]], ["We next investigated whether all groups (data not shown).INTRODUCTIONinfecting MHV\u2212 or mice that were chronically infected MHV with T. cruzi would affect cytokine production and/or alter Cytokine production by spleen cells from mice derived from the course of infection.MHV\u2212 or from chronically infected MHV+ coloniesSpleen cell cultures from BALB/c and C57BL/6 mice comingT. cruzi infection and cytokine production in mice from MHV\u2212 from MHV\u2212 or from chronically MHV-infected (MHV+) colonies or from chronically MHV-infected colonies inoculated colonies produced similar amounts of lL-10 and undetectable with T. cruzi blood forms maintained in MHV\u2212 donor mice levels of IL-4 when stimulated in vitro with Con A or T-AgIn contrast with the marked increase in parasitaemia and (data not shown).", [["spleen cells", "ANATOMY", 210, 222], ["Spleen cell cultures", "ANATOMY", 317, 337], ["colonies", "ANATOMY", 484, 492], ["colonies", "ANATOMY", 526, 534], ["colonies", "ANATOMY", 546, 554], ["blood", "ANATOMY", 620, 625], ["infection", "DISEASE", 260, 269], ["cruzi infection", "DISEASE", 376, 391], ["MHV-infected", "DISEASE", 464, 476], ["MHV-infected", "DISEASE", 513, 525], ["parasitaemia", "DISEASE", 760, 772], ["MHV\u2212", "ORGANISM", 79, 83], ["mice", "ORGANISM", 87, 91], ["MHV", "ORGANISM", 123, 126], ["T. cruzi", "ORGANISM", 132, 140], ["Cytokine", "GENE_OR_GENE_PRODUCT", 187, 195], ["spleen cells", "CELL", 210, 222], ["mice", "ORGANISM", 228, 232], ["MHV\u2212", "ORGANISM", 270, 274], ["MHV", "ORGANISM", 304, 307], ["Spleen cell cultures", "CELL", 317, 337], ["BALB/c", "ORGANISM", 343, 349], ["C57BL/6 mice", "ORGANISM", 354, 366], ["cruzi", "ORGANISM", 376, 381], ["mice", "ORGANISM", 419, 423], ["MHV\u2212 from", "ORGANISM", 429, 438], ["MHV\u2212", "ORGANISM", 439, 443], ["chronically MHV-infected (MHV+) colonies", "ORGANISM", 452, 492], ["chronically MHV", "ORGANISM", 501, 516], ["lL-10", "GENE_OR_GENE_PRODUCT", 583, 588], ["T. cruzi", "ORGANISM", 611, 619], ["blood", "ORGANISM_SUBSTANCE", 620, 625], ["MHV\u2212 donor mice", "ORGANISM", 646, 661], ["IL-4", "GENE_OR_GENE_PRODUCT", 672, 676], ["Con A", "SIMPLE_CHEMICAL", 707, 712], ["T-AgIn", "SIMPLE_CHEMICAL", 716, 722], ["cytokine", "PROTEIN", 154, 162], ["Cytokine", "PROTEIN", 187, 195], ["spleen cells", "CELL_TYPE", 210, 222], ["chronically infected MHV+ coloniesSpleen cell cultures", "CELL_LINE", 283, 337], ["cytokine", "PROTEIN", 396, 404], ["lL", "PROTEIN", 583, 585], ["IL-4", "PROTEIN", 672, 676], ["mice", "SPECIES", 87, 91], ["T. cruzi", "SPECIES", 132, 140], ["mice", "SPECIES", 228, 232], ["mice", "SPECIES", 362, 366], ["cruzi", "SPECIES", 376, 381], ["mice", "SPECIES", 419, 423], ["T. cruzi", "SPECIES", 611, 619], ["mice", "SPECIES", 657, 661], ["MHV", "SPECIES", 79, 82], ["mice", "SPECIES", 87, 91], ["MHV", "SPECIES", 123, 126], ["T. cruzi", "SPECIES", 132, 140], ["mice", "SPECIES", 228, 232], ["MHV", "SPECIES", 270, 273], ["MHV", "SPECIES", 304, 307], ["mice", "SPECIES", 362, 366], ["cruzi", "SPECIES", 376, 381], ["mice", "SPECIES", 419, 423], ["MHV", "SPECIES", 429, 432], ["MHV", "SPECIES", 439, 442], ["MHV", "SPECIES", 464, 467], ["MHV", "SPECIES", 478, 481], ["MHV", "SPECIES", 513, 516], ["T. cruzi", "SPECIES", 611, 619], ["MHV", "SPECIES", 646, 649], ["mice", "SPECIES", 657, 661], ["T. cruzi", "PROBLEM", 132, 140], ["cytokine production", "PROBLEM", 154, 173], ["alter Cytokine production", "TREATMENT", 181, 206], ["infection", "PROBLEM", 260, 269], ["MHV", "PROBLEM", 270, 273], ["chronically infected MHV", "PROBLEM", 283, 307], ["Spleen cell cultures", "TEST", 317, 337], ["BALB", "TEST", 343, 347], ["c", "TEST", 348, 349], ["C57BL", "TEST", 354, 359], ["cruzi infection", "PROBLEM", 376, 391], ["cytokine production", "PROBLEM", 396, 415], ["chronically MHV", "PROBLEM", 452, 467], ["infected (MHV+) colonies", "PROBLEM", 468, 492], ["chronically MHV", "PROBLEM", 501, 516], ["infected colonies inoculated colonies", "PROBLEM", 517, 554], ["T. cruzi blood forms", "TEST", 611, 631], ["donor mice levels of IL", "TREATMENT", 651, 674], ["Con A or T-AgIn contrast", "TEST", 707, 731], ["the marked increase in parasitaemia", "PROBLEM", 737, 772], ["spleen", "ANATOMY", 210, 216], ["infection", "OBSERVATION", 260, 269], ["chronically", "OBSERVATION_MODIFIER", 283, 294], ["infected", "OBSERVATION", 295, 303], ["MHV", "OBSERVATION_MODIFIER", 304, 307], ["coloniesSpleen cell", "OBSERVATION", 309, 328], ["infection", "OBSERVATION", 382, 391], ["cytokine production", "OBSERVATION", 396, 415], ["chronically", "OBSERVATION_MODIFIER", 452, 463], ["MHV", "OBSERVATION", 464, 467], ["infected", "OBSERVATION", 468, 476], ["chronically MHV", "OBSERVATION_MODIFIER", 501, 516], ["infected", "OBSERVATION_MODIFIER", 517, 525], ["colonies", "OBSERVATION_MODIFIER", 526, 534], ["inoculated colonies", "OBSERVATION", 535, 554], ["amounts", "OBSERVATION_MODIFIER", 572, 579], ["lL", "ANATOMY", 583, 585], ["MHV", "ANATOMY", 646, 649], ["marked", "OBSERVATION_MODIFIER", 741, 747], ["increase", "OBSERVATION_MODIFIER", 748, 756], ["parasitaemia", "OBSERVATION", 760, 772]]], ["Production of IFN-c by spleen cells from susceptibility to T. cruzi determined by the situation of acute MHV+ C57BL/6 and BALB/c mice cells to Con A stimulation simultaneous infection with blood parasites derived from was not significantly higher than in spleen cell cultures from acutely infected MHV+ donors as described above, no statis-MHV\u2212 animals (Fig. 2) .", [["spleen cells", "ANATOMY", 23, 35], ["BALB/c mice cells", "ANATOMY", 122, 139], ["blood", "ANATOMY", 189, 194], ["spleen cell cultures", "ANATOMY", 255, 275], ["T. cruzi", "DISEASE", 59, 67], ["Con A", "CHEMICAL", 143, 148], ["infection", "DISEASE", 174, 183], ["IFN-c", "GENE_OR_GENE_PRODUCT", 14, 19], ["spleen cells", "CELL", 23, 35], ["T. cruzi", "ORGANISM", 59, 67], ["MHV+ C57BL/6", "ORGANISM", 105, 117], ["BALB/c mice", "ORGANISM", 122, 133], ["cells", "CELL", 134, 139], ["Con A", "GENE_OR_GENE_PRODUCT", 143, 148], ["blood", "ORGANISM_SUBSTANCE", 189, 194], ["spleen cell cultures", "CELL", 255, 275], ["MHV+ donors", "ORGANISM", 298, 309], ["IFN-c", "PROTEIN", 14, 19], ["spleen cells", "CELL_TYPE", 23, 35], ["spleen cell cultures", "CELL_LINE", 255, 275], ["T. cruzi", "SPECIES", 59, 67], ["mice", "SPECIES", 129, 133], ["T. cruzi", "SPECIES", 59, 67], ["MHV", "SPECIES", 105, 108], ["mice", "SPECIES", 129, 133], ["MHV", "SPECIES", 298, 301], ["MHV", "SPECIES", 340, 343], ["IFN", "PROBLEM", 14, 17], ["spleen cells", "PROBLEM", 23, 35], ["T. cruzi", "TEST", 59, 67], ["acute MHV", "TREATMENT", 99, 108], ["BALB/c mice cells", "TREATMENT", 122, 139], ["A stimulation simultaneous infection", "PROBLEM", 147, 183], ["blood parasites", "TEST", 189, 204], ["spleen cell cultures", "TEST", 255, 275], ["acutely infected MHV+ donors", "PROBLEM", 281, 309], ["statis", "TEST", 333, 339], ["spleen", "ANATOMY", 23, 29], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["MHV", "OBSERVATION", 105, 108], ["infection", "OBSERVATION", 174, 183], ["spleen", "ANATOMY", 255, 261], ["infected MHV", "OBSERVATION", 289, 301]]], ["Production of IFN-c to Con A was tically significant differences of parasitaemia levels or mortunder control by IL-10 both in MHV\u2212 and in MHV+ mice ality were observed between chronically infected MHV+ and because the addition of anti-IL-10 mAb 2A5 to cultures MHV\u2212 BALB/c or C57BL/6 mice infected with T. cruzi.", [["parasitaemia", "DISEASE", 68, 80], ["T. cruzi", "DISEASE", 303, 311], ["IFN-c", "GENE_OR_GENE_PRODUCT", 14, 19], ["Con A", "SIMPLE_CHEMICAL", 23, 28], ["IL-10", "GENE_OR_GENE_PRODUCT", 112, 117], ["MHV\u2212", "ORGANISM", 126, 130], ["MHV+ mice", "ORGANISM", 138, 147], ["MHV", "ORGANISM", 197, 200], ["anti-IL-10", "GENE_OR_GENE_PRODUCT", 230, 240], ["BALB/c", "ORGANISM", 266, 272], ["C57BL/6 mice", "ORGANISM", 276, 288], ["T. cruzi", "ORGANISM", 303, 311], ["IFN", "PROTEIN", 14, 17], ["IL", "PROTEIN", 112, 114], ["anti-IL", "PROTEIN", 230, 237], ["mAb 2A5", "PROTEIN", 241, 248], ["mice", "SPECIES", 143, 147], ["mice", "SPECIES", 284, 288], ["T. cruzi", "SPECIES", 303, 311], ["MHV", "SPECIES", 126, 129], ["MHV", "SPECIES", 138, 141], ["mice", "SPECIES", 143, 147], ["MHV", "SPECIES", 197, 200], ["MHV", "SPECIES", 261, 264], ["mice", "SPECIES", 284, 288], ["T. cruzi", "SPECIES", 303, 311], ["parasitaemia levels", "PROBLEM", 68, 87], ["MHV+ mice ality", "TREATMENT", 138, 153], ["chronically infected MHV", "PROBLEM", 176, 200], ["anti-IL", "TREATMENT", 230, 237], ["mAb", "TREATMENT", 241, 244], ["cultures", "TEST", 252, 260], ["T. cruzi", "PROBLEM", 303, 311]]], ["However, peak T. cruzi parasitaemia levels were attained earlier and were 30-50% higher in BALB/c MHV+ mice as compared to MHV-free mice (data not shown).", [["T. cruzi", "ORGANISM", 14, 22], ["BALB/c MHV+ mice", "ORGANISM", 91, 107], ["MHV", "ORGANISM", 123, 126], ["mice", "ORGANISM", 132, 136], ["T. cruzi", "SPECIES", 14, 22], ["mice", "SPECIES", 103, 107], ["mice", "SPECIES", 132, 136], ["T. cruzi", "SPECIES", 14, 22], ["mice", "SPECIES", 103, 107], ["MHV", "SPECIES", 123, 126], ["mice", "SPECIES", 132, 136], ["peak T. cruzi parasitaemia levels", "TEST", 9, 42], ["MHV", "TEST", 123, 126], ["cruzi parasitaemia", "OBSERVATION", 17, 35]]], ["Differences in cytokine production between T. cruziinfected MHV+ and MHV-free groups of mice were only observed in the first week of infection.", [["infection", "DISEASE", 133, 142], ["T.", "ORGANISM", 43, 45], ["cruziinfected MHV+", "ORGANISM", 46, 64], ["MHV-free groups", "ORGANISM", 69, 84], ["mice", "ORGANISM", 88, 92], ["cytokine", "PROTEIN", 15, 23], ["T. cruziinfected MHV", "SPECIES", 43, 63], ["mice", "SPECIES", 88, 92], ["T. cruziinfected MHV", "SPECIES", 43, 63], ["MHV", "SPECIES", 69, 72], ["mice", "SPECIES", 88, 92], ["cytokine production", "TEST", 15, 34], ["MHV", "PROBLEM", 69, 72], ["infection", "PROBLEM", 133, 142], ["cytokine production", "OBSERVATION", 15, 34], ["MHV", "OBSERVATION_MODIFIER", 69, 72], ["free", "OBSERVATION_MODIFIER", 73, 77], ["infection", "OBSERVATION", 133, 142]]], ["BALB/c mice spleen cell cultures from MHV+ mice infected with T. cruzi produced lower IFN-c levels to Con A and T-Ag stimulation than cultures from MHV\u2212 mice (Fig. 3) .", [["spleen cell cultures", "ANATOMY", 12, 32], ["T-Ag", "CHEMICAL", 112, 116], ["Ag", "CHEMICAL", 114, 116], ["BALB/c mice", "ORGANISM", 0, 11], ["spleen cell cultures", "CELL", 12, 32], ["MHV+ mice", "ORGANISM", 38, 47], ["T. cruzi", "ORGANISM", 62, 70], ["IFN-c", "GENE_OR_GENE_PRODUCT", 86, 91], ["Con A", "SIMPLE_CHEMICAL", 102, 107], ["T-Ag", "GENE_OR_GENE_PRODUCT", 112, 116], ["MHV\u2212 mice", "ORGANISM", 148, 157], ["BALB/c mice spleen cell cultures", "CELL_LINE", 0, 32], ["IFN", "PROTEIN", 86, 89], ["mice", "SPECIES", 7, 11], ["mice", "SPECIES", 43, 47], ["T. cruzi", "SPECIES", 62, 70], ["mice", "SPECIES", 153, 157], ["mice", "SPECIES", 7, 11], ["MHV", "SPECIES", 38, 41], ["mice", "SPECIES", 43, 47], ["T. cruzi", "SPECIES", 62, 70], ["MHV", "SPECIES", 148, 151], ["mice", "SPECIES", 153, 157], ["BALB", "TEST", 0, 4], ["spleen cell cultures", "TEST", 12, 32], ["MHV", "TEST", 38, 41], ["T. cruzi", "TEST", 62, 70], ["T-Ag stimulation", "TREATMENT", 112, 128], ["cultures", "TEST", 134, 142], ["spleen", "ANATOMY", 12, 18], ["cell", "OBSERVATION", 19, 23]]], ["Although the potential to produce IFN-c to polyclonal Con A stimulation was preserved in MHV+C57BL/6 mice, IFN-c production was markedly suppressed on parasite-specific stimulation (Fig. 4) .", [["IFN-c", "GENE_OR_GENE_PRODUCT", 34, 39], ["Con A", "SIMPLE_CHEMICAL", 54, 59], ["MHV+C57BL/6 mice", "ORGANISM", 89, 105], ["IFN-c", "GENE_OR_GENE_PRODUCT", 107, 112], ["IFN", "PROTEIN", 34, 37], ["IFN", "PROTEIN", 107, 110], ["mice", "SPECIES", 101, 105], ["MHV", "SPECIES", 89, 92], ["mice", "SPECIES", 101, 105], ["IFN", "TEST", 34, 37], ["polyclonal Con A stimulation", "TREATMENT", 43, 71], ["IFN-c production", "TREATMENT", 107, 123]]], ["The comparison of IL-10 production levels among BALB/c and C57BL/6 mice, MHV\u2212 or MHV+, infected with T. cruzi yielded no significant differences (data not shown).", [["IL-10", "GENE_OR_GENE_PRODUCT", 18, 23], ["BALB/c", "ORGANISM", 48, 54], ["C57BL/6 mice", "ORGANISM", 59, 71], ["MHV\u2212", "ORGANISM", 73, 77], ["MHV+", "ORGANISM", 81, 85], ["T. cruzi", "ORGANISM", 101, 109], ["IL", "PROTEIN", 18, 20], ["mice", "SPECIES", 67, 71], ["T. cruzi", "SPECIES", 101, 109], ["mice", "SPECIES", 67, 71], ["MHV", "SPECIES", 73, 76], ["MHV", "SPECIES", 81, 84], ["T. cruzi", "SPECIES", 101, 109], ["IL", "TEST", 18, 20], ["production levels", "TEST", 24, 41], ["BALB/c", "TEST", 48, 54], ["C57BL/6 mice", "TREATMENT", 59, 71], ["MHV\u2212", "TREATMENT", 73, 77], ["MHV", "PROBLEM", 81, 84], ["T. cruzi", "TEST", 101, 109], ["MHV", "ANATOMY", 81, 84]]], ["Nevertheless, when BALB/c (but not C57BL/6) spleen cell uninfected MHV+ mice (Fig. 5, normal group) , suggesting mice, suppression of IFN-c responses is limited to the antigenspecific compartment whereas MHV infection affects more that the potential to increased IL-10 production stimulated by MHV infection was, in these mice, maintained in check by severely BALB/c mice by suppression of both polyclonal and specific IFN-c responses.", [["spleen cell", "ANATOMY", 44, 55], ["antigenspecific compartment", "ANATOMY", 168, 195], ["MHV infection", "DISEASE", 204, 217], ["MHV infection", "DISEASE", 294, 307], ["BALB/c (", "ORGANISM", 19, 27], ["C57BL/6) spleen cell uninfected MHV+ mice", "ORGANISM", 35, 76], ["Fig. 5", "ORGANISM", 78, 84], ["mice", "ORGANISM", 113, 117], ["IFN-c", "GENE_OR_GENE_PRODUCT", 134, 139], ["MHV", "ORGANISM", 204, 207], ["IL-10", "GENE_OR_GENE_PRODUCT", 263, 268], ["MHV", "ORGANISM", 294, 297], ["mice", "ORGANISM", 322, 326], ["BALB/c mice", "ORGANISM", 360, 371], ["IFN-c", "GENE_OR_GENE_PRODUCT", 419, 424], ["IFN", "PROTEIN", 134, 137], ["IL-10", "PROTEIN", 263, 268], ["IFN", "PROTEIN", 419, 422], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 322, 326], ["mice", "SPECIES", 367, 371], ["MHV", "SPECIES", 67, 70], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 113, 117], ["MHV", "SPECIES", 204, 207], ["MHV", "SPECIES", 294, 297], ["mice", "SPECIES", 322, 326], ["mice", "SPECIES", 367, 371], ["BALB/c", "TEST", 19, 25], ["IFN", "PROBLEM", 134, 137], ["MHV infection", "PROBLEM", 204, 217], ["increased IL", "TREATMENT", 253, 265], ["MHV infection", "PROBLEM", 294, 307], ["spleen", "ANATOMY", 44, 50], ["cell", "OBSERVATION", 51, 55], ["uninfected MHV", "OBSERVATION", 56, 70], ["MHV", "OBSERVATION_MODIFIER", 204, 207], ["infection", "OBSERVATION", 208, 217], ["MHV", "OBSERVATION_MODIFIER", 294, 297], ["infection", "OBSERVATION", 298, 307]]], ["IFN-c.", [["IFN", "PROTEIN", 0, 3]]], ["Taken together, these results indicate that in C57BL/6DISCUSSIONimmune response have been performed in situations of deliberate infection of mice with MHV laboratory strains of varying Enzootic MHV strains are of low virulence, mostly entervirulence that cause moderate to severe disturbances to the otropic and notoriously difficult to isolate and to grow in immune system.", [["immune system", "ANATOMY", 360, 373], ["infection", "DISEASE", 128, 137], ["C57BL/6DISCUSSIONimmune", "ORGANISM", 47, 70], ["mice", "ORGANISM", 141, 145], ["MHV", "ORGANISM", 151, 154], ["Enzootic MHV strains", "ORGANISM", 185, 205], ["immune system", "ANATOMICAL_SYSTEM", 360, 373], ["mice", "SPECIES", 141, 145], ["mice", "SPECIES", 141, 145], ["MHV", "SPECIES", 151, 154], ["MHV", "SPECIES", 194, 197], ["deliberate infection of mice", "PROBLEM", 117, 145], ["MHV laboratory strains", "PROBLEM", 151, 173], ["varying Enzootic MHV strains", "PROBLEM", 177, 205], ["low virulence", "PROBLEM", 213, 226], ["moderate to severe disturbances to the otropic", "PROBLEM", 261, 307], ["infection", "OBSERVATION", 128, 137], ["varying", "OBSERVATION_MODIFIER", 177, 184], ["Enzootic MHV strains", "OBSERVATION", 185, 205], ["low virulence", "OBSERVATION_MODIFIER", 213, 226], ["moderate", "OBSERVATION_MODIFIER", 261, 269], ["severe", "OBSERVATION_MODIFIER", 273, 279]]], ["Mice infected with the pantropic strain of vitro.1 When the outbreak was detected in the mouse colony, medium-virulence, JHM, show suppression of Con A-induced we unsuccessfully tried to isolate infective viral particles from proliferation, decreased IL-2 and IL-4 synthesis and a delay the plasma and liver of seropositive mice.", [["colony", "ANATOMY", 95, 101], ["plasma", "ANATOMY", 291, 297], ["liver", "ANATOMY", 302, 307], ["Con A", "CHEMICAL", 146, 151], ["Mice", "ORGANISM", 0, 4], ["mouse", "ORGANISM", 89, 94], ["Con A", "SIMPLE_CHEMICAL", 146, 151], ["IL-2", "GENE_OR_GENE_PRODUCT", 251, 255], ["IL-4", "GENE_OR_GENE_PRODUCT", 260, 264], ["plasma", "ORGANISM_SUBSTANCE", 291, 297], ["liver", "ORGAN", 302, 307], ["mice", "ORGANISM", 324, 328], ["Con A", "PROTEIN", 146, 151], ["Mice", "SPECIES", 0, 4], ["mouse", "SPECIES", 89, 94], ["mice", "SPECIES", 324, 328], ["mouse", "SPECIES", 89, 94], ["mice", "SPECIES", 324, 328], ["the pantropic strain of vitro.", "TREATMENT", 19, 49], ["JHM", "PROBLEM", 121, 124], ["infective viral particles", "PROBLEM", 195, 220], ["decreased IL", "TREATMENT", 241, 253], ["IL-4 synthesis", "TREATMENT", 260, 274], ["infective", "OBSERVATION_MODIFIER", 195, 204], ["viral particles", "OBSERVATION", 205, 220], ["proliferation", "OBSERVATION_MODIFIER", 226, 239], ["liver", "ANATOMY", 302, 307], ["seropositive mice", "OBSERVATION", 311, 328]]], ["Immunosuppressing in IFN-c production in the first week of infection, whereas, the animals with cyclophosphamide also failed to promote later in infection, large amounts of IFN-c are produced by viral isolation.", [["infection", "DISEASE", 59, 68], ["cyclophosphamide", "CHEMICAL", 96, 112], ["infection", "DISEASE", 145, 154], ["cyclophosphamide", "CHEMICAL", 96, 112], ["IFN-c", "GENE_OR_GENE_PRODUCT", 21, 26], ["animals", "ORGANISM", 83, 90], ["cyclophosphamide", "SIMPLE_CHEMICAL", 96, 112], ["IFN-c", "GENE_OR_GENE_PRODUCT", 173, 178], ["IFN", "PROTEIN", 21, 24], ["IFN-c", "PROTEIN", 173, 178], ["IFN", "PROBLEM", 21, 24], ["c production", "PROBLEM", 25, 37], ["infection", "PROBLEM", 59, 68], ["cyclophosphamide", "TREATMENT", 96, 112], ["infection", "PROBLEM", 145, 154], ["IFN", "PROBLEM", 173, 176], ["viral isolation", "TREATMENT", 195, 210], ["infection", "OBSERVATION", 59, 68], ["infection", "OBSERVATION", 145, 154], ["large", "OBSERVATION_MODIFIER", 156, 161], ["amounts", "OBSERVATION_MODIFIER", 162, 169], ["viral isolation", "OBSERVATION", 195, 210]]], ["The difficulty in isolating low virulence enzootic BALB/c mice.25-27 Macrophage function was impaired in mice enterotropic MHV, as opposed to polytropic laboratory MHV infected with this strain28 or with naturally occurring MHV strains, has been frequently reported.1,2,20 We had (as many strains.29,30 Increased message levels for IFN-c, IL-4, IL-10, other authors) to rely on serum antibody screening and TNF-a and inducible nitric-oxide synthase (iNOS ) were found serological conversion as a criterion to identify occurrence of in the brain of mice infected with a neurotropic JHM variant MHV infection.", [["Macrophage", "ANATOMY", 69, 79], ["serum", "ANATOMY", 378, 383], ["brain", "ANATOMY", 539, 544], ["nitric-oxide", "CHEMICAL", 427, 439], ["MHV infection", "DISEASE", 593, 606], ["nitric-oxide", "CHEMICAL", 427, 439], ["BALB/c mice", "ORGANISM", 51, 62], ["Macrophage", "CELL", 69, 79], ["mice enterotropic MHV", "ORGANISM", 105, 126], ["polytropic laboratory MHV", "ORGANISM", 142, 167], ["strain28", "GENE_OR_GENE_PRODUCT", 187, 195], ["MHV strains", "ORGANISM", 224, 235], ["IFN-c", "GENE_OR_GENE_PRODUCT", 332, 337], ["IL-4", "GENE_OR_GENE_PRODUCT", 339, 343], ["IL-10", "GENE_OR_GENE_PRODUCT", 345, 350], ["serum", "ORGANISM_SUBSTANCE", 378, 383], ["TNF-a", "GENE_OR_GENE_PRODUCT", 407, 412], ["inducible nitric-oxide synthase", "GENE_OR_GENE_PRODUCT", 417, 448], ["iNOS", "GENE_OR_GENE_PRODUCT", 450, 454], ["brain", "ORGAN", 539, 544], ["mice", "ORGANISM", 548, 552], ["MHV", "ORGANISM", 593, 596], ["IFN", "PROTEIN", 332, 335], ["IL", "PROTEIN", 339, 341], ["IL", "PROTEIN", 345, 347], ["serum antibody", "PROTEIN", 378, 392], ["TNF", "PROTEIN", 407, 410], ["inducible nitric-oxide synthase", "PROTEIN", 417, 448], ["iNOS", "PROTEIN", 450, 454], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 548, 552], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 105, 109], ["MHV", "SPECIES", 123, 126], ["MHV", "SPECIES", 164, 167], ["MHV", "SPECIES", 224, 227], ["mice", "SPECIES", 548, 552], ["MHV", "SPECIES", 593, 596], ["The difficulty in isolating low virulence enzootic BALB", "PROBLEM", 0, 55], ["Macrophage function", "TEST", 69, 88], ["mice enterotropic MHV", "TREATMENT", 105, 126], ["this strain28", "PROBLEM", 182, 195], ["naturally occurring MHV strains", "PROBLEM", 204, 235], ["IFN", "TEST", 332, 335], ["IL", "TEST", 339, 341], ["serum antibody screening", "TEST", 378, 402], ["TNF", "TEST", 407, 410], ["inducible nitric-oxide synthase", "TREATMENT", 417, 448], ["a neurotropic JHM variant MHV infection", "PROBLEM", 567, 606], ["low virulence", "OBSERVATION_MODIFIER", 28, 41], ["enzootic", "OBSERVATION_MODIFIER", 42, 50], ["MHV", "OBSERVATION_MODIFIER", 164, 167], ["infected", "OBSERVATION", 168, 176], ["MHV strains", "OBSERVATION", 224, 235], ["brain", "ANATOMY", 539, 544], ["MHV", "OBSERVATION_MODIFIER", 593, 596], ["infection", "OBSERVATION", 597, 606]]], ["Serological testing, although highly specific, strain.31 MHV A-59 is yet another laboratory strain, but does not distinguish between acute and chronic MHV infection of relatively low virulence that, although subclinical, is and thus we will discuss the immunological alterations found accompanied by increased production of IFN-c and suppresin the group of mice that had recently become seropositive for sion of Con A spleen responses.32,33 MHV (recent MHV-testers) in comparison with those foundDISCUSSIONThere have been few reports on immunological alterations in mice originating from colonies with longstanding record of resulting from natural MHV outbreaks.", [["spleen", "ANATOMY", 418, 424], ["colonies", "ANATOMY", 588, 596], ["infection", "DISEASE", 155, 164], ["MHV A-59", "ORGANISM", 57, 65], ["MHV", "ORGANISM", 151, 154], ["IFN-c", "GENE_OR_GENE_PRODUCT", 324, 329], ["mice", "ORGANISM", 357, 361], ["spleen", "ORGAN", 418, 424], ["mice", "ORGANISM", 566, 570], ["MHV", "ORGANISM", 648, 651], ["IFN", "PROTEIN", 324, 327], ["mice", "SPECIES", 357, 361], ["mice", "SPECIES", 566, 570], ["MHV A-59", "SPECIES", 57, 65], ["MHV", "SPECIES", 151, 154], ["mice", "SPECIES", 357, 361], ["MHV", "SPECIES", 441, 444], ["mice", "SPECIES", 566, 570], ["MHV", "SPECIES", 648, 651], ["Serological testing", "TEST", 0, 19], ["strain", "PROBLEM", 47, 53], ["another laboratory strain", "PROBLEM", 73, 98], ["acute and chronic MHV infection", "PROBLEM", 133, 164], ["relatively low virulence", "PROBLEM", 168, 192], ["the immunological alterations", "PROBLEM", 249, 278], ["immunological alterations", "PROBLEM", 537, 562], ["natural MHV outbreaks", "PROBLEM", 640, 661], ["acute", "OBSERVATION_MODIFIER", 133, 138], ["chronic", "OBSERVATION_MODIFIER", 143, 150], ["MHV", "OBSERVATION_MODIFIER", 151, 154], ["infection", "OBSERVATION", 155, 164], ["relatively", "OBSERVATION_MODIFIER", 168, 178], ["low virulence", "OBSERVATION_MODIFIER", 179, 192], ["increased", "OBSERVATION_MODIFIER", 300, 309], ["production", "OBSERVATION_MODIFIER", 310, 320], ["spleen", "ANATOMY", 418, 424], ["natural MHV", "OBSERVATION", 640, 651]]], ["However, established MHV seropositivity.", [["MHV", "ORGANISM", 21, 24], ["MHV", "SPECIES", 21, 24], ["MHV", "OBSERVATION_MODIFIER", 21, 24], ["seropositivity", "OBSERVATION", 25, 39]]], ["Both groups of mice were serologically 'chronic' natural infection with MHV was reported to affect negative on testing for several other mouse pathogenic viruses mostly splenic T lymphocytes, with a 20-50% decrease in and for Mycoplasma pulmonis (see the Materials and Methods).DISCUSSIONproliferative responses to Con A and resistance to the effects We have found a much more severe course of T. cruzi of nor-adrenalin or dibutyryl-cAMP.", [["splenic T lymphocytes", "ANATOMY", 169, 190], ["infection", "DISEASE", 57, 66], ["Con A", "CHEMICAL", 315, 320], ["nor-adrenalin", "CHEMICAL", 406, 419], ["dibutyryl-cAMP", "CHEMICAL", 423, 437], ["nor-adrenalin", "CHEMICAL", 406, 419], ["dibutyryl-cAMP", "CHEMICAL", 423, 437], ["mice", "ORGANISM", 15, 19], ["MHV", "ORGANISM", 72, 75], ["mouse", "ORGANISM", 137, 142], ["splenic T lymphocytes", "CELL", 169, 190], ["Mycoplasma pulmonis", "ORGANISM", 226, 245], ["Con A", "SIMPLE_CHEMICAL", 315, 320], ["T. cruzi", "ORGANISM", 394, 402], ["nor-adrenalin", "SIMPLE_CHEMICAL", 406, 419], ["dibutyryl-cAMP", "SIMPLE_CHEMICAL", 423, 437], ["splenic T lymphocytes", "CELL_TYPE", 169, 190], ["mice", "SPECIES", 15, 19], ["mouse", "SPECIES", 137, 142], ["Mycoplasma pulmonis", "SPECIES", 226, 245], ["T. cruzi", "SPECIES", 394, 402], ["mice", "SPECIES", 15, 19], ["MHV", "SPECIES", 72, 75], ["mouse", "SPECIES", 137, 142], ["Mycoplasma pulmonis", "SPECIES", 226, 245], ["T. cruzi", "SPECIES", 394, 402], ["serologically 'chronic' natural infection", "PROBLEM", 25, 66], ["MHV", "PROBLEM", 72, 75], ["testing", "TEST", 111, 118], ["several other mouse pathogenic viruses", "PROBLEM", 123, 161], ["Mycoplasma pulmonis", "PROBLEM", 226, 245], ["dibutyryl", "TREATMENT", 423, 432], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["infection", "OBSERVATION", 57, 66], ["pathogenic", "OBSERVATION_MODIFIER", 143, 153], ["viruses", "OBSERVATION", 154, 161], ["splenic", "ANATOMY", 169, 176], ["T lymphocytes", "OBSERVATION", 177, 190], ["pulmonis", "ANATOMY", 237, 245]]], ["34 We found that lymphoinfection in MHV\u2212 mice infected with blood forms obtained proliferative responses of spleen cells from BALB/c and from mouse colonies that had recently become seropositive C57BL/6 mice, MHV+ or MHV\u2212 recipient mice to Con A, for MHV, as compared with mice inoculated with parasites T-Ag, or anti-CD3 stimulation were not significantly different. derived from MHV\u2212 donors; increased susceptibility to infec-Suppressed lymphoproliferative responses to these stimuli, tion was accompanied by increased synthesis of IL-10 by commonly seen in the course of T. cruzi infection,11 were spleen cell cultures.", [["blood", "ANATOMY", 60, 65], ["spleen cells", "ANATOMY", 108, 120], ["BALB/c", "ANATOMY", 126, 132], ["colonies", "ANATOMY", 148, 156], ["spleen cell cultures", "ANATOMY", 601, 621], ["T. cruzi infection", "DISEASE", 574, 592], ["Ag", "CHEMICAL", 306, 308], ["MHV\u2212 mice", "ORGANISM", 36, 45], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["spleen cells", "CELL", 108, 120], ["BALB/c", "ORGANISM", 126, 132], ["mouse", "ORGANISM", 142, 147], ["C57BL/6 mice", "ORGANISM", 195, 207], ["MHV+", "ORGANISM", 209, 213], ["MHV\u2212 recipient mice", "ORGANISM", 217, 236], ["Con A", "GENE_OR_GENE_PRODUCT", 240, 245], ["MHV", "ORGANISM", 251, 254], ["mice", "ORGANISM", 273, 277], ["T-Ag", "GENE_OR_GENE_PRODUCT", 304, 308], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 313, 321], ["MHV\u2212 donors", "ORGANISM", 381, 392], ["IL-10", "GENE_OR_GENE_PRODUCT", 534, 539], ["T. cruzi", "ORGANISM", 574, 582], ["spleen cell cultures", "CELL", 601, 621], ["spleen cells", "CELL_TYPE", 108, 120], ["BALB/c and from mouse colonies", "CELL_LINE", 126, 156], ["Ag", "PROTEIN", 306, 308], ["anti-CD3", "PROTEIN", 313, 321], ["IL", "PROTEIN", 534, 536], ["spleen cell cultures", "CELL_LINE", 601, 621], ["mice", "SPECIES", 41, 45], ["mouse", "SPECIES", 142, 147], ["mice", "SPECIES", 203, 207], ["mice", "SPECIES", 232, 236], ["mice", "SPECIES", 273, 277], ["T. cruzi", "SPECIES", 574, 582], ["MHV", "SPECIES", 36, 39], ["mice", "SPECIES", 41, 45], ["mouse", "SPECIES", 142, 147], ["mice", "SPECIES", 203, 207], ["MHV", "SPECIES", 209, 212], ["MHV", "SPECIES", 217, 220], ["mice", "SPECIES", 232, 236], ["MHV", "SPECIES", 251, 254], ["mice", "SPECIES", 273, 277], ["MHV", "SPECIES", 381, 384], ["T. cruzi", "SPECIES", 574, 582], ["lymphoinfection", "PROBLEM", 17, 32], ["blood forms", "TEST", 60, 71], ["spleen cells", "PROBLEM", 108, 120], ["BALB/c", "PROBLEM", 126, 132], ["mouse colonies", "PROBLEM", 142, 156], ["MHV", "PROBLEM", 251, 254], ["parasites", "PROBLEM", 294, 303], ["anti-CD3 stimulation", "TREATMENT", 313, 333], ["increased susceptibility to infec", "PROBLEM", 394, 427], ["Suppressed lymphoproliferative responses", "PROBLEM", 428, 468], ["these stimuli", "TEST", 472, 485], ["increased synthesis of IL", "PROBLEM", 511, 536], ["T. cruzi infection", "PROBLEM", 574, 592], ["spleen cell cultures", "TEST", 601, 621], ["lymphoinfection", "OBSERVATION", 17, 32], ["MHV", "ANATOMY", 36, 39], ["spleen", "ANATOMY", 108, 114], ["significantly different", "OBSERVATION_MODIFIER", 343, 366], ["increased", "OBSERVATION_MODIFIER", 511, 520], ["cruzi infection", "OBSERVATION", 577, 592], ["spleen", "ANATOMY", 601, 607]]], ["Interleukin-10 down-regulates IL-12 and observed from day 11 of infection, with minimal levels of IFN-c production, besides antagonizing IFN-c-and TNF-asuppression seen on day 19 and recovery by day 27 (data not dependent macrophage activation and intracellular T. cruzi shown).", [["macrophage", "ANATOMY", 222, 232], ["intracellular", "ANATOMY", 248, 261], ["infection", "DISEASE", 64, 73], ["Interleukin-10", "GENE_OR_GENE_PRODUCT", 0, 14], ["IL-12", "GENE_OR_GENE_PRODUCT", 30, 35], ["IFN-c", "GENE_OR_GENE_PRODUCT", 98, 103], ["IFN-c", "GENE_OR_GENE_PRODUCT", 137, 142], ["TNF", "GENE_OR_GENE_PRODUCT", 147, 150], ["macrophage", "CELL", 222, 232], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 248, 261], ["T. cruzi", "ORGANISM", 262, 270], ["Interleukin-10", "PROTEIN", 0, 14], ["IL-12", "PROTEIN", 30, 35], ["IFN", "PROTEIN", 98, 101], ["IFN", "PROTEIN", 137, 140], ["TNF", "PROTEIN", 147, 150], ["T. cruzi", "SPECIES", 262, 270], ["T. cruzi", "SPECIES", 262, 270], ["Interleukin", "TEST", 0, 11], ["infection", "PROBLEM", 64, 73], ["IFN-c production", "PROBLEM", 98, 114], ["antagonizing IFN", "TREATMENT", 124, 140], ["TNF", "TREATMENT", 147, 150], ["dependent macrophage activation", "PROBLEM", 212, 243], ["intracellular T. cruzi", "TEST", 248, 270], ["infection", "OBSERVATION", 64, 73], ["minimal", "OBSERVATION_MODIFIER", 80, 87]]], ["Thus, in the course of T. cruzi infection, we did not killing.12,13,17,21-23 In spite of the enhanced IL-10 secretion by observe, neither in recently seropositive recipient mice nor in spleen cells from MHV+ recipients, no decrease of IFN-c mice from chronically MHV-infected colonies, suppression of levels, in comparison to recipients of MHV\u2212 donors could be lymphoproliferation to Con A, to parasite antigens or to antidetected in these same cultures.", [["spleen cells", "ANATOMY", 185, 197], ["colonies", "ANATOMY", 276, 284], ["T. cruzi infection", "DISEASE", 23, 41], ["12,13,17,21-23", "CHEMICAL", 62, 76], ["MHV-infected", "DISEASE", 263, 275], ["lymphoproliferation", "DISEASE", 361, 380], ["T. cruzi", "ORGANISM", 23, 31], ["IL-10", "GENE_OR_GENE_PRODUCT", 102, 107], ["mice", "ORGANISM", 173, 177], ["spleen cells", "CELL", 185, 197], ["MHV+ recipients", "ORGANISM", 203, 218], ["IFN-c", "GENE_OR_GENE_PRODUCT", 235, 240], ["mice", "ORGANISM", 241, 245], ["chronically MHV", "ORGANISM", 251, 266], ["recipients", "ORGANISM", 326, 336], ["MHV\u2212 donors", "ORGANISM", 340, 351], ["Con A", "SIMPLE_CHEMICAL", 384, 389], ["IL", "PROTEIN", 102, 104], ["spleen cells", "CELL_TYPE", 185, 197], ["IFN", "PROTEIN", 235, 238], ["parasite antigens", "PROTEIN", 394, 411], ["T. cruzi", "SPECIES", 23, 31], ["mice", "SPECIES", 173, 177], ["mice", "SPECIES", 241, 245], ["T. cruzi", "SPECIES", 23, 31], ["mice", "SPECIES", 173, 177], ["MHV", "SPECIES", 203, 206], ["mice", "SPECIES", 241, 245], ["MHV", "SPECIES", 263, 266], ["MHV", "SPECIES", 340, 343], ["T. cruzi infection", "PROBLEM", 23, 41], ["the enhanced IL", "TREATMENT", 89, 104], ["decrease of IFN", "PROBLEM", 223, 238], ["chronically MHV", "PROBLEM", 251, 266], ["infected colonies", "PROBLEM", 267, 284], ["suppression of levels", "PROBLEM", 286, 307], ["MHV\u2212 donors", "TREATMENT", 340, 351], ["lymphoproliferation", "PROBLEM", 361, 380], ["parasite antigens", "PROBLEM", 394, 411], ["these same cultures", "TEST", 434, 453], ["cruzi infection", "OBSERVATION", 26, 41], ["spleen", "ANATOMY", 185, 191], ["no", "UNCERTAINTY", 220, 222], ["decrease", "OBSERVATION_MODIFIER", 223, 231], ["infected colonies", "OBSERVATION", 267, 284], ["MHV", "OBSERVATION", 340, 343]]], ["However, the data on enhanced CD3 stimulation that could be ascribed to the viral infection.", [["viral infection", "DISEASE", 76, 91], ["CD3", "GENE_OR_GENE_PRODUCT", 30, 33], ["CD3", "PROTEIN", 30, 33], ["enhanced CD3 stimulation", "TREATMENT", 21, 45], ["the viral infection", "PROBLEM", 72, 91], ["viral", "OBSERVATION_MODIFIER", 76, 81], ["infection", "OBSERVATION", 82, 91]]], ["IFN-c synthesis by anti-IL-10 mAb treatment, showed that However, its occurrence could have been masked by the intense endogenous IL-10 was down-regulating IFN-c production in suppression characteristic of acute T. cruzi infection. this situation of probable acute concomitant infection with Our results on the aggravation of T. cruzi infection in the parasite and the virus.", [["anti-IL-10 mAb", "CHEMICAL", 19, 33], ["T. cruzi infection", "DISEASE", 212, 230], ["infection", "DISEASE", 277, 286], ["T. cruzi infection", "DISEASE", 326, 344], ["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["anti-IL-10 mAb", "GENE_OR_GENE_PRODUCT", 19, 33], ["IL-10", "GENE_OR_GENE_PRODUCT", 130, 135], ["IFN-c", "GENE_OR_GENE_PRODUCT", 156, 161], ["T. cruzi", "ORGANISM", 212, 220], ["T. cruzi", "ORGANISM", 326, 334], ["IFN", "PROTEIN", 0, 3], ["IL", "PROTEIN", 130, 132], ["IFN", "PROTEIN", 156, 159], ["T. cruzi", "SPECIES", 212, 220], ["T. cruzi", "SPECIES", 326, 334], ["T. cruzi", "SPECIES", 212, 220], ["T. cruzi", "SPECIES", 326, 334], ["IFN-c synthesis", "TREATMENT", 0, 15], ["anti-IL-10 mAb treatment", "TREATMENT", 19, 43], ["the intense endogenous IL", "PROBLEM", 107, 132], ["acute T. cruzi infection", "PROBLEM", 206, 230], ["acute concomitant infection", "PROBLEM", 259, 286], ["T. cruzi infection", "PROBLEM", 326, 344], ["the parasite", "PROBLEM", 348, 360], ["the virus", "PROBLEM", 365, 374], ["intense", "OBSERVATION_MODIFIER", 111, 118], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["cruzi infection", "OBSERVATION", 215, 230], ["probable", "UNCERTAINTY", 250, 258], ["acute", "OBSERVATION_MODIFIER", 259, 264], ["concomitant", "OBSERVATION_MODIFIER", 265, 276], ["infection", "OBSERVATION", 277, 286], ["cruzi infection", "OBSERVATION", 329, 344]]], ["The maintenance of in vitro IFN-c BALB/c and C57BL/6 mice by using parasite inocula mainsecretion rates in the presence of increased IL-10 concentained in mice that had positive serology for MHV are in trations has been described upon treatment of T. cruzi-infected agreement with a previous report on CBA/J mice infected with mice with high doses of rIL-10 that aggravate infection.12DISCUSSIONT. cruzi derived from corona virus-positive mice.35,36 These Both mouse strains, BALB/c and C57BL/6, respectively, authors were able to demonstrate, in the plasma, infective susceptible and resistant to T. cruzi, showed increased parasitavirus particles that could be neutralized by anti-MHV antiemia and augmented IL-10 production, but increased mortality serum.", [["plasma", "ANATOMY", 551, 557], ["serum", "ANATOMY", 752, 757], ["rIL-10", "CHEMICAL", 351, 357], ["infection", "DISEASE", 373, 382], ["IFN-c BALB/c", "ORGANISM", 28, 40], ["C57BL/6 mice", "ORGANISM", 45, 57], ["parasite inocula mainsecretion", "ORGANISM", 67, 97], ["IL-10", "GENE_OR_GENE_PRODUCT", 133, 138], ["mice", "ORGANISM", 155, 159], ["MHV", "ORGANISM", 191, 194], ["T. cruzi-", "ORGANISM", 248, 257], ["CBA/J mice", "ORGANISM", 302, 312], ["mice", "ORGANISM", 327, 331], ["rIL-10", "GENE_OR_GENE_PRODUCT", 351, 357], ["cruzi", "ORGANISM", 398, 403], ["corona virus", "ORGANISM", 417, 429], ["mice", "ORGANISM", 439, 443], ["mouse", "ORGANISM", 461, 466], ["BALB/c", "ORGANISM", 476, 482], ["C57BL/6", "ORGANISM", 487, 494], ["plasma", "ORGANISM_SUBSTANCE", 551, 557], ["T. cruzi", "ORGANISM", 598, 606], ["IL-10", "GENE_OR_GENE_PRODUCT", 710, 715], ["serum", "ORGANISM_SUBSTANCE", 752, 757], ["IFN", "PROTEIN", 28, 31], ["IL-10", "PROTEIN", 133, 138], ["IL", "PROTEIN", 710, 712], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 308, 312], ["mice", "SPECIES", 327, 331], ["cruzi", "SPECIES", 398, 403], ["mice", "SPECIES", 439, 443], ["mouse", "SPECIES", 461, 466], ["T. cruzi", "SPECIES", 598, 606], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 155, 159], ["MHV", "SPECIES", 191, 194], ["T. cruzi-", "SPECIES", 248, 257], ["mice", "SPECIES", 308, 312], ["mice", "SPECIES", 327, 331], ["cruzi", "SPECIES", 398, 403], ["mice", "SPECIES", 439, 443], ["mouse", "SPECIES", 461, 466], ["T. cruzi", "SPECIES", 598, 606], ["anti-MHV", "SPECIES", 678, 686], ["vitro IFN", "TREATMENT", 22, 31], ["BALB/c and C57BL/6 mice", "TREATMENT", 34, 57], ["parasite inocula mainsecretion rates", "TREATMENT", 67, 103], ["increased IL", "TREATMENT", 123, 135], ["positive serology", "PROBLEM", 169, 186], ["MHV", "PROBLEM", 191, 194], ["CBA/J mice", "TREATMENT", 302, 312], ["high doses of rIL", "TREATMENT", 337, 354], ["aggravate infection", "PROBLEM", 363, 382], ["cruzi", "PROBLEM", 398, 403], ["corona virus", "TEST", 417, 429], ["These Both mouse strains", "TEST", 450, 474], ["BALB/c", "TEST", 476, 482], ["infective", "PROBLEM", 559, 568], ["T. cruzi", "TEST", 598, 606], ["increased parasitavirus particles", "PROBLEM", 615, 648], ["anti-MHV antiemia", "PROBLEM", 678, 695], ["augmented IL", "TREATMENT", 700, 712], ["increased mortality serum", "PROBLEM", 732, 757], ["increased", "OBSERVATION_MODIFIER", 123, 132], ["IL", "OBSERVATION", 133, 135], ["infection", "OBSERVATION", 373, 382], ["infective", "OBSERVATION", 559, 568]]], ["Nevertheless, the underlying mechanisms leading to as a consequence of MHV infection was not observed for increased susceptibility to the parasite were not explored.", [["MHV infection", "DISEASE", 71, 84], ["MHV", "ORGANISM", 71, 74], ["MHV", "SPECIES", 71, 74], ["the underlying mechanisms", "PROBLEM", 14, 39], ["MHV infection", "PROBLEM", 71, 84], ["increased susceptibility to the parasite", "PROBLEM", 106, 146], ["MHV", "OBSERVATION_MODIFIER", 71, 74], ["infection", "OBSERVATION", 75, 84]]], ["C57BL/6 mice and they maintained their resistant phenotypeDISCUSSIONWe further investigated the influence of a longstanding to T. cruzi infection.", [["T. cruzi infection", "DISEASE", 127, 145], ["C57BL/6 mice", "ORGANISM", 0, 12], ["T. cruzi", "ORGANISM", 127, 135], ["mice", "SPECIES", 8, 12], ["T. cruzi", "SPECIES", 127, 135], ["mice", "SPECIES", 8, 12], ["T. cruzi", "SPECIES", 127, 135], ["T. cruzi infection", "PROBLEM", 127, 145], ["cruzi infection", "OBSERVATION", 130, 145]]], ["Although mouse strain resistance toDISCUSSION(1 year) established endemic MHV infection on the course of MHV infection is highly dependent on the MHV strain, studies T. cruzi infection and immune response.", [["MHV infection", "DISEASE", 74, 87], ["MHV infection", "DISEASE", 105, 118], ["T. cruzi infection", "DISEASE", 166, 184], ["mouse", "ORGANISM", 9, 14], ["MHV", "ORGANISM", 74, 77], ["MHV", "ORGANISM", 105, 108], ["MHV strain", "ORGANISM", 146, 156], ["T. cruzi", "ORGANISM", 166, 174], ["mouse", "SPECIES", 9, 14], ["T. cruzi", "SPECIES", 166, 174], ["mouse", "SPECIES", 9, 14], ["MHV", "SPECIES", 74, 77], ["MHV", "SPECIES", 105, 108], ["MHV", "SPECIES", 146, 149], ["T. cruzi", "SPECIES", 166, 174], ["endemic MHV infection", "PROBLEM", 66, 87], ["MHV infection", "PROBLEM", 105, 118], ["the MHV strain", "PROBLEM", 142, 156], ["T. cruzi infection", "PROBLEM", 166, 184], ["immune response", "PROBLEM", 189, 204], ["strain resistance", "OBSERVATION", 15, 32], ["endemic", "OBSERVATION_MODIFIER", 66, 73], ["MHV", "OBSERVATION_MODIFIER", 74, 77], ["infection", "OBSERVATION", 78, 87], ["MHV", "OBSERVATION_MODIFIER", 105, 108], ["infection", "OBSERVATION", 109, 118], ["highly dependent", "OBSERVATION_MODIFIER", 122, 138], ["cruzi infection", "OBSERVATION", 169, 184]]], ["In contrast with the with laboratory MHV-strains have concluded that indifferently marked effects on the immune response observed in MHV\u2212 to the degree of MHV-strain virulence, replication in macrohosts infected with T. cruzi derived from recently MHV+ mice, phages does always occur.24 Viral replication inside macrothe disturbances of immune response found in mice from phages may directly interfere with T. cruzi killing ability by chronically MHV-infected colonies were milder.", [["colonies", "ANATOMY", 460, 468], ["chronically MHV-infected", "DISEASE", 435, 459], ["MHV-strains", "ORGANISM", 37, 48], ["MHV\u2212", "ORGANISM", 133, 137], ["MHV-strain", "ORGANISM", 155, 165], ["T. cruzi", "ORGANISM", 217, 225], ["MHV+ mice", "ORGANISM", 248, 257], ["mice", "ORGANISM", 362, 366], ["T. cruzi", "ORGANISM", 407, 415], ["chronically MHV", "ORGANISM", 435, 450], ["colonies", "CELL", 460, 468], ["chronically MHV-infected colonies", "CELL_LINE", 435, 468], ["T. cruzi", "SPECIES", 217, 225], ["mice", "SPECIES", 253, 257], ["mice", "SPECIES", 362, 366], ["T. cruzi", "SPECIES", 407, 415], ["MHV", "SPECIES", 37, 40], ["MHV", "SPECIES", 133, 136], ["MHV", "SPECIES", 155, 158], ["T. cruzi", "SPECIES", 217, 225], ["MHV", "SPECIES", 248, 251], ["mice", "SPECIES", 253, 257], ["mice", "SPECIES", 362, 366], ["T. cruzi", "SPECIES", 407, 415], ["MHV", "SPECIES", 447, 450], ["the immune response", "PROBLEM", 101, 120], ["MHV", "PROBLEM", 155, 158], ["strain virulence", "PROBLEM", 159, 175], ["Viral replication", "TREATMENT", 287, 304], ["immune response", "PROBLEM", 337, 352], ["infected colonies", "PROBLEM", 451, 468], ["marked", "OBSERVATION_MODIFIER", 83, 89], ["MHV", "OBSERVATION", 155, 158], ["strain virulence", "OBSERVATION", 159, 175], ["immune response", "OBSERVATION", 337, 352], ["infected colonies", "OBSERVATION", 451, 468]]], ["Production these cells and stimulate a number of macrophage functions of IL-10 was similar between MHV+ and MHV\u2212 mice, while including IL-10 synthesis.", [["cells", "ANATOMY", 17, 22], ["macrophage", "ANATOMY", 49, 59], ["cells", "CELL", 17, 22], ["macrophage", "CELL", 49, 59], ["IL-10", "GENE_OR_GENE_PRODUCT", 73, 78], ["MHV+", "ORGANISM", 99, 103], ["MHV\u2212 mice", "ORGANISM", 108, 117], ["IL-10", "GENE_OR_GENE_PRODUCT", 135, 140], ["IL-10", "PROTEIN", 73, 78], ["IL", "PROTEIN", 135, 137], ["mice", "SPECIES", 113, 117], ["MHV", "SPECIES", 99, 102], ["MHV", "SPECIES", 108, 111], ["mice", "SPECIES", 113, 117], ["Production these cells", "PROBLEM", 0, 22], ["IL", "TEST", 73, 75], ["MHV", "ANATOMY", 108, 111]]], ["In this regard, C57BL/6 mice are parasite-antigen-stimulated IFN-c production was lower in T. semisusceptible to most MHV strains;1,2 as production of cruzi-infected BALB/c and C57BL/6 mice.", [["C57BL/6 mice", "ORGANISM", 16, 28], ["IFN-c", "GENE_OR_GENE_PRODUCT", 61, 66], ["T. semisusceptible", "ORGANISM", 91, 109], ["MHV strains", "ORGANISM", 118, 129], ["BALB/c", "ORGANISM", 166, 172], ["C57BL/6 mice", "ORGANISM", 177, 189], ["IFN", "PROTEIN", 61, 64], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 24, 28], ["T. semisusceptible", "SPECIES", 91, 109], ["MHV", "SPECIES", 118, 121], ["mice", "SPECIES", 185, 189], ["parasite", "TEST", 33, 41], ["c production", "PROBLEM", 65, 77], ["most MHV strains", "PROBLEM", 113, 129], ["cruzi-infected BALB", "TREATMENT", 151, 170]]], ["However, when IL-10 by MHV-infected C57BL/6 mice (but not by BALB/c neutralization of IFN-c in the cultures unmasked the full mice) was CD4+-activation independent, virus-infected or potential of IL-10 secretion, MHV+ BALB/c mice (but not virus-stimulated macrophages could be the main source of C57BL/6), showed higher IL-10 production levels.", [["macrophages", "ANATOMY", 256, 267], ["IL-10", "GENE_OR_GENE_PRODUCT", 14, 19], ["MHV-infected", "ORGANISM", 23, 35], ["C57BL/6 mice", "ORGANISM", 36, 48], ["BALB/c", "ORGANISM", 61, 67], ["IFN-c", "GENE_OR_GENE_PRODUCT", 86, 91], ["mice", "ORGANISM", 126, 130], ["CD4", "GENE_OR_GENE_PRODUCT", 136, 139], ["IL-10", "GENE_OR_GENE_PRODUCT", 196, 201], ["MHV+ BALB/c mice", "ORGANISM", 213, 229], ["macrophages", "CELL", 256, 267], ["C57BL/6", "ORGANISM", 296, 303], ["IL-10", "GENE_OR_GENE_PRODUCT", 320, 325], ["IL", "PROTEIN", 14, 16], ["IFN-c", "PROTEIN", 86, 91], ["CD4", "PROTEIN", 136, 139], ["macrophages", "CELL_TYPE", 256, 267], ["IL", "PROTEIN", 320, 322], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 225, 229], ["MHV", "SPECIES", 23, 26], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 126, 130], ["MHV", "SPECIES", 213, 216], ["mice", "SPECIES", 225, 229], ["IL", "TEST", 14, 16], ["IFN", "TEST", 86, 89], ["the cultures", "TEST", 95, 107], ["CD4", "TEST", 136, 139], ["activation independent", "PROBLEM", 141, 163], ["virus", "PROBLEM", 165, 170], ["IL", "TEST", 196, 198], ["MHV", "TEST", 213, 216], ["BALB/c mice", "PROBLEM", 218, 229], ["virus", "PROBLEM", 239, 244], ["stimulated macrophages", "PROBLEM", 245, 267]]], ["This result this cytokine.DISCUSSIONis", [["cytokine", "PROTEIN", 17, 25]]]]}